BackgroundUsing	O
antibodies	O
to	O
specific	O
protein	O
antigens	O
is	O
the	O
method	O
of	O
choice	O
to	O
assign	O
and	O
identify	O
cell	O
lineage	O
through	O
simultaneous	O
analysis	O
of	O
surface	O
molecules	O
and	O
intracellular	O
markers	O
.	O

Embryonic	O
stem	O
cell	O
research	O
can	O
be	O
benefited	O
from	O
using	O
antibodies	O
specific	O
to	O
transcriptional	O
factors	O
/	O
markers	O
that	O
contribute	O
to	O
the	O
""""	O
stemness	O
""""	O
phenotype	O
or	O
critical	O
for	O
cell	O
lineage	O
.	O

ResultsIn	O
this	O
report	O
,	O
we	O
have	O
developed	O
and	O
validated	O
antibodies	O
(	O
either	O
monoclonal	O
or	O
polyclonal	O
)	O
specific	O
to	O
human	O
embryonic	O
stem	O
cell	O
antigens	O
and	O
early	O
differentiation	O
transcriptional	O
factors	O
/	O
markers	O
that	O
are	O
critical	O
for	O
cell	O
differentiation	O
into	O
definite	O
lineage	O
.	O

ConclusionThese	O
antibodies	O
enable	O
stem	O
cell	O
biologists	O
to	O
conveniently	O
identify	O
stem	O
cell	O
characteristics	O
and	O
to	O
quantitatively	O
assess	O
differentiation	O
.	O

Although	O
the	O
stem	O
cell	O
concept	O
was	O
introduced	O
decades	O
ago	O
,	O
to	O
date	O
,	O
stem	O
cells	O
can	O
only	O
be	O
defined	O
functionally	O
,	O
not	O
morphologically	O
or	O
phenotypically	O
.	O

Two	O
functions	O
define	O
stem	O
cells	O
.	O

Firstly	O
,	O
they	O
are	O
self	O
-	O
renewing	O
,	O
thus	O
able	O
to	O
propagate	O
to	O
generate	O
additional	O
stem	O
cells	O
.	O

Secondly	O
they	O
can	O
differentiate	O
into	O
various	O
progenitor	O
cells	O
,	O
which	O
commit	O
to	O
further	O
maturation	O
along	O
a	O
specific	O
lineage	O
.	O

While	O
stem	O
cells	O
can	O
be	O
best	O
defined	O
functionally	O
,	O
a	O
good	O
number	O
of	O
molecular	O
markers	O
have	O
been	O
used	O
to	O
prospectively	O
identify	O
various	O
stem	O
cell	O
populations	O
.	O

Although	O
the	O
functional	O
importance	O
of	O
many	O
of	O
these	O
antigens	O
remains	O
unknown	O
,	O
their	O
unique	O
expression	O
pattern	O
and	O
timing	O
of	O
expression	O
provide	O
a	O
useful	O
tool	O
for	O
scientists	O
to	O
identify	O
as	O
well	O
as	O
isolate	O
stem	O
cells	O
.	O

Embryonic	O
stem	O
cells	O
(	O
ESC	O
)	O
,	O
derived	O
from	O
the	O
inner	O
cell	O
mass	O
of	O
pre	O
-	O
implantation	O
embryos	O
,	O
have	O
been	O
recognized	O
as	O
the	O
earliest	O
stem	O
cell	O
population	O
[	O
1,2	O
]	O
.	O

This	O
pluripotent	O
population	O
can	O
differentiate	O
into	O
all	O
somatic	O
tissue	O
including	O
germ	O
cells	O
.	O

In	O
the	O
case	O
of	O
human	O
ESC	O
,	O
they	O
can	O
differentiate	O
into	O
some	O
extra	O
-	O
embryonic	O
derivatives	O
as	O
well	O
.	O

Like	O
mouse	O
ESC	O
,	O
human	O
ES	O
cells	O
can	O
be	O
maintained	O
and	O
propagated	O
on	O
mouse	O
fibroblast	O
feeders	O
for	O
extended	O
periods	O
in	O
media	O
containing	O
basic	O
fibroblast	O
growth	O
factor	O
(	O
bFGF	O
)	O
[	O
3	O
]	O
.	O

Gene	O
expression	O
of	O
undifferentiated	O
human	O
ES	O
cells	O
has	O
been	O
investigated	O
among	O
several	O
ES	O
cell	O
lines	O
by	O
a	O
variety	O
of	O
techniques	O
.	O

They	O
include	O
comparison	O
with	O
databases	O
,	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
,	O
focused	O
cDNA	O
microarrays	O
,	O
and	O
immunocytochemistry	O
.	O

A	O
list	O
of	O
molecules	O
comprised	O
of	O
known	O
ES	O
-	O
specific	O
or	O
-highly	O
expressed	O
genes	O
and	O
candidates	O
that	O
can	O
serve	O
as	O
markers	O
for	O
human	O
ESCs	O
and	O
may	O
also	O
contribute	O
to	O
the	O
""""	O
stemness	O
""""	O
phenotype	O
has	O
been	O
established	O
[	O
3	O
-	O
11	O
]	O
.	O

For	O
example	O
,	O
pluripotent	O
ESC	O
can	O
be	O
characterized	O
by	O
high	O
level	O
expression	O
of	O
Oct3	O
/	O
4	O
(	O
POU	O
domain	O
,	O
class	O
5	O
,	O
transcription	O
factor	O
1	O
,	O
Pou5f1	O
)	O
and	O
Nanog	O
,	O
which	O
are	O
a	O
member	O
of	O
POU	O
domain	O
and	O
homeobox	O
transcription	O
factors	O
respectively	O
.	O

A	O
critical	O
amount	O
of	O
Oct3	O
/	O
4	O
and	O
Nanog	O
expression	O
is	O
required	O
to	O
sustain	O
stem	O
-	O
cell	O
pluripotency	O
and	O
both	O
of	O
these	O
markers	O
are	O
downregulated	O
as	O
cells	O
differentiate	O
in	O
vitro	O
and	O
in	O
vivo	O
[	O
4	O
-	O
9	O
]	O
.	O

Antibodies	O
to	O
Oct3	O
/	O
4	O
which	O
cross	O
react	O
with	O
human	O
Oct	O
3	O
/	O
4	O
have	O
been	O
widely	O
used	O
to	O
monitor	O
the	O
presence	O
of	O
undifferentiated	O
ESC	O
.	O

No	O
single	O
marker	O
however	O
is	O
sufficient	O
or	O
unique	O
for	O
identifying	O
ESCs	O
.	O

Oct3	O
/	O
4	O
for	O
example	O
is	O
expressed	O
by	O
germ	O
cells	O
and	O
may	O
be	O
expressed	O
by	O
specific	O
populations	O
later	O
in	O
development	O
.	O

Likewise	O
,	O
Nanog	O
has	O
been	O
shown	O
to	O
express	O
in	O
other	O
tissues	O
.	O

We	O
and	O
other	O
have	O
noted	O
however	O
,	O
that	O
while	O
no	O
single	O
marker	O
is	O
sufficient	O
a	O
constellation	O
of	O
positive	O
and	O
negative	O
markers	O
can	O
in	O
concert	O
unambiguously	O
allow	O
one	O
to	O
define	O
the	O
state	O
of	O
ESC	O
cultures	O
and	O
that	O
surface	O
markers	O
in	O
combination	O
can	O
be	O
used	O
to	O
prospectively	O
sort	O
for	O
ESC	O
.	O

Based	O
on	O
published	O
data	O
at	O
the	O
level	O
of	O
gene	O
expression	O
,	O
we	O
have	O
cloned	O
a	O
number	O
of	O
candidate	O
marker	O
genes	O
.	O

We	O
have	O
also	O
expressed	O
the	O
recombinant	O
protein	O
and	O
generated	O
a	O
panel	O
of	O
monoclonal	O
or	O
polyclonal	O
antibodies	O
to	O
these	O
proteins	O
.	O

Using	O
these	O
antibodies	O
we	O
have	O
confirmed	O
the	O
specificity	O
and	O
selectivity	O
of	O
these	O
antibodies	O
on	O
several	O
ESC	O
lines	O
and	O
established	O
their	O
utility	O
as	O
stem	O
cells	O
markers	O
.	O

Our	O
results	O
confirm	O
the	O
expression	O
pattern	O
and	O
timing	O
of	O
these	O
cell	O
markers	O
at	O
the	O
protein	O
level	O
,	O
whereas	O
previous	O
data	O
reported	O
at	O
the	O
level	O
of	O
gene	O
expression	O
.	O

Characterization	O
of	O
undifferentiated	O
human	O
ES	O
cells	O
and	O
differentiated	O
EBs	O
by	O
antibodiesAll	O
monoclonal	O
antibodies	O
were	O
initially	O
selected	O
for	O
their	O
abilities	O
to	O
recognize	O
recombinant	O
proteins	O
in	O
direct	O
ELISAs	O
.	O

A	O
subset	O
were	O
also	O
tested	O
by	O
Western	O
Blot	O
analysis	O
using	O
recombinant	O
proteins	O
and	O
cell	O
lysate	O
to	O
confirm	O
binding	O
to	O
a	O
single	O
epitope	O
.	O

The	O
best	O
clone	O
was	O
later	O
screened	O
for	O
its	O
applications	O
for	O
immunocytochemistry	O
and	O
flow	O
cytometry	O
using	O
various	O
cell	O
lines	O
.	O

Human	O
peripheral	O
blood	O
platelets	O
were	O
used	O
for	O
screening	O
mouse	O
anti	O
-	O
human	O
CD9	O
antibody	O
.	O

MCF-7	B
cells	O
were	O
used	O
for	O
screening	O
mouse	O
anti	O
-	O
human	O
E	O
-	O
Cadherin	O
and	O
PODXL	O
(	O
podocalyxin	O
-	O
like	O
)	O
antibodies	O
.	O

MG-63	B
cells	O
were	O
used	O
for	O
screening	O
mouse	O
anti	O
-	O
human	O
GATA1	O
(	O
GATA	O
binding	O
protein	O
1	O
)	O
antibody	O
.	O

Beta	B
-	I
TC6	I
cells	O
were	O
used	O
for	O
screening	O
for	O
mouse	O
anti	O
-	O
human	O
/	O
mouse	O
PDX-1	O
(	O
pancreatic	O
duodenal	O
homeobox-1	O
)	O
antibody	O
.	O

NTERA-2	B
cells	O
were	O
used	O
for	O
screening	O
mouse	O
anti	O
-	O
human	O
Oct3	O
/	O
4	O
and	O
SOX2	O
(	O
sex	O
-	O
determining	O
region	O
Y	O
-	O
box	O
2	O
)	O
antibodies	O
.	O

All	O
polyclonal	O
antibodies	O
were	O
affinity	O
-	O
purified	O
using	O
recombinant	O
proteins	O
and	O
validated	O
by	O
direct	O
ELISAs	O
and	O
Western	O
.	O

Caco-2	B
cells	O
were	O
used	O
for	O
validation	O
of	O
goat	O
anti	O
-	O
human	O
GATA6	O
antibody	O
and	O
NTERA-2	B
cells	O
were	O
used	O
for	O
validation	O
of	O
goat	O
anti	O
-	O
human	O
Nanog	O
and	O
anti	O
-	O
human	O
Oct3	O
/	O
4	O
antibodies	O
(	O
Summarized	O
in	O
Table	O
1	O
)	O
.Table	O
1Summary	O
list	O
of	O
antibody	O
verification	O
by	O
western	O
blot	O
.	O

AntibodySample	O
used	O
for	O
analysisMol	O
.	O

Wt	O
.	O

(	O
KD	O
)	O
Gt	O
×	O
hBrachyurymouse	O
ES	O
-	O
derived	O
EB	O
lysate48Ms	O
×	O
hDPPA5N	O
/	O
AN	O
/	O
AGt	O
×	O
hGATA6Caco2	O
cell	B
lysate65Gt	O
×	O
hNanogNTERA-2	O
cell	O
lysate33Gt	O
×	O
hOct	O
3	O
/	O
4NTERA-2	O
cell	O
lysate39Gt	O
×	O
hPDX1beta	O
-	B
TC	I
6	I
cell	O
lysate32Gt	O
×	O
hSOX17mouse	O
ES	O
-	O
derived	O
EB	O
lysate45Ms	O
×	O
hCD9PBMC25Rt	O
×	O
hGATA-1N	O
/	O
AN	O
/	O
AMs	O
×	O
hE	O
-	O
CadherinMCF-7	O
cell	B
lysate97Ms	O
×	O
hPODXLMCF-7	O
cell	B
lysate57Ms	O
×	O
hSOX2NTERA-2	O
cell	O
lysate36N	O
/	O
A	O
:	O
1	O
.	O

DPPA5	O
is	O
still	O
being	O
subcloned	O
.	O

Only	O
Elisa	O
verification	O
is	O
available.2	O
.	O

The	O
clone	O
for	O
GATA-1	O
(	O
MAB1779	O
)	O
does	O
not	O
work	O
for	O
Western	O
blot	O
application	O
but	O
is	O
useful	O
for	O
IHC	O
,	O
The	O
clone	O
picked	O
for	O
Western	O
blot	O
analysis	O
does	O
not	O
work	O
for	O
IHC	O
(	O
MAB17791	O
,	O
see	O
data	O
in	O
)	O
.After	O

antibodies	O
were	O
validated	O
in	O
direct	O
ELISAs	O
,	O
Western	O
blot	O
or	O
cell	O
lines	O
(	O
Fig.	O
1	O
and	O
data	O
not	O
shown	O
)	O
,	O
they	O
were	O
used	O
to	O
examine	O
the	O
expression	O
of	O
individual	O
molecules	O
in	O
undifferentiated	O
human	O
ES	O
cells	O
and	O
differentiated	O
EBs	O
.	O

When	O
examined	O
by	O
immunohistochemistry	O
,	O
high	O
level	O
of	O
expressions	O
of	O
Oct3	O
/	O
4	O
,	O
SOX2	O
,	O
E	O
-	O
Cadherin	O
,	O
PODXL	O
and	O
Nanog	O
were	O
observed	O
in	O
undifferentiated	O
human	O
ES	O
cells	O
(	O
Fig.	O
2A	O
,	O
2B	O
and	O
2C	O
)	O
.	O

DPPA5	O
(	O
developmental	O
pluripotency	O
associated	O
5	O
)	O
expression	O
was	O
also	O
observed	O
in	O
undifferentiated	O
human	O
ES	O
cells	O
(	O
data	O
not	O
shown	O
)	O
.	O

We	O
noted	O
that	O
a	O
subset	O
of	O
the	O
proteins	O
used	O
were	O
membrane	O
bound	O
proteins	O
.	O

To	O
test	O
if	O
any	O
of	O
the	O
antibodies	O
generated	O
could	O
recognize	O
an	O
extracellular	O
epitope	O
and	O
thus	O
be	O
used	O
for	O
live	O
cell	O
sorting	O
,	O
we	O
repeated	O
staining	O
of	O
live	O
cells	O
as	O
previously	O
described	O
.	O

The	O
CD9	O
,	O
E	O
-	O
Cadherin	O
and	O
PODXL	O
antibodies	O
recognized	O
an	O
extracellular	O
epitope	O
and	O
their	O
ability	O
to	O
select	O
cells	O
by	O
FACS	O
was	O
confirmed	O
(	O
Fig.	O
3	O
)	O
.	O

Minimal	O
or	O
no	O
expressions	O
of	O
Oct3	O
/	O
4	O
,	O
E	O
-	O
Cadherin	O
,	O
PODXL	O
and	O
Nanog	O
were	O
detected	O
in	O
the	O
differentiated	O
EBs	O
(	O
Fig.	O
2D	O
,	O
2E	O
and	O
2F	O
)	O
.	O

However	O
,	O
SOX2	O
expression	O
,	O
which	O
is	O
observed	O
in	O
neural	O
progenitor	O
cells	O
,	O
is	O
persistent	O
in	O
subsets	O
of	O
EBs	O
.	O

Figure	O
1Western	O
blot	O
analysis	O
for	O
Gt	O
×	O
hOct3	O
/	O
4	O
(	O
A	O
)	O
,	O
Gt	O
×	O
hNanog	O
(	O
B	O
)	O
and	O
Ms	O
×	O
hSOX2	O
(	O
C	O
)	O
in	O
NTERA-2	B
cell	O
lysate	O
,	O
Ms	O
×	O
hE	O
-	O
Cadherin	O
(	O
D	O
)	O
in	O
MCF-7	B
cell	O
lysate	O
,	O
Ms	O
×	O
hCD9	O
(	O
E	O
)	O
in	O
PBMC	O
lysate	O
and	O
Ms	O
×	O
hPDX-1	O
(	O
F	O
)	O
in	O
β	B
-	I
TC-6	I
cell	B
lysate	O
.	O

Numbers	O
indicate	O
the	O
positions	O
of	O
molecular	O
weight	O
markers	O
.	O

Figure	O
2Undifferentiated	O
human	O
ES	O
cells	O
(	O
A	O
,	O
B	O
,	O
and	O
C	O
)	O
and	O
differentiated	O
EBs	O
(	O
D	O
,	O
E	O
and	O
F	O
)	O
were	O
analyzed	O
using	O
antibodies	O
to	O
indicated	O
molecular	O
markers	O
.	O

Immunostaining	O
with	O
goat	O
anti	O
-	O
human	O
Oct3	O
/	O
4	O
(	O
Red	O
in	O
A	O
and	O
D	O
)	O
,	O
mouse	O
anti	O
-	O
human	O
SOX2	O
(	O
Green	O
in	O
A	O
and	O
D	O
)	O
,	O
goat	O
anti	O
-	O
human	O
E	O
-	O
Cadherin	O
(	O
Red	O
in	O
B	O
and	O
E	O
)	O
,	O
mouse	O
anti	O
-	O
human	O
PODXL	O
(	O
Green	O
in	O
B	O
and	O
E	O
)	O
,	O
and	O
goat	O
anti	O
-	O
human	O
Nanog	O
(	O
Red	O
in	O
C	O
and	O
F	O
)	O
,	O
are	O
contrasted	O
with	O
DAPI	O
nuclear	O
staining	O
(	O
Blue	O
in	O
C	O
-	O
F	O
)	O
.	O

Note	O
the	O
dramatic	O
downregulation	O
of	O
ESC	O
specific	O
markers	O
(	O
Oct3	O
/	O
4	O
,	O
E	O
-	O
Cadherin	O
,	O
PODXL	O
,	O
and	O
Nanog	O
)	O
in	O
EBs	O
.	O

However	O
,	O
SOX2	O
expression	O
is	O
persistent	O
in	O
subsets	O
of	O
EB	O
cells	O
.	O

Scale	O
bars	O
=	O
100	O
μm	O
.	O

Figure	O
3Human	O
embryonic	O
stem	O
cells	O
stained	O
with	O
anti	O
-	O
CD9	O
(	O
A	O
)	O
,	O
anti	O
-	O
E	O
-	O
Cadherin	O
(	O
B	O
)	O
,	O
and	O
anti	O
-	O
PODXL	O
(	O
C	O
)	O
and	O
antigen	O
expression	O
detected	O
by	O
a	O
flow	O
cytometer	O
.	O

The	O
specific	O
staining	O
is	O
indicated	O
by	O
green	O
histogram	O
and	O
corresponding	O
isotype	O
control	O
is	O
indicated	O
by	O
black	O
histogram	O
.	O

Suspension	O
culture	O
with	O
FGF	O
withdrawal	O
is	O
known	O
to	O
induce	O
differentiation	O
of	O
ES	O
cells	O
to	O
all	O
three	O
germ	O
layer	O
precursors	O
[	O
12	O
]	O
.	O

The	O
differentiation	O
status	O
of	O
the	O
EB	O
used	O
here	O
was	O
detected	O
to	O
contain	O
all	O
germ	O
cell	O
markers	O
by	O
RT	O
-	O
PCR	O
(	O
Fig.	O
4	O
)	O
.	O

In	O
order	O
to	O
examine	O
how	O
more	O
antibodies	O
can	O
be	O
used	O
for	O
characterization	O
of	O
early	O
differentiation	O
events	O
from	O
human	O
ES	O
cells	O
,	O
we	O
examined	O
the	O
expressions	O
of	O
endodermal	O
markers	O
,	O
SOX17	O
,	O
GATA6	O
and	O
PDX-1	O
,	O
and	O
mesodermal	O
markers	O
,	O
Brachyury	O
and	O
GATA1	O
,	O
in	O
the	O
undifferentiated	O
human	O
ES	O
cells	O
and	O
differentiated	O
EBs	O
.	O

Expressions	O
of	O
SOX17	O
,	O
GATA6	O
,	O
PDX-1	O
,	O
Brachyury	O
and	O
GATA1	O
were	O
not	O
detected	O
in	O
undifferentiated	O
human	O
ES	O
cells	O
(	O
data	O
not	O
shown	O
)	O
.	O

In	O
contrast	O
to	O
the	O
undifferentiated	O
ES	O
cells	O
,	O
subpopulations	O
of	O
SOX17-	O
,	O
GATA6-	O
,	O
Brachyury-	O
and	O
GATA1-positive	O
cells	O
were	O
observed	O
(	O
Fig	O
4	O
)	O
.	O

These	O
results	O
suggest	O
that	O
both	O
endodermal	O
and	O
mesodermal	O
precursors	O
exist	O
in	O
EBs	O
with	O
FGF	O
withdrawal	O
for	O
8	O
days	O
.	O

However	O
,	O
no	O
PDX-1-positive	O
cells	O
were	O
seen	O
in	O
EBs	O
differentiated	O
with	O
the	O
same	O
treatment	O
(	O
data	O
not	O
shown	O
)	O
.Figure	O
4Differentiated	O
EBs	O
were	O
analyzed	O
by	O
either	O
immunocytochemistry	O
or	O
RT	O
-	O
PCR	O
to	O
the	O
indicated	O
molecular	O
markers	O
.	O

(	O
A	O
)	O
Immunostaining	O
with	O
goat	O
anti	O
-	O
human	O
SOX17	O
(	O
Red	O
)	O
,	O
is	O
contrasted	O
with	O
Fluoro	O
Nissl	O
nuclear	O
staining	O
(	O
Green	O
)	O
.	O

(	O
B	O
)	O
Immunostaining	O
with	O
goat	O
anti	O
-	O
human	O
GATA6	O
(	O
Red	O
)	O
,	O
is	O
contrasted	O
with	O
DAPI	O
nuclear	O
staining	O
(	O
Blue	O
)	O
.	O

(	O
C	O
)	O
Immunostaining	O
with	O
goat	O
anti	O
-	O
human	O
brachyury	O
(	O
Red	O
)	O
,	O
is	O
contrasted	O
with	O
DAPI	O
nuclear	O
staining	O
(	O
Blue	O
)	O
.	O

(	O
D	O
)	O
Immunostaining	O
with	O
mouse	O
anti	O
-	O
human	O
GATA1	O
(	O
Red	O
)	O
.	O

Note	O
that	O
each	O
antibody	O
recognizes	O
subsets	O
of	O
EB	O
cells	O
.	O

Scale	O
bars	O
=	O
100	O
μm	O
.	O

(	O
E	O
)	O
The	O
differentiation	O
status	O
of	O
EB	O
is	O
detected	O
by	O
RT	O
-	O
PCR	O
using	O
different	O
germ	O
layer	O
cell	O
markers	O
.	O

Selected	O
endoderm	O
markers	O
AFP	O
,	O
FoxA2	O
;	O
mesoderm	O
markers	O
Hand1	O
,	O
MSX1	O
and	O
ectoderm	O
marker	O
Msl1	O
were	O
all	O
highly	O
expressed	O
in	O
the	O
EB	O
samples	O
while	O
their	O
expression	O
was	O
either	O
undetectable	O
or	O
at	O
low	O
level	O
in	O
the	O
ES	O
samples	O
.	O

G3PDH	O
was	O
a	O
positive	O
control	O
showing	O
similar	O
amount	O
of	O
RNA	O
samples	O
were	O
used	O
for	O
analysis	O
.	O

Examination	O
of	O
cross	O
-	O
reactivity	O
of	O
antibodies	O
on	O
mouse	O
ES	O
and	O
differentiated	O
cellsWe	O
have	O
also	O
examined	O
the	O
cross	O
-	O
reactivities	O
of	O
these	O
antibodies	O
to	O
mouse	O
ES	O
cells	O
using	O
mouse	O
D3	B
ES	O
cell	O
line	O
and	O
mouse	O
fetal	O
endodermal	O
tissue	O
.	O

Cross	O
-	O
reactivity	O
to	O
mouse	O
of	O
goat	O
anti	O
-	O
Oct3	O
/	O
4	O
,	O
goat	O
anti	O
-	O
PDX-1	O
,	O
goat	O
anti	O
-	O
SOX17	O
and	O
mouse	O
anti	O
-	O
SOX2	O
was	O
detected	O
.	O

Minimal	O
cross	O
-	O
reactivity	O
to	O
mouse	O
,	O
measured	O
by	O
10	O
%	O
intensity	O
to	O
human	O
by	O
higher	O
than	O
control	O
cells	O
,	O
was	O
observed	O
in	O
mouse	O
anti	O
-	O
CD9	O
and	O
mouse	O
anti	O
-	O
E	O
-	O
cadherin	O
antibodies	O
.	O

Goat	O
anti	O
-	O
Nanog	O
and	O
mouse	O
anti	O
-	O
PODXL	O
antibodies	O
appear	O
to	O
be	O
human	O
-	O
specific	O
as	O
well	O
(	O
data	O
not	O
shown	O
)	O
.	O

The	O
subtypes	O
of	O
monoclonal	O
antibodies	O
were	O
also	O
identified	O
in	O
the	O
best	O
clones	O
.	O

These	O
results	O
are	O
summarized	O
in	O
Table	O
2.Table	O
2Summary	O
of	O
antibodies	O
detection	O
in	O
ES	O
and	O
EB	O
samples	O
.	O

AntibodyESEBReactivity	O
to	O
mouseIsotype	O
of	O
monoclonal	O
antibody	O
(	O
Clone	O
No.	O
)	O
Gt	O
×	O
hBrachyuryNoYesNT*Ms	O
×	O
hDPPA5YesNT*NT*ND*Gt	O
×	O
hGATA6NoYesNT*Gt	O
×	O
hNanogYesDownNoGt	O
×	O
hOct	O
3	O
/	O
4YesDownYesGt	O
×	O
hPDX-1NoNoYesGt	O
×	O
hSOX17NoYesYesMs	O
×	O
hCD9YesNoMinimalMouse	O
IgG2B	O
(	O
clone	O
209306	O
)	O
Ms	O
×	O
hE	O
-	O
cadherinYesNoMinimalMouse	O
IgG2B	O
(	O
clone	O
180224	O
)	O
Ms	O
×	O
hGATA1NoYesNT*Rat	O
IgG2B	O
(	O
clone	O
234732	O
)	O
Ms	O
×	O
hPODXLYesNoNoMouse	O
IgG2A	O
(	O
clone	O
222328	O
)	O
Ms	O
×	O
hSOX2YesYesYesMouse	O
IgG2A	O
(	O
clone	O
245610	O
)	O
*NT	O
,	O
Not	O
tested	O
;	O
ND	O
,	O
Not	O
determined	O
.	O

The	O
expression	O
patterns	O
detected	O
using	O
antibodies	O
developed	O
in	O
our	O
facility	O
are	O
consistent	O
with	O
data	O
reported	O
using	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
or	O
cDNA	O
microarrays	O
.	O

Moreover	O
several	O
of	O
the	O
monoclonal	O
antibodies	O
have	O
differing	O
heavy	O
chain	O
subunits	O
allowing	O
double	O
labeling	O
using	O
subtype	O
specific	O
markers	O
to	O
be	O
performed	O
.	O

In	O
summary	O
,	O
we	O
have	O
developed	O
a	O
useful	O
collection	O
of	O
antibodies	O
that	O
would	O
be	O
useful	O
for	O
identification	O
of	O
stem	O
cell	O
characteristics	O
and	O
assessment	O
of	O
differentiation	O
.	O

Several	O
additional	O
antibodies	O
to	O
the	O
molecules	O
that	O
have	O
been	O
identified	O
as	O
potential	O
cell	O
lineage	O
markers	O
[	O
13	O
]	O
are	O
currently	O
under	O
development	O
using	O
the	O
same	O
approach	O
.	O

Cloning	O
and	O
expression	O
of	O
Brachyury	O
,	O
DPPA5	O
,	O
CD9	O
,	O
E	O
-	O
Cadherin	O
,	O
GATA1	O
,	O
GATA6	O
,	O
Nanog	O
,	O
Oct3	O
/	O
4	O
,	O
PDX-1	O
,	O
PODXL	O
,	O
SOX2	O
and	O
SOX17Brachyury	O
(	O
aa	O
.	O

1–202	O
)	O
,	O
DPPA5	O
(	O
a.a	O
.	O

1–116	O
)	O
,	O
GATA1	O
(	O
a.a	O
.	O
1–413	O
)	O
,	O
GATA6	O
(	O
aa	O
.	O

1–449	O
)	O
,	O
Nanog	O
(	O
aa	O
.	O

153–305	O
)	O
,	O
Oct3	O
/	O
4	O
(	O
aa	O
.	O
1–265	O
)	O
,	O
PDX-1	O
(	O
aa	O
.	O

1–283	O
)	O
,	O
SOX2	O
(	O
aa	O
.	O
135–317	O
)	O
and	O
SOX17	O
(	O
aa	O
.	O
177–414	O
)	O
were	O
expressed	O
in	O
E.	O
Coli	O
and	O
extracellular	O
domains	O
of	O
CD9	O
,	O
E	O
-	O
Cadherin	O
,	O
PODXL	O
were	O
expressed	O
in	O
mouse	O
NSO	O
cells	O
.	O

All	O
proteins	O
were	O
purified	O
and	O
sequenced	O
before	O
they	O
were	O
used	O
as	O
antigens	O
for	O
immunizations	O
and	O
as	O
substrate	O
for	O
antibody	O
screening	O
and	O
subcloning	O
.	O

Production	O
and	O
purification	O
of	O
antibodiesAll	O
monoclonal	O
antibodies	O
were	O
derived	O
from	O
fusions	O
of	O
mouse	O
myeloma	O
with	O
B	O
cells	O
obtained	O
from	O
BALB	O
/	O
c	O
mice	O
which	O
had	O
been	O
immunized	O
with	O
purified	O
antigen	O
.	O

The	O
IgG	O
fraction	O
of	O
the	O
culture	O
supernatant	O
was	O
purified	O
by	O
Protein	O
G	O
affinity	O
chromatography	O
(	O
Sigma	O
)	O
.	O

Each	O
panel	O
of	O
antibodies	O
was	O
screened	O
and	O
selected	O
for	O
their	O
abilities	O
to	O
detect	O
purified	O
recombinant	O
antigen	O
in	O
direct	O
ELISA	O
and	O
Western	O
blot	O
.	O

All	O
polyclonal	O
antibodies	O
were	O
derived	O
from	O
sera	O
of	O
goats	O
which	O
had	O
been	O
immunized	O
and	O
boost	O
it	O
with	O
purified	O
antigen	O
.	O

Antibody	O
was	O
purified	O
from	O
the	O
sera	O
by	O
an	O
antigen	O
-	O
affinity	O
chromatography	O
.	O

Cells	O
and	O
cell	O
cultureHuman	O
Caco-2	B
,	O
MG-63	B
,	O
MCF-7	B
,	O
NTERA-2	B
and	O
mouse	O
D3	B
cells	O
were	O
purchased	O
from	O
American	O
Type	O
Culture	O
Collection	O
(	O
ATCC	O
)	O
.	O

Cells	O
were	O
cultured	O
according	O
to	O
the	O
ATCC	O
instructions	O
.	O

Information	O
regarding	O
human	O
ES	O
cell	O
line	O
HSF-6	B
(	O
NIH	O
code	O
UC06	B
)	O
can	O
be	O
obtained	O
at	O
the	O
website	O
[	O
14	O
]	O
.	O

Undifferentiated	O
human	O
ES	O
cells	O
were	O
cultured	O
according	O
to	O
the	O
protocol	O
provided	O
by	O
the	O
University	O
of	O
California	O
,	O
San	O
Francisco	O
in	O
human	O
ES	O
culture	O
medium	O
[	O
DMEM	O
supplemented	O
with	O
20	O
%	O
KnockOut	O
Serum	O
Replacement	O
(	O
Invitrogen	O
)	O
and	O
5	O
ng	O
/	O
mL	O
of	O
bFGF	O
(	O
R&D	O
Systems	O
)	O
]	O
.	O

To	O
induce	O
formation	O
of	O
embryoid	O
bodies	O
(	O
EBs	O
)	O
,	O
ES	O
colonies	O
were	O
harvested	O
,	O
separated	O
from	O
the	O
MEF	O
feeder	O
cells	O
by	O
gravity	O
,	O
gently	O
resuspended	O
in	O
ES	O
culture	O
medium	O
and	O
transferred	O
to	O
non	O
-	O
adherent	O
suspension	O
culture	O
dishes	O
(	O
Corning	O
)	O
.	O

Unless	O
otherwise	O
noted	O
,	O
EBs	O
derived	O
from	O
human	O
ES	O
cell	O
aggregates	O
were	O
cultured	O
for	O
8	O
days	O
in	O
ES	O
culture	O
medium	O
deprived	O
of	O
bFGF	O
and	O
used	O
for	O
analysis	O
by	O
immunohistochemistry	O
as	O
described	O
.	O

Western	O
blotCells	O
are	O
solubilized	O
in	O
hot	O
2	O
×	O
SDS	O
gel	O
sample	O
buffer	O
(	O
20	O
mM	O
dithiothreitol	O
,	O
6	O
%	O
SDS	O
,	O
0.25	O
M	O
Tris	O
,	O
pH	O
6.8	O
,	O
10	O
%	O
glycerol	O
,	O
10	O
mM	O
NaF	O
and	O
bromophenyl	O
blue	O
)	O
at	O
2	O
×	O
106	O
per	O
mL.	O
The	O
extracts	O
are	O
heated	O
in	O
a	O
boiling	O
water	O
bath	O
for	O
5	O
minutes	O
and	O
sonicated	O
with	O
a	O
probe	O
sonicator	O
with	O
3–4	O
bursts	O
of	O
5–10	O
seconds	O
each	O
.	O

Samples	O
are	O
diluted	O
with	O
1	O
×	O
SDS	O
sample	O
buffer	O
to	O
the	O
desired	O
loading	O
of	O
1–5	O
×	O
103	O
per	O
lane	O
.	O

Lysates	O
were	O
resolved	O
by	O
SDS	O
-	O
PAGE	O
,	O
transferred	O
to	O
Immobilon	O
-	O
P	O
membrane	O
,	O
and	O
immunoblotted	O
with	O
0.5	O
μg	O
/	O
mL	O
primary	O
Abs	O
as	O
described	O
in	O
R&D	O
Systems	O
Website	O
[	O
15	O
]	O
.	O

ImmunohistochemistryAntibodies	O
were	O
used	O
with	O
the	O
appropriate	O
secondary	O
reagents	O
at	O
a	O
concentration	O
of	O
5	O
to	O
10	O
μg	O
/	O
ml	O
.	O

Cells	O
or	O
sections	O
of	O
EBs	O
were	O
fixed	O
with	O
4	O
%	O
paraformaldehyde	O
in	O
PBS	O
at	O
room	O
temperature	O
for	O
20	O
min	O
,	O
then	O
blocked	O
and	O
permeabilized	O
with	O
0.1	O
%	O
Triton	O
X-100	O
,	O
1	O
%	O
BSA	O
,	O
10	O
%	O
normal	O
donkey	O
serum	O
in	O
PBS	O
at	O
room	O
temperature	O
for	O
45	O
min	O
.	O

After	O
blocking	O
,	O
cells	O
were	O
incubated	O
with	O
diluted	O
primary	O
antibody	O
overnight	O
at	O
4	O
°	O
C	O
followed	O
by	O
coupled	O
anti	O
-	O
mouse	O
or	O
anti	O
-	O
goat	O
IgG	O
(	O
Molecular	O
Probes	O
)	O
at	O
room	O
temperature	O
in	O
the	O
dark	O
for	O
an	O
hour	O
.	O

Between	O
each	O
step	O
cells	O
were	O
washed	O
with	O
PBS	O
with	O
0.1	O
%	O
BSA	O
.	O

RT	O
-	O
PCRTotal	O
RNA	O
was	O
extracted	O
from	O
EBs	O
using	O
Trizol	O
LS	O
(	O
Invitrogen	O
)	O
.	O

cDNA	O
was	O
synthesized	O
by	O
using	O
Superscript	O
II	O
reverse	O
transcriptase	O
(	O
Invitrogen	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
recommendations	O
.	O

The	O
PCR	O
primers	O
are	O
available	O
upon	O
request	O
.	O

Flow	O
cytometryAntibodies	O
were	O
prepared	O
at	O
the	O
concentration	O
of	O
0.1	O
mg	O
/	O
mL.	O
10	O
μL	O
of	O
the	O
stock	O
solution	O
was	O
added	O
to	O
1	O
–	O
2.5	O
×	O
105	O
cells	O
in	O
a	O
total	O
reaction	O
volume	O
not	O
exceeding	O
200	O
μL.	O
The	O
sample	O
was	O
then	O
incubated	O
for	O
20	O
min	O
at	O
2–8	O
°	O
C	O
.	O

Following	O
incubation	O
,	O
excess	O
antibody	O
was	O
removed	O
by	O
washing	O
cells	O
twice	O
with	O
FACS	O
buffer	O
(	O
2	O
%	O
FCS	O
and	O
0.1	O
%	O
sodium	O
azide	O
in	O
Hank	O
's	O
buffer	O
)	O
.	O

After	O
wash	O
,	O
cells	O
were	O
resuspend	O
in	O
200	O
μL	O
of	O
FACS	O
buffer	O
and	O
the	O
binding	O
of	O
unlabeled	O
monoclonal	O
antibodies	O
was	O
visualized	O
by	O
adding	O
10	O
μL	O
of	O
a	O
25	O
μg	O
/	O
mL	O
stock	O
solution	O
of	O
a	O
secondary	O
developing	O
reagent	O
such	O
as	O
goat	O
anti	O
-	O
mouse	O
IgG	O
conjugated	O
to	O
a	O
fluorochrome	O
for	O
20	O
min	O
at	O
2–8	O
°	O
C	O
.	O

Following	O
incubation	O
,	O
cells	O
were	O
washed	O
once	O
with	O
FACS	O
buffer	O
,	O
once	O
with	O
PBS	O
.	O

After	O
wash	O
,	O
cells	O
were	O
resuspend	O
in	O
400	O
μL	O
of	O
PBS	O
and	O
analyzed	O
on	O
a	O
FACScant	O
flow	O
cytometer	O
(	O
Becton	O
-	O
Dickinson	O
,	O
Mountain	O
View	O
,	O
CA	O
)	O
.	O

Five	O
thousand	O
events	O
were	O
collected	O
and	O
analyzed	O
using	O
CELL	O
Quest	O
software	O
.	O

BackgroundIn	O
order	O
to	O
compare	O
the	O
gene	O
expression	O
profiles	O
of	O
human	O
embryonic	O
stem	O
cell	O
(	O
hESC	O
)	O
lines	O
and	O
their	O
differentiated	O
progeny	O
and	O
to	O
monitor	O
feeder	O
contaminations	O
,	O
we	O
have	O
examined	O
gene	O
expression	O
in	O
seven	O
hESC	O
lines	O
and	O
human	O
fibroblast	O
feeder	O
cells	O
using	O
Illumina	O
®	O
bead	O
arrays	O
that	O
contain	O
probes	O
for	O
24,131	O
transcript	O
probes	O
.	O

ResultsA	O
total	O
of	O
48	O
different	O
samples	O
(	O
including	O
duplicates	O
)	O
grown	O
in	O
multiple	O
laboratories	O
under	O
different	O
conditions	O
were	O
analyzed	O
and	O
pairwise	O
comparisons	O
were	O
performed	O
in	O
all	O
groups	O
.	O

Hierarchical	O
clustering	O
showed	O
that	O
blinded	O
duplicates	O
were	O
correctly	O
identified	O
as	O
the	O
closest	O
related	O
samples	O
.	O

hESC	O
lines	O
clustered	O
together	O
irrespective	O
of	O
the	O
laboratory	O
in	O
which	O
they	O
were	O
maintained	O
.	O

hESCs	O
could	O
be	O
readily	O
distinguished	O
from	O
embryoid	O
bodies	O
(	O
EB	O
)	O
differentiated	O
from	O
them	O
and	O
the	O
karyotypically	O
abnormal	O
hESC	O
line	O
BG01V	B
.	O

The	O
embryonal	O
carcinoma	O
(	O
EC	O
)	O
line	O
NTera2	B
is	O
a	O
useful	O
model	O
for	O
evaluating	O
characteristics	O
of	O
hESCs	O
.	O

Expression	O
of	O
subsets	O
of	O
individual	O
genes	O
was	O
validated	O
by	O
comparing	O
with	O
published	O
databases	O
,	O
MPSS	O
(	O
Massively	O
Parallel	O
Signature	O
Sequencing	O
)	O
libraries	O
,	O
and	O
parallel	O
analysis	O
by	O
microarray	O
and	O
RT	O
-	O
PCR.Conclusionwe	O
show	O
that	O
Illumina	O
's	O
bead	O
array	O
platform	O
is	O
a	O
reliable	O
,	O
reproducible	O
and	O
robust	O
method	O
for	O
developing	O
base	O
global	O
profiles	O
of	O
cells	O
and	O
identifying	O
similarities	O
and	O
differences	O
in	O
large	O
number	O
of	O
samples	O
.	O

Embryonic	O
stem	O
cells	O
(	O
ESCs	O
)	O
,	O
derived	O
from	O
the	O
inner	O
cell	O
mass	O
of	O
pre	O
-	O
implantation	O
embryos	O
,	O
have	O
been	O
recognized	O
as	O
the	O
most	O
pluripotent	O
stem	O
cell	O
population	O
.	O

Human	O
ES	O
cells	O
(	O
hESCs	O
)	O
can	O
be	O
maintained	O
and	O
propagated	O
on	O
mouse	O
or	O
human	O
fibroblast	O
feeders	O
for	O
extended	O
periods	O
in	O
media	O
containing	O
basic	O
fibroblast	O
growth	O
factor	O
(	O
bFGF	O
)	O
[	O
1	O
-	O
4	O
]	O
while	O
retaining	O
the	O
ability	O
to	O
differentiate	O
into	O
ectoderm	O
,	O
endoderm	O
and	O
mesoderm	O
as	O
well	O
as	O
trophoectoderm	O
and	O
germ	O
cells	O
.	O

Gene	O
expression	O
in	O
hESC	O
has	O
been	O
investigated	O
by	O
a	O
variety	O
of	O
techniques	O
including	O
massively	O
parallel	O
signature	O
sequencing	O
(	O
MPSS	O
)	O
,	O
serial	O
analysis	O
of	O
gene	O
expression	O
(	O
SAGE	O
)	O
,	O
expressed	O
sequence	O
tag	O
(	O
EST	O
)	O
scan	O
,	O
large	O
scale	O
microarrays	O
,	O
focused	O
cDNA	O
microarrays	O
,	O
and	O
immunocytochemistry	O
[	O
5	O
-	O
7	O
]	O
.	O

Markers	O
for	O
hESCs	O
that	O
may	O
also	O
contribute	O
to	O
the	O
""""	O
stemness	O
""""	O
phenotype	O
have	O
been	O
established	O
and	O
markers	O
that	O
distinguish	O
ESCs	O
from	O
embryoid	O
bodies	O
(	O
EB	O
)	O
have	O
been	O
developed	O
.	O

Novel	O
stage	O
-	O
specific	O
genes	O
that	O
distinguish	O
between	O
hESCs	O
and	O
EBs	O
have	O
been	O
identified	O
and	O
allelic	O
differences	O
between	O
ESC	O
have	O
begun	O
to	O
be	O
recognized	O
[	O
8	O
-	O
10	O
]	O
.	O

As	O
the	O
potential	O
of	O
hESCs	O
and	O
their	O
derivatives	O
for	O
regenerative	O
medicine	O
is	O
being	O
evaluated	O
,	O
it	O
has	O
become	O
clear	O
that	O
the	O
overall	O
state	O
of	O
the	O
cells	O
,	O
degree	O
of	O
contamination	O
and	O
comparisons	O
of	O
the	O
more	O
than	O
a	O
hundred	O
different	O
newly	O
derived	O
lines	O
will	O
need	O
to	O
be	O
performed	O
.	O

It	O
will	O
be	O
necessary	O
to	O
develop	O
methods	O
to	O
monitor	O
and	O
assess	O
hESC	O
and	O
their	O
derivatives	O
on	O
a	O
routine	O
basis	O
.	O

Since	O
differentiated	O
cells	O
are	O
often	O
scattered	O
within	O
or	O
at	O
the	O
edge	O
of	O
colonies	O
[	O
11	O
]	O
and	O
the	O
differentiation	O
is	O
so	O
subtle	O
that	O
morphological	O
characteristics	O
and	O
even	O
immunohistochemistry	O
are	O
insufficient	O
to	O
detect	O
it	O
,	O
larger	O
scale	O
methods	O
of	O
analysis	O
need	O
to	O
be	O
developed	O
.	O

Our	O
strategy	O
was	O
to	O
compare	O
a	O
variety	O
of	O
different	O
hESC	O
lines	O
that	O
were	O
derived	O
and	O
expanded	O
by	O
three	O
different	O
institutions	O
(	O
WiCell	O
Research	O
Institute	O
,	O
BresaGen	O
,	O
Inc.	O
,	O
and	O
Technion	O
-	O
Israel	O
Institute	O
of	O
Technology	O
)	O
,	O
and	O
cultured	O
in	O
two	O
separate	O
laboratories	O
(	O
Burnham	O
Institute	O
and	O
NIA	O
)	O
to	O
a	O
baseline	O
set	O
of	O
data	O
against	O
which	O
cell	O
samples	O
can	O
be	O
compared	O
.	O

By	O
using	O
cells	O
grown	O
in	O
different	O
conditions	O
we	O
expected	O
to	O
be	O
able	O
to	O
identify	O
core	O
commonalities	O
and	O
by	O
comparing	O
feeders	O
and	O
embryoid	O
bodies	O
(	O
EB	O
)	O
with	O
hESC	O
identify	O
measures	O
of	O
contamination	O
and	O
early	O
markers	O
of	O
differentiation	O
.	O

Further	O
,	O
by	O
comparing	O
embryonal	O
carcinoma	O
cell	O
(	O
EC	O
)	O
and	O
karyotypically	O
variant	O
lines	O
with	O
hESC	O
,	O
we	O
would	O
be	O
able	O
to	O
directly	O
assess	O
their	O
utility	O
as	O
surrogates	O
(	O
for	O
quality	O
control	O
purposes	O
)	O
for	O
hESC	O
.	O

We	O
employed	O
a	O
pre	O
-	O
commercial	O
prototype	O
of	O
the	O
Illumina	O
HumanRef-8	O
BeadChip	O
[	O
12	O
]	O
,	O
a	O
genome	O
-	O
scale	O
bead	O
based	O
array	O
technology	O
that	O
combines	O
the	O
sensitivity	O
and	O
low	O
cost	O
of	O
a	O
focused	O
array	O
with	O
the	O
coverage	O
of	O
a	O
large	O
scale	O
array	O
,	O
while	O
requiring	O
much	O
smaller	O
sample	O
sizes	O
than	O
MPSS	O
,	O
EST	O
scan	O
or	O
SAGE	O
.	O

We	O
show	O
that	O
the	O
Illumina	O
bead	O
based	O
array	O
correctly	O
identified	O
blinded	O
duplicates	O
as	O
the	O
closest	O
related	O
samples	O
and	O
readily	O
distinguished	O
between	O
hESC	O
lines	O
,	O
as	O
well	O
as	O
between	O
ESCs	O
and	O
EBs	O
derived	O
from	O
them	O
.	O

This	O
array	O
allowed	O
us	O
to	O
estimate	O
the	O
degree	O
of	O
feeder	O
contamination	O
present	O
in	O
the	O
cultures	O
.	O

Similarities	O
and	O
differences	O
between	O
EC	O
line	O
NTera2	B
and	O
hESC	O
lines	O
could	O
be	O
determined	O
and	O
verified	O
,	O
and	O
the	O
database	O
comparisons	O
allowed	O
us	O
to	O
identify	O
core	O
self	O
-	O
renewal	O
pathways	O
that	O
regulate	O
hESC	O
propagation	O
.	O

Multiple	O
hESC	O
lines	O
can	O
be	O
assessed	O
by	O
Illumina	O
bead	O
arrayForty	O
-	O
eight	O
samples	O
were	O
selected	O
from	O
multiple	O
laboratories	O
and	O
gene	O
expression	O
profiles	O
were	O
examined	O
using	O
a	O
bead	O
array	O
containing	O
24,131	O
transcripts	O
derived	O
from	O
the	O
Human	O
RefSeq	O
database	O
that	O
included	O
full	O
length	O
and	O
splice	O
variants	O
.	O

Each	O
gene	O
was	O
represented	O
by	O
sequences	O
containing	O
an	O
average	O
of	O
thirty	O
beads	O
to	O
provide	O
an	O
internal	O
measure	O
of	O
reliability	O
.	O

Samples	O
included	O
7	O
hESC	O
lines	O
BG01	B
,	O
BG02	B
,	O
BG03	B
,	O
I6	B
,	O
H1	B
,	O
H7	B
and	O
H9	B
,	O
EBs	O
that	O
were	O
differentiated	O
from	O
hESCs	O
of	O
the	O
three	O
BG	O
lines	O
,	O
human	O
fibroblast	O
feeder	O
HS27	B
(	O
ATCC	O
)	O
,	O
hESC	O
-	O
derived	O
fibroblasts	O
,	O
karyotypically	O
abnormal	O
hESC	O
line	O
BG01	B
Variant	I
(	O
BG01V	B
)	O
[	O
13	O
]	O
and	O
EC	O
line	O
NTera2	B
[	O
14	O
]	O
.	O

Samples	O
were	O
blinded	O
and	O
biological	O
and	O
technical	O
repeats	O
were	O
examined	O
at	O
the	O
same	O
time	O
.	O

A	O
single	O
slide	O
contained	O
eight	O
replicates	O
and	O
six	O
such	O
slides	O
were	O
used	O
for	O
the	O
present	O
set	O
of	O
samples	O
.	O

Results	O
were	O
normalized	O
to	O
average	O
following	O
Illumina	O
Beadstudio	O
manual	O
and	O
the	O
quality	O
of	O
each	O
sample	O
was	O
assessed	O
by	O
immunocytochemitsry	O
and	O
RT	O
-	O
PCR	O
prior	O
to	O
subjecting	O
them	O
for	O
analysis	O
(	O
data	O
not	O
shown	O
)	O
.	O

Results	O
from	O
the	O
entire	O
sample	O
set	O
are	O
available	O
for	O
download	O
as	O
an	O
excel	O
spreadsheet	O
(	O
Additional	O
file	O
1	O
)	O
and	O
a	O
CD	O
of	O
the	O
results	O
is	O
available	O
upon	O
request	O
.	O

The	O
total	O
number	O
of	O
genes	O
identified	O
as	O
expressed	O
at	O
>	O
0.99	O
confidence	O
is	O
summarized	O
in	O
Table	O
1	O
.	O

Intensity	O
results	O
are	O
reported	O
in	O
arbitrary	O
units	O
and	O
ranged	O
from	O
10	O
to	O
20,000	O
(	O
a	O
two	O
thousand	O
fold	O
range	O
)	O
.	O

Although	O
the	O
sensitivity	O
of	O
the	O
array	O
has	O
been	O
reported	O
to	O
be	O
high	O
,	O
in	O
the	O
present	O
report	O
we	O
have	O
restricted	O
our	O
analysis	O
to	O
expression	O
of	O
at	O
least	O
100	O
units	O
in	O
any	O
one	O
sample	O
.	O

Using	O
this	O
cutoff	O
,	O
on	O
average	O
cells	O
expressed	O
approximately	O
8,000	O
transcripts	O
(	O
Table	O
1	O
,	O
2	O
)	O
,	O
a	O
number	O
similar	O
to	O
the	O
number	O
detected	O
by	O
SAGE	O
,	O
MPSS	O
and	O
EST	O
analysis	O
[	O
5	O
-	O
7,10,15,16	O
]	O
.	O

As	O
with	O
other	O
analysis	O
,	O
genes	O
with	O
the	O
highest	O
abundance	O
were	O
housekeeping	O
genes	O
,	O
ribosomal	O
genes	O
and	O
structural	O
genes	O
(	O
Table	O
2	O
and	O
Additional	O
file	O
1	O
)	O
.	O

These	O
genes	O
were	O
similar	O
in	O
most	O
samples	O
though	O
relative	O
levels	O
varied	O
.	O

Table	O
1Correlation	O
coefficients	O
of	O
paired	O
samples	O
in	O
this	O
bead	O
array	O
In	O
order	O
to	O
test	O
the	O
reproducibility	O
and	O
reliability	O
of	O
the	O
bead	O
array	O
,	O
duplicate	O
samples	O
of	O
hESC	O
lines	O
H9	B
,	O
I6	B
,	O
and	O
EC	O
line	O
NTera2	B
and	O
human	O
fibroblast	O
feeders	O
(	O
HS27	B
)	O
were	O
run	O
at	O
the	O
same	O
time	O
and	O
correlation	O
coefficients	O
(	O
R2	O
)	O
of	O
duplicates	O
were	O
generated	O
using	O
the	O
entire	O
data	O
of	O
all	O
genes	O
with	O
expression	O
level	O
>	O
0	O
(	O
§	O
)	O
,	O
or	O
genes	O
with	O
detection	O
confidence	O
>	O
0.99	O
(	O
*	O
)	O
,	O
or	O
genes	O
with	O
detection	O
confidence	O
>	O
0.99	O
and	O
expression	O
level	O
>	O
100	O
arbitrary	O
units	O
(	O
#	O
)	O
.	O

Note	O
that	O
the	O
correlation	O
coefficients	O
are	O
in	O
the	O
range	O
of	O
0.9382–0.9761	O
and	O
the	O
number	O
of	O
genes	O
was	O
in	O
the	O
range	O
of	O
10,000–14,000.Duplicate	O
SamplesNo	O
.	O
of	O
all	O
genes	O
(	O
expr.>0	O
)	O
§R2of	O
all	O
genes	O
(	O
expr	O
.	O

>	O
0	O
)	O
No	O
.	O
of	O
genes	O
(	O
>	O
0.99	O
)	O
*R2	O
of	O
genes	O
(	O
>	O
0.99	O
)	O
*No	O
.	O
(	O
>	O
0.99	O
,	O
level>100	O
)	O
#H918,8990.868113,6720.97087,408I619,1390.866312,5700.97616,826NTera219,1620.874114,0360.93827,147Feeder18,1570.872410,6060.97517,021Table	O
2Distribution	O
of	O
genes	O
with	O
expression	O
levels	O
<	O
50	O
and	O
>	O
50–10,000	O
as	O
detected	O
by	O
Illumina	O
bead	O
array	O
in	O
8	O
hESC	O
populations	O
All	O
human	O
ESC	O
samples	O
were	O
hybridized	O
in	O
one	O
experiment	O
and	O
the	O
relative	O
detection	O
levels	O
of	O
genes	O
were	O
binned	O
to	O
obtain	O
a	O
global	O
overview	O
of	O
transcription	O
,	O
approximately	O
8	O
,	O
000	O
genes	O
(	O
~50	O
%	O
)	O
were	O
greater	O
than	O
100	O
arbitrary	O
units	O
.	O

The	O
numbers	O
are	O
similar	O
to	O
results	O
obtained	O
by	O
other	O
large	O
scale	O
analysis	O
such	O
as	O
MPSS.Abundance	O
(	O
relative	O
detection	O
levels	O
)	O
H9H9	B
on	O
human	O
feedersI6BG01BG02BG03BG01VPooled	O
(	O
H1	B
,	O
H7	B
,	O
H9	B
)	O
No.%No.%No.%No.%No.%No.%No.%No.%<502,90921.26,06738.43,55925.34,52830.74,25630.54,70632.24194.35,80334.4>5010,81778.89,74761.610,48474.710,23269.39,69469.59,91567.89,43895.711,08565.6>1008,12659.27,53947.77,40952.87,70352.27,49653.77,43050.87,23073.38,21748.7>5003,07722.42,94718.62,62618.73,06520.82,95021.12,85219.52,85128.92,94117.4>10001,62911.91,62510.31,49010.61,63811.11,58911.41,51710.41,56615.91,5549.2>50002481.82571.62561.82561.72631.92621.82752.82511.5>10000900.7940.61120.8920.61000.71070.71011.0940.6Total	O
No.	O
of	O
genes	O
detected	O
at	O
>	O
0.99	O
confidence13,72615,81414,04314,76013,95014,6219,85716,888One	O
of	O
the	O
advantages	O
of	O
the	O
Illumina	O
arrays	O
is	O
the	O
ability	O
of	O
running	O
multiple	O
samples	O
simultaneously	O
thus	O
allowing	O
multiple	O
pairwise	O
comparisons	O
to	O
be	O
performed	O
readily	O
.	O

To	O
show	O
the	O
similarity	O
of	O
relative	O
gene	O
expression	O
between	O
samples	O
,	O
we	O
have	O
used	O
Illumina	O
Beadstudio	O
and	O
clustering	O
software	O
packages	O
Pcluster	O
[	O
17	O
]	O
and	O
TreeView	O
[	O
18	O
]	O
to	O
generate	O
a	O
heat	O
-	O
map	O
(	O
Figure	O
1	O
)	O
and	O
a	O
dendrogram	O
(	O
Figure	O
2	O
)	O
.	O

Based	O
on	O
their	O
properties	O
,	O
we	O
classified	O
some	O
of	O
our	O
samples	O
into	O
four	O
groups	O
,	O
(	O
A	O
)	O
undifferentiated	O
hESCs	O
(	O
including	O
a	O
sample	O
from	O
karyotypically	O
abnormal	O
variant	O
,	O
designated	O
as	O
""""	O
ES	O
""""	O
,	O
n	O
=	O
11	O
)	O
;	O
(	O
B	O
)	O
differentiated	O
ES	O
cells	O
and	O
EBs	O
(	O
designated	O
as	O
""""	O
EB	O
""""	O
,	O
n	O
=	O
6	O
)	O
;	O
(	O
C	O
)	O
hESC	O
derived	O
neural	O
cells	O
(	O
designated	O
as	O
""""	O
NS	O
""""	O
,	O
n	O
=	O
3	O
)	O
;	O
and	O
(	O
D	O
)	O
hESC	O
derived	O
mesenchyme	O
and	O
human	O
fibroblast	O
feeder	O
cells	O
(	O
designated	O
as	O
""""	O
FB	O
""""	O
,	O
n	O
=	O
5	O
)	O
and	O
these	O
groups	O
were	O
shown	O
in	O
the	O
heat	O
-	O
map	O
.	O

Comparing	O
the	O
overall	O
pattern	O
of	O
expression	O
,	O
we	O
made	O
several	O
important	O
observations	O
:	O
1	O
)	O
Duplicates	O
clustered	O
close	O
to	O
each	O
other	O
and	O
were	O
more	O
related	O
to	O
each	O
other	O
than	O
to	O
any	O
other	O
sample	O
;	O
2	O
)	O
ESCs	O
appeared	O
more	O
similar	O
to	O
each	O
other	O
than	O
to	O
EBs	O
;	O
3	O
)	O
NTera2	B
cells	O
appeared	O
more	O
similar	O
to	O
ESCs	O
while	O
differentiated	O
NTera2	B
and	O
EBs	O
can	O
be	O
readily	O
distinguished	O
from	O
their	O
parent	O
populations	O
(	O
Figure	O
2	O
)	O
;	O
4	O
)	O
BG01V	B
appeared	O
similar	O
to	O
undifferentiated	O
BG01	B
cells	O
;	O
5	O
)	O
In	O
general	O
ESC	O
lines	O
grown	O
in	O
one	O
laboratory	O
appeared	O
more	O
similar	O
than	O
samples	O
grown	O
in	O
other	O
laboratories	O
,	O
suggesting	O
that	O
culture	O
conditions	O
affected	O
gene	O
expression	O
but	O
that	O
this	O
effect	O
was	O
much	O
smaller	O
than	O
the	O
effect	O
of	O
differentiation	O
.	O

Figure	O
1Unsupervised	O
two	O
-	O
way	O
hierarchical	O
cluster	O
analysis	O
of	O
differentially	O
expressed	O
genes	O
illustrated	O
in	O
a	O
heat	O
-	O
map	O
.	O

Each	O
row	O
represents	O
the	O
relative	O
levels	O
of	O
expression	O
of	O
a	O
single	O
gene	O
.	O

Each	O
column	O
represents	O
a	O
sample	O
.	O

The	O
samples	O
include	O
four	O
groups	O
of	O
cells	O
,	O
ES	O
designates	O
11	O
samples	O
of	O
hESCs	O
,	O
EB	O
contains	O
6	O
samples	O
of	O
differentiated	O
ESCs	O
and	O
EBs	O
,	O
NS	O
consists	O
of	O
3	O
hESC	O
derived	O
neural	O
cells	O
and	O
FB	O
is	O
a	O
collection	O
of	O
hESC	O
derived	O
mesenchyme	O
and	O
fibroblasts	O
.	O

High	O
expressions	O
relative	O
to	O
mean	O
are	O
colored	O
red	O
.	O

Low	O
expressions	O
are	O
colored	O
green	O
.	O

Black	O
represents	O
no	O
significant	O
change	O
in	O
expression	O
level	O
between	O
mean	O
and	O
sample	O
.	O

Samples	O
cluster	O
closer	O
within	O
their	O
own	O
group	O
than	O
samples	O
from	O
other	O
groups	O
.	O

Figure	O
2Dendrogram	O
of	O
unsupervised	O
one	O
-	O
way	O
hierarchical	O
clustering	O
analysis	O
of	O
relative	O
expression	O
of	O
genes	O
in	O
selected	O
samples	O
.	O

The	O
clustering	O
analysis	O
was	O
based	O
on	O
the	O
average	O
linkage	O
and	O
Euclidean	O
distances	O
as	O
the	O
similarity	O
metric	O
using	O
differentially	O
expressed	O
genes	O
identified	O
by	O
ANOVA	O
(	O
p	O
<	O
0.05	O
)	O
.	O

hESCs	O
clustered	O
together	O
and	O
BG	O
lines	O
cultured	O
in	O
the	O
same	O
laboratory	O
shared	O
the	O
largest	O
similarities	O
.	O

EBs	O
were	O
separated	O
from	O
hESCs	O
from	O
which	O
they	O
were	O
derived	O
.	O

EC	O
line	O
NTera2	B
and	O
feeder	O
cells	O
can	O
be	O
distinguished	O
from	O
hESCs	O
respectively	O
.	O

The	O
global	O
analysis	O
suggested	O
that	O
the	O
bead	O
arrays	O
used	O
were	O
sufficiently	O
sensitive	O
such	O
that	O
individual	O
subsets	O
of	O
genes	O
could	O
be	O
analyzed	O
,	O
different	O
populations	O
of	O
cells	O
could	O
be	O
readily	O
distinguished	O
and	O
that	O
a	O
subset	O
of	O
candidate	O
genes	O
could	O
be	O
sufficient	O
to	O
distinguish	O
between	O
groups	O
of	O
cells	O
.	O

The	O
comparison	O
across	O
multiple	O
samples	O
will	O
allow	O
a	O
set	O
of	O
core	O
stem	O
cell	O
markers	O
to	O
be	O
identified	O
.	O

In	O
subsequent	O
sections	O
we	O
have	O
performed	O
such	O
analysis	O
.	O

Readers	O
are	O
urged	O
to	O
analyze	O
the	O
expression	O
of	O
desired	O
genes	O
directly	O
as	O
it	O
is	O
impossible	O
to	O
test	O
every	O
gene	O
given	O
the	O
large	O
body	O
of	O
data	O
generated	O
.	O

Comparison	O
between	O
MPSS	O
and	O
Illumina	O
bead	O
array	O
resultsWe	O
have	O
previously	O
used	O
EST	O
scan	O
and	O
MPSS	O
to	O
analyze	O
pooled	O
samples	O
of	O
ESCs	O
and	O
EBs	O
from	O
three	O
different	O
WiCell	O
lines	O
(	O
H1	B
,	O
H7	B
and	O
H9	B
)	O
[	O
5	O
]	O
.	O

Comparison	O
between	O
the	O
two	O
methodologies	O
indicated	O
that	O
while	O
there	O
is	O
good	O
concordance	O
for	O
genes	O
expressed	O
at	O
high	O
levels	O
,	O
this	O
does	O
not	O
hold	O
for	O
genes	O
expressed	O
at	O
lower	O
levels	O
.	O

As	O
a	O
test	O
of	O
the	O
quality	O
of	O
the	O
data	O
generated	O
in	O
these	O
experiments	O
and	O
to	O
evaluate	O
whether	O
comparisons	O
can	O
be	O
made	O
across	O
different	O
methodologies	O
,	O
we	O
re	O
-	O
ran	O
the	O
identical	O
samples	O
on	O
the	O
bead	O
array	O
platform	O
.	O

The	O
complete	O
comparison	O
of	O
gene	O
expression	O
is	O
shown	O
in	O
Additional	O
file	O
2	O
and	O
is	O
summarized	O
in	O
Tables	O
3	O
and	O
Table	O
4	O
.	O

Overall	O
,	O
concordance	O
in	O
Illumina	O
array	O
was	O
better	O
than	O
that	O
evident	O
between	O
EST	O
scan	O
and	O
MPSS	O
datasets	O
[	O
9	O
]	O
,	O
but	O
clearly	O
showed	O
much	O
wider	O
differences	O
than	O
that	O
seen	O
with	O
running	O
duplicates	O
in	O
the	O
same	O
assay	O
format	O
.	O

Nevertheless	O
,	O
this	O
comparison	O
provides	O
an	O
independent	O
verification	O
of	O
the	O
data	O
and	O
suggests	O
that	O
if	O
a	O
sample	O
is	O
detected	O
in	O
more	O
than	O
one	O
large	O
-	O
scale	O
analysis	O
,	O
the	O
reliability	O
of	O
the	O
gene	O
expression	O
detection	O
is	O
high	O
,	O
which	O
also	O
reduces	O
the	O
number	O
of	O
individual	O
genes	O
needed	O
to	O
be	O
verified	O
.	O

Caution	O
should	O
be	O
observed	O
in	O
comparing	O
different	O
samples	O
run	O
on	O
different	O
platforms	O
,	O
especially	O
when	O
there	O
has	O
not	O
been	O
rigorous	O
bioinformatic	O
matching	O
of	O
the	O
source	O
sequences	O
used	O
to	O
identify	O
genes	O
in	O
the	O
platforms	O
.	O

Often	O
genes	O
called	O
by	O
the	O
same	O
symbol	O
originate	O
from	O
different	O
database	O
records	O
,	O
which	O
may	O
originate	O
from	O
different	O
splice	O
variants	O
or	O
contain	O
sequence	O
differences	O
due	O
to	O
polymorphisms	O
or	O
outright	O
error	O
[	O
19	O
]	O
.Table	O
3Expression	O
of	O
hESC	O
specific	O
markers	O
in	O
pooled	O
hESC	O
sample	O
as	O
detected	O
by	O
Illumina	O
bead	O
array	O
The	O
expression	O
of	O
previously	O
identified	O
hESC	O
markers	O
was	O
examined	O
in	O
all	O
hESC	O
samples	O
(	O
the	O
values	O
displayed	O
represent	O
the	O
expression	O
level	O
of	O
pooled	O
H1	B
,	O
H7	B
and	O
H9	B
)	O
.	O

Most	O
of	O
the	O
genes	O
were	O
also	O
identified	O
using	O
Illumina	O
bead	O
array	O
in	O
all	O
8	O
hESC	O
populations	O
in	O
this	O
study	O
(	O
1	O
*	O
)	O
,	O
the	O
gene	O
CER1	O
was	O
detected	O
in	O
all	O
except	O
one	O
duplicate	O
of	O
H9	B
(	O
2	O
*	O
)	O
,	O
Nanog	O
was	O
not	O
detected	O
in	O
all	O
populations	O
(	O
3	O
*	O
)	O
and	O
Sox2	O
,	O
Lin41	O
,	O
NR6A1	O
and	O
FoxD3	O
were	O
not	O
detected	O
in	O
the	O
array	O
although	O
they	O
were	O
present	O
in	O
the	O
chips	O
for	O
hybridization	O
(	O
4*	O
)	O
.AccessionSymbolPooled	O
ES	O
(	O
H1	B
,	O
7	B
,	O
9	B
)	O
CommentsNM_003641.1IFITM188441*NM_020997.2LEFTB6579.61*NM_024674.3LIN283944.11*NM_175849.1DNMT3B33911*NM_003212.1TDGF131691*NM_001769.2CD92930.81*NM_000165.2GJA12404.41*NM_021195.2CLDN62247.21*NM_004360.2CDH11972.91*NM_021127.1PMAIP11601.51*NM_032805.1ZNF2061504.51*NM_003577.1UTF11444.11*XM_050625.2SFRP21353.91*NM_006548.3IMP-212061*NM_152312.2GYLTL1B1066.61*NM_015973.2GAL1043.31*NM_003240.2EBAF944.11*NM_054023.2SCGB3A2890.51*NM_020990.2CKMT1742.41*NM_033668.1ITGB1694.71*NM_003744.3NUMB618.31*NM_007015.1LECT1597.41*NM_021912.2GABRB3482.71*NM_006729.2DIAPH2467.11*NM_000222.1KIT188.91*NM_005454.1CER1151.52*NM_024865.1NANOG56.93*NM_002701.1POU5F1694.41*NM_003106SOX2ND4*NM_006458.2LIN41ND4*NM_001489.3NR6A1ND4*NM_012183FOXD3ND4*Table	O
4Comparison	O
of	O
MPSS	O
and	O
Illumina	O
bead	O
array	O
results	O
The	O
samples	O
were	O
analyzed	O
by	O
MPSS	O
and	O
bead	O
array	O
.	O

The	O
number	O
of	O
genes	O
detected	O
by	O
each	O
method	O
and	O
the	O
degree	O
of	O
overlap	O
is	O
summarized	O
.	O

Note	O
much	O
higher	O
degree	O
of	O
overlap	O
when	O
the	O
top	O
2000	O
hits	O
were	O
compared	O
.	O

*	O
:	O
Most	O
of	O
the	O
genes	O
detected	O
by	O
MPSS	O
were	O
novel	O
genes	O
not	O
included	O
in	O
the	O
bead	O
array	O
.	O

ESNo.%Common	O
in	O
both	O
(	O
Top	O
2000	O
hits	O
)	O
1,62281.1Common	O
in	O
both	O
(	O
All	O
hits	O
)	O
5,07146.0By	O
bead	O
array	O
only3,46231.4By	O
MPSS	O
only	O
*	O
2,50422.7Total11,037100EBNo.%Common	O
in	O
both	O
(	O
All	O
hits	O
)	O
5,16843.1By	O
bead	O
array	O
only4,13134.4By	O
MPSS	O
only	O
*	O
2,69422.5Total11,993100	O
Human	O
feeders	O
and	O
hESCs	O
can	O
be	O
readily	O
distinguished	O
and	O
contamination	O
can	O
be	O
readily	O
assessedFor	O
all	O
samples	O
,	O
we	O
conducted	O
an	O
unsupervised	O
one	O
-	O
way	O
hierarchical	O
clustering	O
analysis	O
.	O

The	O
clustering	O
analysis	O
was	O
based	O
on	O
the	O
average	O
linkage	O
and	O
Euclidean	O
distances	O
as	O
the	O
similarity	O
metric	O
using	O
differentially	O
expressed	O
genes	O
identified	O
by	O
ANOVA	O
(	O
P	O
<	O
0.05	O
)	O
.	O

The	O
analysis	O
revealed	O
the	O
underlying	O
features	O
and	O
variation	O
patterns	O
of	O
gene	O
expression	O
in	O
each	O
cell	O
types	O
.	O

Figure	O
2	O
shows	O
results	O
of	O
the	O
cluster	O
analysis	O
of	O
relative	O
gene	O
expression	O
in	O
selected	O
samples	O
.	O

As	O
one	O
of	O
our	O
purposes	O
of	O
this	O
study	O
was	O
to	O
distinguish	O
between	O
human	O
fibroblast	O
feeders	O
cells	O
and	O
hESCs	O
and	O
hEBs	O
,	O
wishing	O
to	O
readily	O
detect	O
feeder	O
contamination	O
in	O
hESCs	O
,	O
we	O
included	O
one	O
of	O
the	O
human	O
feeder	O
cells	O
HS27	B
(	O
ATCC	O
)	O
in	O
this	O
study	O
.	O

We	O
have	O
been	O
using	O
HS27	B
as	O
feeder	O
cells	O
for	O
H9	B
hESCs	O
for	O
more	O
than	O
two	O
years	O
and	O
all	O
hESCs	O
grown	O
on	O
HS27	B
had	O
normal	O
karyotype	O
,	O
expressed	O
all	O
undifferentiated	O
markers	O
,	O
and	O
made	O
teratomas	O
with	O
all	O
germ	O
layers	O
(	O
data	O
not	O
show	O
)	O
.	O

The	O
global	O
pairwise	O
comparison	O
clearly	O
showed	O
that	O
human	O
feeders	O
were	O
far	O
more	O
dissimilar	O
to	O
hESCs	O
than	O
hESCs	O
grown	O
in	O
different	O
laboratories	O
,	O
hESCs	O
compared	O
to	O
their	O
differentiated	O
EBs	O
that	O
contained	O
mesodermal	O
tissue	O
,	O
and	O
hESCs	O
compared	O
to	O
the	O
karyotypically	O
variant	O
hESC	O
line	O
BG01V	B
.	O

Pairwise	O
comparisons	O
of	O
human	O
feeders	O
with	O
hESCs	O
resulted	O
in	O
a	O
correlation	O
coefficient	O
of	O
0.66	O
,	O
which	O
was	O
less	O
than	O
the	O
correlation	O
coefficient	O
of	O
0.71–0.74	O
observed	O
between	O
hESCs	O
and	O
their	O
corresponding	O
EBs	O
.	O

The	O
large	O
difference	O
between	O
human	O
feeders	O
and	O
hESCs	O
suggested	O
that	O
it	O
would	O
be	O
possible	O
to	O
identify	O
markers	O
that	O
were	O
robust	O
and	O
reliable	O
in	O
distinguishing	O
the	O
two	O
populations	O
,	O
and	O
these	O
markers	O
would	O
be	O
sufficiently	O
sensitive	O
in	O
detecting	O
contamination	O
of	O
feeders	O
.	O

We	O
examined	O
the	O
data	O
to	O
develop	O
a	O
list	O
of	O
genes	O
that	O
had	O
high	O
levels	O
of	O
expression	O
in	O
human	O
feeder	O
cells	O
maintained	O
in	O
hESC	O
medium	O
but	O
whose	O
expression	O
was	O
low	O
or	O
absent	O
in	O
either	O
ESCs	O
or	O
EBs	O
.	O

The	O
absence	O
of	O
expression	O
in	O
EBs	O
was	O
used	O
as	O
a	O
control	O
for	O
spontaneous	O
differentiation	O
of	O
ESC	O
colonies	O
(	O
including	O
mesodermal	O
differentiation	O
)	O
which	O
may	O
occur	O
and	O
the	O
markers	O
selected	O
should	O
be	O
able	O
to	O
distinguish	O
between	O
these	O
two	O
events	O
.	O

A	O
complete	O
list	O
of	O
genes	O
expressed	O
at	O
least	O
ten	O
-	O
fold	O
higher	O
in	O
human	O
feeders	O
is	O
provided	O
in	O
Figure	O
3	O
.	O

Quantitative	O
RT	O
-	O
PCR	O
(	O
qPCR	O
)	O
was	O
used	O
to	O
verify	O
the	O
fold	O
change	O
of	O
the	O
expression	O
of	O
4	O
genes	O
,	O
including	O
THBS1	O
,	O
MMP3	O
,	O
TNFRSF11B	O
and	O
KRTHA4	O
(	O
Figure	O
3C	O
)	O
.	O

Further	O
confirmation	O
can	O
also	O
be	O
done	O
using	O
immunocytochemistry	O
,	O
as	O
antibodies	O
against	O
these	O
genes	O
are	O
commercially	O
available	O
.	O

Figure	O
3Human	O
fibroblast	O
feeder	O
cells	O
can	O
be	O
distinguished	O
from	O
hESCs	O
and	O
EBs	O
.	O

Bead	O
array	O
identified	O
lists	O
of	O
genes	O
that	O
were	O
uniquely	O
expressed	O
in	O
human	O
fibroblast	O
feeders	O
as	O
compared	O
to	O
hESCs	O
(	O
A	O
)	O
and	O
hEBs	O
(	O
B	O
)	O
.	O

The	O
four	O
genes	O
whose	O
expression	O
was	O
confirmed	O
by	O
qPCR	O
(	O
C	O
)	O
were	O
in	O
bold	O
.	O

In	O
the	O
graph	O
(	O
C	O
)	O
,	O
gene	O
expression	O
of	O
each	O
gene	O
in	O
feeder	O
cells	O
was	O
designated	O
as	O
1	O
fold	O
and	O
the	O
bars	O
represented	O
fold	O
decrease	O
for	O
each	O
gene	O
.	O

Thus	O
this	O
comparison	O
allowed	O
us	O
to	O
distinguish	O
between	O
hESCs	O
and	O
human	O
feeders	O
and	O
identify	O
candidate	O
markers	O
that	O
could	O
detect	O
feeder	O
cell	O
contamination	O
should	O
human	O
feeders	O
be	O
used	O
in	O
the	O
propagation	O
of	O
hESCs	O
.	O

hESCs	O
and	O
EBs	O
can	O
be	O
distinguished	O
from	O
each	O
otherIllumina	O
bead	O
array	O
analysis	O
confirmed	O
that	O
hESCs	O
could	O
be	O
readily	O
distinguished	O
from	O
EBs	O
by	O
global	O
analysis	O
.	O

This	O
raised	O
the	O
possibility	O
that	O
specific	O
subsets	O
of	O
markers	O
could	O
be	O
identified	O
.	O

We	O
and	O
others	O
have	O
used	O
MPSS	O
and	O
EST	O
scan	O
and	O
generated	O
array	O
data	O
to	O
make	O
lists	O
of	O
hESC	O
-	O
specific	O
genes	O
[	O
5,9,10,20	O
]	O
.	O

As	O
discussed	O
above	O
,	O
most	O
hESC	O
markers	O
identified	O
by	O
MPSS	O
have	O
been	O
detected	O
in	O
the	O
present	O
bead	O
array	O
analysis	O
(	O
Table	O
3	O
)	O
,	O
confirming	O
the	O
utility	O
of	O
these	O
previously	O
identified	O
markers	O
for	O
use	O
in	O
assessing	O
undifferentiated	O
status	O
of	O
hESCs	O
.	O

In	O
addition	O
,	O
we	O
have	O
generated	O
a	O
list	O
of	O
genes	O
differentially	O
expressed	O
at	O
higher	O
level	O
in	O
EBs	O
than	O
in	O
hESCs	O
,	O
a	O
subset	O
of	O
which	O
is	O
shown	O
in	O
Table	O
5	O
.	O

These	O
markers	O
were	O
common	O
to	O
all	O
EB	O
samples	O
tested	O
and	O
included	O
genes	O
known	O
to	O
be	O
expressed	O
in	O
ectoderm	O
,	O
endoderm	O
and	O
mesoderm	O
.	O

The	O
entire	O
set	O
of	O
differentially	O
expressed	O
genes	O
is	O
provided	O
in	O
Additional	O
file	O
3	O
.	O

Thus	O
,	O
the	O
bead	O
array	O
format	O
,	O
which	O
allows	O
multiple	O
pairwise	O
comparisons	O
,	O
can	O
be	O
used	O
to	O
identify	O
genes	O
that	O
are	O
expressed	O
by	O
all	O
differentiating	O
EB	O
samples	O
in	O
the	O
present	O
study	O
.	O

Our	O
data	O
suggested	O
that	O
a	O
core	O
set	O
of	O
limited	O
markers	O
might	O
be	O
sufficient	O
to	O
monitor	O
the	O
process	O
of	O
differentiation	O
.	O

By	O
suitable	O
selection	O
of	O
different	O
germ	O
cell	O
layer	O
specific	O
markers	O
one	O
may	O
also	O
assess	O
the	O
overall	O
quality	O
of	O
differentiation	O
toward	O
germ	O
cells	O
.	O

Table	O
5Genes	O
which	O
are	O
differentially	O
expressed	O
at	O
higher	O
levels	O
in	O
EBs	O
than	O
in	O
hESCsSymbolAll	O
EBAll	O
ESEB	O
/	O
ESRELN11120.52224.0SST1394.25.5253.5SLC40A11210.19.1133.0IGF24896.938.4127.5SLN2017.817118.7DCN7588.176.299.6ANXA84048.941.996.6AQP11665.420.581.2APOB1256.415.879.5AHSG1414.320.868.0NID21476.731.447.0FGB221052.442.2LUM8439.4205.441.1MGP2772.469.839.7THBD1206.434.435.1SERPINA11255.643.728.7HAND112294437.428.1HBE11106.542.626.0TTR7661.2347.122.1HBG21601.185.618.7COL2A11636.291.817.8KIAA09771370.87817.6AFP8941552.316.2COL3A11355796714.0IGFBP38446.3603.414.0PAX61577.8118.213.3APOA19398.1709.813.2FRZB3523.7315.711.2SPON21548.7159.49.7CEBPD1100.2122.79.0DLK13355.8374.89.0RDC11589.7192.18.3BMP41851.5227.38.1PITX21057.9131.28.1ACTA25045629.88.0GAS11215.61547.9AGTRL11053.8135.17.8COL5A15876.4765.47.7CDKN1C3134.1412.97.6CXCL142220.5312.67.1DOK41011.1145.27.0ARHGDIB1635.3246.56.6FLRT21879.5314.36.0MSX12771.8499.75.5	O
Smaller	O
but	O
distinct	O
differences	O
among	O
undifferentiated	O
hESC	O
linesOur	O
cluster	O
analysis	O
indicated	O
that	O
BG01	B
,	O
BG02	B
and	O
BG03	B
cell	O
lines	O
were	O
overall	O
more	O
similar	O
to	O
each	O
other	O
than	O
to	O
other	O
lines	O
(	O
Figure	O
1	O
and	O
2	O
)	O
,	O
but	O
nevertheless	O
showed	O
additional	O
differences	O
than	O
technical	O
or	O
biological	O
repeats	O
of	O
the	O
same	O
sample	O
.	O

This	O
raised	O
the	O
possibility	O
that	O
this	O
microarray	O
strategy	O
may	O
be	O
sufficiently	O
sensitive	O
to	O
identify	O
relatively	O
cell	O
type	O
specific	O
candidate	O
genes	O
that	O
could	O
be	O
used	O
to	O
distinguish	O
one	O
hESC	O
population	O
from	O
another	O
or	O
to	O
identify	O
differences	O
that	O
were	O
due	O
to	O
varied	O
isolation	O
and	O
growth	O
conditions	O
.	O

As	O
a	O
test	O
we	O
looked	O
for	O
differences	O
between	O
BG01	B
,	O
BG02	B
and	O
BG03	B
,	O
which	O
were	O
grown	O
in	O
the	O
same	O
laboratory	O
under	O
the	O
same	O
conditions	O
.	O

Lists	O
of	O
candidate	O
genes	O
are	O
shown	O
in	O
Figure	O
4A	O
,	O
C	O
and	O
4E	O
and	O
the	O
comparison	O
of	O
these	O
three	O
lines	O
are	O
shown	O
in	O
scatter	O
plots	O
in	O
Figure	O
4B	O
,	O
D	O
and	O
4F.Figure	O
4BG	O
lines	O
show	O
small	O
but	O
distinct	O
differences	O
as	O
assessed	O
by	O
bead	O
array	O
.	O

These	O
three	O
hESC	O
lines	O
share	O
high	O
similarities	O
as	O
shown	O
by	O
the	O
scatterplots	O
of	O
BG01	B
vs	O
BG02	B
(	O
B	O
)	O
,	O
BG01	B
vs	O
BG03	B
(	O
D	O
)	O
and	O
BG02	B
vs	O
BG03	B
(	O
F	O
)	O
.	O

Comparisons	O
of	O
all	O
three	O
lines	O
were	O
made	O
and	O
lists	O
of	O
selected	O
genes	O
that	O
were	O
specifically	O
expressed	O
in	O
BG01	B
(	O
A	O
)	O
,	O
BG02	B
(	O
C	O
)	O
and	O
BG03	B
(	O
F	O
)	O
are	O
shown	O
.	O

Correlation	O
coefficients	O
(	O
R2	O
)	O
were	O
generated	O
using	O
all	O
genes	O
with	O
expression	O
level	O
>	O
0	O
(	O
black	O
and	O
blue	O
dots	O
)	O
,	O
or	O
all	O
genes	O
with	O
detection	O
confidence	O
>	O
0.99	O
(	O
blue	O
dots	O
)	O
.	O

Genes	O
outside	O
the	O
two	O
thin	O
red	O
lines	O
were	O
detected	O
at	O
>	O
2.5-	O
fold	O
difference	O
.	O

We	O
reasoned	O
as	O
well	O
that	O
such	O
a	O
global	O
comparison	O
should	O
allow	O
us	O
to	O
distinguish	O
between	O
male	O
and	O
female	O
lines	O
if	O
genes	O
present	O
on	O
the	O
Y	O
chromosome	O
were	O
expressed	O
at	O
high	O
levels	O
in	O
the	O
undifferentiated	O
state	O
and	O
were	O
detected	O
by	O
the	O
bead	O
array	O
.	O

Several	O
such	O
candidate	O
genes	O
were	O
identified	O
.	O

The	O
most	O
robust	O
were	O
RPS4Y	O
,	O
RPS4Y2	O
,	O
and	O
EIF1AY	O
(	O
Figure	O
5	O
)	O
.	O

To	O
confirm	O
that	O
these	O
were	O
useful	O
markers	O
,	O
we	O
designed	O
RT	O
-	O
PCR	O
primers	O
and	O
tested	O
their	O
expression	O
in	O
a	O
male	O
(	O
BG01	B
)	O
and	O
a	O
female	O
(	O
BG03	B
)	O
line	O
(	O
Figure	O
5B	O
)	O
.	O

We	O
noted	O
that	O
several	O
of	O
these	O
continued	O
to	O
be	O
expressed	O
at	O
high	O
levels	O
as	O
ESCs	O
differentiated	O
to	O
form	O
EBs	O
and	O
upon	O
further	O
differentiation	O
(	O
data	O
not	O
shown	O
)	O
,	O
suggesting	O
that	O
these	O
markers	O
might	O
be	O
used	O
in	O
adult	O
stem	O
cell	O
and	O
germ	O
cell	O
populations	O
as	O
well	O
.	O

Figure	O
5Male	O
and	O
female	O
hESC	O
lines	O
can	O
be	O
distinguished	O
by	O
genes	O
identified	O
by	O
bead	O
array	O
.	O

Five	O
potential	O
genes	O
RPS4Y	O
,	O
RPS4Y2	O
,	O
EIF1AY	O
,	O
VCY	O
,	O
and	O
AMELY	O
are	O
located	O
in	O
the	O
Y	O
chromosome	O
.	O

By	O
comparing	O
the	O
expression	O
level	O
of	O
these	O
genes	O
in	O
all	O
hESC	O
lines	O
,	O
we	O
have	O
found	O
that	O
3	O
out	O
of	O
5	O
were	O
specifically	O
expressed	O
in	O
male	O
hESC	O
lines	O
I6	B
,	O
BG01	B
and	O
BG02	B
(	O
A	O
)	O
and	O
this	O
was	O
verified	O
by	O
RT	O
-	O
PCR	O
in	O
male	O
line	O
BG01	B
and	O
female	O
line	O
BG03	B
(	O
B	O
)	O
.	O

G3PDH	O
was	O
used	O
as	O
an	O
internal	O
control	O
.	O

*	O
:	O
represents	O
the	O
gene	O
expression	O
level	O
is	O
detected	O
at	O
<	O
0.99	O
confidence	O
.	O

In	O
summary	O
,	O
our	O
data	O
suggest	O
that	O
the	O
bead	O
array	O
format	O
is	O
sufficiently	O
sensitive	O
and	O
global	O
that	O
it	O
can	O
distinguish	O
one	O
cell	O
line	O
from	O
another	O
even	O
if	O
those	O
two	O
cell	O
lines	O
are	O
grown	O
in	O
the	O
same	O
laboratory	O
under	O
virtually	O
identical	O
conditions	O
.	O

Bead	O
array	O
can	O
also	O
be	O
used	O
to	O
distinguish	O
between	O
male	O
and	O
female	O
lines	O
.	O

Comparison	O
of	O
diploid	O
pluripotent	O
cells	O
with	O
NTera2	B
and	O
BG01	B
variantOur	B
previous	O
results	O
have	O
suggested	O
that	O
EC	O
lines	O
share	O
many	O
of	O
the	O
properties	O
of	O
hESCs	O
and	O
can	O
be	O
used	O
as	O
a	O
useful	O
model	O
for	O
initial	O
testing	O
of	O
biological	O
questions	O
[	O
21	O
]	O
.	O

More	O
recently	O
we	O
have	O
identified	O
BG01V	B
as	O
a	O
karyotypically	O
abnormal	O
variant	O
that	O
behaves	O
much	O
like	O
its	O
normal	O
counterpart	O
BG01	B
,	O
but	O
is	O
not	O
subject	O
to	O
the	O
same	O
constraints	O
of	O
use	O
as	O
karyotypically	O
normal	O
hESCs	O
[	O
13	O
]	O
.	O

Given	O
the	O
sensitivity	O
of	O
the	O
bead	O
array	O
analysis	O
,	O
we	O
tested	O
its	O
ability	O
to	O
detect	O
the	O
overall	O
similarities	O
and	O
differences	O
between	O
NTera2	B
and	O
a	O
pooled	O
ESC	O
sample	O
or	O
between	O
the	O
karyotypically	O
abnormal	O
BG01V	B
and	O
its	O
normal	O
parent	O
line	O
(	O
Figure	O
6	O
)	O
.Figure	O
6Diploid	O
pluripotent	O
EC	O
cell	O
line	O
NTera2	B
and	O
karyotypically	O
abnormal	O
hESC	O
line	O
BG01V	B
can	O
be	O
distinguished	O
from	O
normal	O
hESCs	O
using	O
Illumina	O
array	O
.	O

Comparison	O
of	O
NTera2	B
and	O
pooled	O
hESC	O
sample	O
resulted	O
a	O
correlation	O
coefficient	O
of	O
0.8997	O
.	O

Two	O
lists	O
of	O
genes	O
,	O
which	O
were	O
specifically	O
expressed	O
in	O
NTera2	B
(	O
C	O
)	O
or	O
in	O
hESCs	O
(	O
E	O
)	O
were	O
identified	O
.	O

Likewise	O
,	O
while	O
sharing	O
similarities	O
with	O
BG01	B
(	O
B	O
,	O
correlation	O
coefficient=	O
0.9043	O
)	O
,	O
BG01V	B
was	O
different	O
from	O
BG01	B
in	O
expression	O
for	O
many	O
genes	O
,	O
particularly	O
genes	O
from	O
the	O
TGFβ	O
pathway	O
(	O
D	O
,	O
F	O
)	O
.	O

Black	O
dots	O
represent	O
genes	O
that	O
were	O
detected	O
at	O
>	O
0	O
expression	O
level	O
,	O
blue	O
dots	O
represent	O
genes	O
that	O
were	O
detected	O
both	O
at	O
>	O
0	O
expression	O
level	O
and	O
at	O
>	O
0.99	O
confidence	O
.	O

Genes	O
plotted	O
outside	O
the	O
two	O
thin	O
red	O
lines	O
were	O
detected	O
at	O
>	O
2.5-	O
fold	O
difference	O
.	O

Our	O
results	O
showed	O
that	O
,	O
while	O
NTera2	B
shared	O
a	O
high	O
similarity	O
with	O
hESCs	O
[	O
21	O
]	O
,	O
it	O
did	O
have	O
important	O
differences	O
with	O
hESC	O
lines	O
.	O

Examining	O
these	O
differences	O
(	O
summarized	O
in	O
Figure	O
6C	O
and	O
6E	O
)	O
,	O
we	O
noted	O
that	O
some	O
reflected	O
the	O
origin	O
of	O
the	O
tumor	O
cells	O
from	O
which	O
this	O
line	O
was	O
derived	O
[	O
14	O
]	O
.	O

Several	O
germ	O
cell	O
markers	O
such	O
as	O
GAGE2	O
,	O
GAGE7	O
and	O
GAGE8	O
were	O
highly	O
expressed	O
in	O
NTera2	B
but	O
were	O
absent	O
(	O
or	O
present	O
at	O
low	O
levels	O
)	O
in	O
any	O
of	O
the	O
hESC	O
lines	O
examined	O
(	O
See	O
Figure	O
6C	O
and	O
Additional	O
file	O
1	O
.	O

Note	O
that	O
the	O
GAGE	O
genes	O
are	O
highly	O
similar	O
in	O
sequence	O
,	O
making	O
it	O
difficult	O
to	O
distinguish	O
one	O
family	O
member	O
from	O
another	O
through	O
hybridization	O
;	O
thus	O
,	O
while	O
all	O
of	O
these	O
GAGE	O
gene	O
probes	O
gave	O
positive	O
signal	O
,	O
it	O
is	O
difficult	O
to	O
say	O
if	O
the	O
signal	O
came	O
from	O
the	O
specific	O
gene	O
itself	O
or	O
from	O
cross	O
-	O
hybridization	O
from	O
one	O
of	O
the	O
other	O
family	O
members	O
)	O
.	O

None	O
of	O
these	O
were	O
present	O
in	O
BG01V	B
,	O
indicating	O
that	O
the	O
karyotypically	O
abnormal	O
variant	O
is	O
not	O
the	O
equivalent	O
of	O
a	O
teratocarcinoma	O
line	O
such	O
as	O
NTera2	B
.	O

In	O
addition	O
to	O
the	O
expression	O
of	O
germ	O
cell	O
markers	O
,	O
we	O
noticed	O
a	O
significant	O
difference	O
in	O
the	O
expression	O
of	O
genes	O
in	O
the	O
TGFβ	O
pathway	O
,	O
such	O
as	O
GDF3	O
(	O
Figure	O
6C	O
)	O
,	O
TGFBI	O
,	O
CDKN1A	O
,	O
IGFBP7	O
,	O
IGFBP3	O
,	O
NODAL	O
,	O
CER1	O
and	O
BMP2	O
(	O
Figure	O
6E	O
)	O
.	O

This	O
is	O
consistent	O
with	O
the	O
postulated	O
role	O
of	O
this	O
pathway	O
in	O
germ	O
cell	O
differentiation	O
[	O
22,23	O
]	O
and	O
suggests	O
that	O
TGFβ	O
pathway	O
can	O
not	O
be	O
reliably	O
tested	O
using	O
NTera2	B
as	O
a	O
model	O
for	O
hESC.The	O
BG01V	B
showed	O
clear	O
differences	O
from	O
its	O
normal	O
counterpart	O
and	O
some	O
major	O
changes	O
are	O
summarized	O
in	O
Figure	O
6D	O
and	O
6F	O
.	O

Early	O
markers	O
of	O
differentiation	O
appeared	O
to	O
be	O
present	O
at	O
higher	O
levels	O
in	O
BG01V	B
as	O
compared	O
to	O
any	O
of	O
the	O
hESC	O
lines	O
examined	O
,	O
although	O
hESC	O
specific	O
genes	O
continued	O
to	O
be	O
expressed	O
at	O
high	O
levels	O
(	O
see	O
Additional	O
file	O
4	O
)	O
.	O

In	O
particular	O
,	O
the	O
Wnt	O
pathway	O
and	O
the	O
TGFβ	O
signaling	O
pathway	O
(	O
Figure	O
6D	O
)	O
,	O
both	O
of	O
which	O
involved	O
in	O
the	O
early	O
process	O
of	O
differentiation	O
[	O
24,25	O
]	O
,	O
appeared	O
to	O
be	O
activated	O
(	O
Additional	O
file	O
4	O
)	O
,	O
suggesting	O
that	O
the	O
role	O
of	O
growth	O
factors	O
and	O
signaling	O
in	O
these	O
early	O
events	O
can	O
not	O
be	O
readily	O
studied	O
in	O
this	O
cell	O
line	O
.	O

In	O
summary	O
,	O
the	O
analysis	O
highlighted	O
the	O
utility	O
of	O
the	O
potential	O
reference	O
standards	O
NTera2	B
and	O
BG01V	B
,	O
demonstrated	O
their	O
general	O
similarity	O
and	O
provided	O
detail	O
on	O
potential	O
caveats	O
to	O
their	O
application	O
.	O

Global	O
arrays	O
provide	O
a	O
snapshot	O
of	O
the	O
state	O
of	O
the	O
cells	O
and	O
identify	O
core	O
self	O
-	O
renewal	O
pathwaysWe	O
have	O
utilized	O
a	O
small	O
fraction	O
of	O
the	O
data	O
to	O
demonstrate	O
the	O
overall	O
utility	O
of	O
this	O
approach	O
and	O
its	O
sensitivity	O
in	O
identifying	O
small	O
differences	O
in	O
cell	O
populations	O
.	O

An	O
additional	O
potential	O
application	O
of	O
such	O
an	O
analysis	O
is	O
the	O
ability	O
to	O
examine	O
the	O
general	O
state	O
of	O
a	O
particular	O
signaling	O
pathway	O
and	O
determine	O
whether	O
it	O
is	O
active	O
.	O

By	O
comparing	O
across	O
many	O
samples	O
,	O
a	O
procedure	O
previously	O
expensive	O
and	O
difficult	O
in	O
terms	O
of	O
the	O
RNA	O
and	O
replicate	O
requirement	O
,	O
one	O
can	O
rapidly	O
identify	O
key	O
regulatory	O
pathways	O
.	O

To	O
test	O
whether	O
we	O
could	O
use	O
such	O
multiple	O
pairwise	O
comparisons	O
to	O
elucidate	O
the	O
major	O
regulatory	O
pathways	O
that	O
may	O
be	O
required	O
for	O
hESC	O
self	O
-	O
renewal	O
,	O
we	O
examined	O
several	O
metabolic	O
pathways	O
.	O

The	O
results	O
of	O
the	O
analysis	O
of	O
the	O
insulin	O
/	O
insulin	O
-	O
like	O
growth	O
factor	O
(	O
IGF	O
)	O
signaling	O
pathway	O
are	O
shown	O
in	O
Figure	O
7	O
.	O

Using	O
the	O
same	O
4	O
groups	O
of	O
samples	O
as	O
in	O
Figure	O
1	O
,	O
we	O
conducted	O
PAM	O
(	O
Prediction	O
Analysis	O
of	O
Microarray	O
)	O
[	O
26	O
]	O
,	O
in	O
search	O
for	O
biomarkers	O
used	O
in	O
diagnostic	O
identification	O
of	O
these	O
four	O
groups	O
,	O
ES	O
,	O
EB	O
,	O
NS	O
,	O
and	O
FB	O
.	O

In	O
PAM	O
,	O
a	O
list	O
of	O
significant	O
IGF	O
pathway	O
genes	O
whose	O
expression	O
characterizes	O
each	O
diagnostic	O
class	O
was	O
obtained	O
.	O

The	O
average	O
gene	O
expression	O
level	O
in	O
each	O
class	O
was	O
divided	O
by	O
the	O
within	O
-	O
class	O
standard	O
deviation	O
.	O

The	O
nearest	O
centroid	O
classification	O
computed	O
took	O
the	O
gene	O
expression	O
profile	O
from	O
a	O
new	O
sample	O
and	O
compared	O
it	O
to	O
each	O
of	O
these	O
class	O
centroids	O
.	O

For	O
cross	O
-	O
validation	O
of	O
prediction	O
results	O
,	O
multiple	O
classification	O
processes	O
were	O
performed	O
on	O
two	O
data	O
sets	O
randomly	O
constructed	O
each	O
time	O
from	O
the	O
entire	O
gene	O
expression	O
dataset	O
.	O

The	O
first	O
dataset	O
,	O
consisting	O
of	O
70	O
%	O
of	O
the	O
total	O
data	O
,	O
was	O
used	O
as	O
the	O
training	O
dataset	O
,	O
and	O
the	O
other	O
dataset	O
,	O
containing	O
the	O
remaining	O
30	O
%	O
of	O
data	O
,	O
was	O
used	O
for	O
the	O
data	O
prediction	O
and	O
verification	O
process	O
.	O

The	O
final	O
biomarkers	O
were	O
determined	O
in	O
such	O
a	O
way	O
that	O
the	O
misclassification	O
error	O
rate	O
was	O
minimal	O
.	O

The	O
resulting	O
graph	O
(	O
Figure	O
7	O
)	O
showed	O
the	O
shrunken	O
class	O
centroids	O
for	O
genes	O
that	O
had	O
at	O
least	O
one	O
nonzero	O
difference	O
in	O
each	O
diagnostic	O
class	O
.	O

The	O
genes	O
with	O
nonzero	O
components	O
in	O
each	O
class	O
were	O
almost	O
mutually	O
exclusive	O
and	O
represented	O
candidate	O
biomarkers	O
for	O
the	O
diagnosis	O
of	O
each	O
class	O
.	O

All	O
data	O
analyses	O
were	O
performed	O
using	O
the	O
bioconductor	O
package	O
[	O
17	O
]	O
.Figure	O
7Identification	O
of	O
diagnostic	O
markers	O
by	O
PAM	O
.	O

The	O
shrunken	O
class	O
centroids	O
for	O
genes	O
which	O
have	O
at	O
least	O
one	O
nonzero	O
difference	O
are	O
shown	O
.	O

The	O
genes	O
with	O
nonzero	O
components	O
in	O
each	O
class	O
were	O
almost	O
mutually	O
exclusive	O
and	O
were	O
the	O
candidate	O
molecular	O
markers	O
for	O
the	O
diagnosis	O
of	O
the	O
four	O
groups	O
of	O
cell	O
populations	O
,	O
including	O
,	O
(	O
from	O
left	O
to	O
right	O
)	O
hESC	O
derived	O
mesenchyme	O
and	O
human	O
fibroblast	O
feeder	O
cells	O
(	O
""""	O
FB	O
""""	O
,	O
n	O
=	O
5	O
)	O
,	O
undifferentiated	O
hESCs	O
(	O
""""	O
ES	O
""""	O
,	O
n	O
=	O
11	O
)	O
,	O
hESC	O
derived	O
neural	O
cells	O
(	O
""""	O
NS	O
""""	O
,	O
n	O
=	O
3	O
)	O
,	O
and	O
differentiated	O
ES	O
cells	O
and	O
EB	O
,	O
(	O
""""	O
EB	O
""""	O
,	O
n	O
=	O
6	O
)	O
.	O

The	O
identified	O
biomarkers	O
can	O
be	O
used	O
to	O
distinguish	O
the	O
four	O
groups	O
of	O
cell	O
populations	O
.	O

Undifferentiated	O
hESCs	O
have	O
been	O
analyzed	O
by	O
EST	O
scan	O
,	O
MPSS	O
,	O
SAGE	O
and	O
microarray	O
[	O
5,10,16	O
]	O
.	O

The	O
goal	O
of	O
these	O
experiments	O
including	O
our	O
own	O
is	O
to	O
develop	O
a	O
low	O
cost	O
reliable	O
method	O
to	O
assess	O
multiple	O
samples	O
to	O
generate	O
a	O
global	O
database	O
of	O
markers	O
and	O
to	O
provide	O
a	O
method	O
of	O
identifying	O
core	O
measures	O
of	O
similarities	O
and	O
differences	O
across	O
multiple	O
laboratories	O
.	O

We	O
and	O
others	O
have	O
proposed	O
three	O
alternative	O
methods	O
of	O
assessment	O
:	O
Quantitative	O
RT	O
-	O
PCR	O
[	O
9,20	O
]	O
,	O
focused	O
arrays	O
[	O
27	O
]	O
or	O
a	O
large	O
scale	O
array	O
with	O
bioinformatics	O
tools	O
being	O
utilized	O
to	O
focus	O
on	O
appropriate	O
subsets	O
of	O
genes	O
[	O
5,7,15,16,28	O
]	O
.	O

Each	O
of	O
these	O
methods	O
has	O
its	O
advantages	O
and	O
disadvantages	O
.	O

The	O
present	O
results	O
suggest	O
that	O
the	O
global	O
Illumina	O
bead	O
array	O
retains	O
the	O
advantages	O
of	O
low	O
cost	O
per	O
sample	O
associated	O
with	O
focused	O
arrays	O
yet	O
still	O
has	O
the	O
strength	O
of	O
the	O
global	O
attributes	O
of	O
MPSS	O
or	O
EST	O
scan	O
while	O
requiring	O
much	O
less	O
RNA	O
and	O
turnaround	O
time	O
.	O

To	O
test	O
this	O
array	O
format	O
we	O
examined	O
samples	O
from	O
a	O
variety	O
of	O
laboratories	O
in	O
a	O
blinded	O
fashion	O
to	O
determine	O
whether	O
the	O
array	O
was	O
sufficiently	O
sensitive	O
and	O
rapid	O
for	O
routine	O
assessment	O
.	O

Duplicates	O
using	O
100	O
ng	O
of	O
RNA	O
were	O
run	O
and	O
results	O
obtained	O
forty	O
-	O
eight	O
hours	O
later	O
.	O

The	O
resolution	O
was	O
sufficient	O
that	O
ESC	O
samples	O
could	O
be	O
distinguished	O
from	O
one	O
another	O
and	O
a	O
variant	O
karyotypically	O
abnormal	O
subclone	O
could	O
be	O
distinguished	O
from	O
the	O
parent	O
population	O
(	O
correlation	O
coefficient	O
=	O
0.9043	O
)	O
.	O

Aliquots	O
of	O
the	O
pooled	O
ES	O
and	O
pooled	O
EB	O
samples	O
,	O
which	O
we	O
had	O
prepared	O
for	O
MPSS	O
,	O
were	O
included	O
in	O
this	O
run	O
to	O
compare	O
these	O
two	O
methods	O
directly	O
.	O

The	O
current	O
analysis	O
confirms	O
that	O
comparison	O
across	O
platforms	O
is	O
difficult	O
and	O
that	O
only	O
positive	O
results	O
can	O
be	O
treated	O
with	O
any	O
reliability	O
.	O

The	O
absence	O
of	O
expression	O
can	O
not	O
be	O
readily	O
interpreted	O
.	O

In	O
particular	O
,	O
genes	O
expressed	O
at	O
low	O
levels	O
(	O
greater	O
than	O
70	O
%	O
of	O
all	O
genes	O
detected	O
)	O
should	O
not	O
be	O
assessed	O
in	O
cross	O
platform	O
comparisons	O
.	O

The	O
limited	O
concordance	O
at	O
low	O
levels	O
raises	O
a	O
question	O
as	O
to	O
how	O
many	O
genes	O
are	O
actually	O
expressed	O
by	O
any	O
one	O
cell	O
line	O
and	O
whether	O
the	O
cutoff	O
of	O
3	O
tpm	O
used	O
for	O
MPSS	O
or	O
100	O
intensity	O
units	O
for	O
bead	O
arrays	O
is	O
a	O
reasonable	O
cutoff	O
.	O

We	O
used	O
100	O
units	O
for	O
our	O
analysis	O
and	O
we	O
would	O
suggest	O
that	O
readers	O
exercise	O
similar	O
caution	O
.	O

Nevertheless	O
even	O
at	O
this	O
higher	O
cutoff	O
the	O
arrays	O
were	O
remarkably	O
sensitive	O
and	O
allowed	O
us	O
to	O
readily	O
distinguish	O
between	O
samples	O
including	O
cells	O
grown	O
in	O
the	O
same	O
laboratory	O
.	O

The	O
basis	O
of	O
the	O
sensitivity	O
could	O
be	O
attributed	O
to	O
a	O
limited	O
set	O
of	O
genes	O
and	O
those	O
genes	O
could	O
be	O
identified	O
for	O
future	O
use	O
.	O

For	O
example	O
BG01V	B
,	O
while	O
much	O
more	O
similar	O
to	O
BG01	B
than	O
to	O
any	O
other	O
cell	O
type	O
,	O
could	O
still	O
be	O
distinguished	O
from	O
a	O
biological	O
replicate	O
of	O
BG01	B
by	O
the	O
expression	O
of	O
a	O
particular	O
subset	O
of	O
differentiation	O
markers	O
(	O
Figure	O
6	O
)	O
.	O

EC	O
cells	O
such	O
as	O
NTera2	B
could	O
be	O
distinguished	O
from	O
hESCs	O
by	O
the	O
expression	O
of	O
germ	O
cell	O
markers	O
and	O
the	O
presence	O
of	O
a	O
partially	O
inactivated	O
TGFβ	O
(	O
BMP	O
)	O
signaling	O
pathway	O
(	O
Figure	O
6	O
)	O
.	O

Distinguishing	O
ESCs	O
from	O
EBs	O
was	O
relatively	O
straightforward	O
.	O

We	O
have	O
confirmed	O
the	O
utility	O
of	O
previously	O
identified	O
markers	O
for	O
use	O
in	O
this	O
platform	O
as	O
well	O
as	O
identified	O
an	O
additional	O
set	O
of	O
markers	O
that	O
can	O
serve	O
as	O
biomarkers	O
to	O
distinguish	O
between	O
the	O
hESC	O
and	O
EB	O
states	O
.	O

A	O
subset	O
of	O
these	O
markers	O
have	O
been	O
used	O
to	O
develop	O
a	O
qPCR	O
assay	O
that	O
shows	O
such	O
a	O
high	O
sensitivity	O
that	O
changes	O
in	O
cell	O
behavior	O
can	O
be	O
detected	O
after	O
as	O
little	O
as	O
twenty	O
-	O
four	O
hours	O
and	O
the	O
development	O
of	O
EBs	O
can	O
be	O
reliably	O
staged	O
[	O
10,20	O
]	O
.	O

During	O
the	O
identification	O
of	O
ES	O
and	O
EB	O
specific	O
markers	O
,	O
we	O
have	O
noticed	O
that	O
some	O
known	O
hESC	O
markers	O
,	O
such	O
as	O
Nanog	O
,	O
was	O
not	O
detected	O
in	O
all	O
populations	O
of	O
hESCs	O
that	O
were	O
included	O
in	O
this	O
analysis	O
.	O

Several	O
ESC	O
-	O
specific	O
gene	O
,	O
including	O
Lin41	O
,	O
Sox2	O
and	O
FoxD3	O
,	O
were	O
not	O
detected	O
in	O
the	O
array	O
either	O
(	O
Table	O
3	O
)	O
.	O

We	O
believe	O
that	O
the	O
problem	O
with	O
Lin	O
41	O
,	O
Sox2	O
and	O
FoxD3	O
is	O
a	O
technical	O
one	O
as	O
we	O
were	O
able	O
to	O
confirm	O
expression	O
using	O
alternate	O
methods	O
.	O

We	O
are	O
in	O
progress	O
of	O
redesigning	O
appropriate	O
probes	O
for	O
these	O
genes	O
.	O

In	O
the	O
case	O
of	O
the	O
gene	O
Nanog	O
,	O
there	O
are	O
several	O
pseudo	O
genes	O
in	O
the	O
genome	O
for	O
Nanog	O
and	O
it	O
has	O
been	O
a	O
major	O
technical	O
challenge	O
designing	O
primers	O
or	O
probes	O
that	O
are	O
specific	O
and	O
sensitive	O
.	O

We	O
believe	O
that	O
a	O
partial	O
explanation	O
for	O
the	O
variability	O
in	O
Nanog	O
expression	O
is	O
due	O
to	O
the	O
lack	O
of	O
sensitivity	O
to	O
this	O
gene	O
.	O

However	O
,	O
immunocytochemistry	O
while	O
not	O
strictly	O
quantitative	O
shows	O
similar	O
variability	O
when	O
used	O
to	O
assess	O
Nanog	O
expression	O
in	O
different	O
cell	O
lines	O
[	O
9,27,28	O
]	O
.	O

This	O
large	O
comparison	O
between	O
samples	O
allowed	O
us	O
to	O
identify	O
markers	O
that	O
distinguish	O
human	O
feeder	O
cells	O
from	O
hESC	O
.	O

While	O
we	O
have	O
listed	O
19	O
potential	O
markers	O
(	O
Figure	O
3	O
)	O
and	O
identified	O
several	O
hundred	O
potential	O
markers	O
as	O
shown	O
in	O
Additional	O
file	O
5	O
,	O
we	O
suggest	O
that	O
as	O
few	O
as	O
3–4	O
genes	O
may	O
be	O
sufficient	O
.	O

Previously	O
we	O
found	O
that	O
as	O
few	O
as	O
four	O
were	O
satisfactory	O
to	O
distinguish	O
between	O
hESCs	O
and	O
hEBs	O
,	O
which	O
are	O
two	O
much	O
more	O
closely	O
related	O
samples	O
[	O
9	O
]	O
.	O

In	O
this	O
study	O
we	O
have	O
confirmed	O
by	O
qPCR	O
the	O
differential	O
expression	O
of	O
four	O
genes	O
,	O
THBS1	O
,	O
MMP3	O
,	O
TNFRSF11B	O
and	O
KRTH4	O
,	O
to	O
separate	O
human	O
fibroblast	O
feeders	O
and	O
hESCs	O
(	O
Figure	O
3	O
)	O
.	O

Several	O
markers	O
such	O
as	O
MMP3	O
and	O
TNFRSF11B	O
have	O
commercially	O
available	O
antibodies	O
(	O
R&D	O
systems	O
)	O
that	O
may	O
be	O
used	O
to	O
further	O
confirm	O
contamination	O
of	O
feeder	O
cells	O
by	O
immunocytochemistry	O
.	O

Efforts	O
to	O
identify	O
other	O
useful	O
antibodies	O
based	O
on	O
these	O
results	O
continue	O
[	O
29	O
]	O
.	O

While	O
we	O
have	O
focused	O
on	O
the	O
immediate	O
utility	O
of	O
the	O
Illumina	O
array	O
platform	O
,	O
it	O
is	O
important	O
to	O
remember	O
that	O
this	O
array	O
provides	O
a	O
global	O
snapshot	O
of	O
cell	O
state	O
and	O
the	O
data	O
obtained	O
can	O
be	O
readily	O
compared	O
in	O
order	O
to	O
determine	O
key	O
signaling	O
pathways	O
.	O

The	O
ability	O
to	O
compare	O
multiple	O
samples	O
in	O
one	O
run	O
enhances	O
data	O
selectivity	O
and	O
reliability	O
.	O

To	O
make	O
such	O
analysis	O
more	O
readily	O
available	O
,	O
we	O
utilized	O
several	O
software	O
tools	O
including	O
the	O
software	O
package	O
available	O
through	O
Illumina	O
.	O

The	O
BeadStudio	O
software	O
provided	O
with	O
the	O
BeadLab	O
and	O
BeadStudio	O
genetic	O
analysis	O
systems	O
for	O
use	O
with	O
the	O
bead	O
array	O
datasets	O
provides	O
a	O
useful	O
set	O
of	O
analytical	O
and	O
presentation	O
tools	O
that	O
allow	O
straightforward	O
comparisons	O
,	O
which	O
are	O
sufficient	O
for	O
average	O
users	O
.	O

For	O
detailed	O
analysis	O
we	O
recommend	O
using	O
more	O
specific	O
commercial	O
tools	O
or	O
software	O
packages	O
developed	O
by	O
NCBI	O
.	O

In	O
summary	O
,	O
the	O
Illumina	O
bead	O
array	O
has	O
several	O
key	O
strengths	O
including	O
high	O
throughput	O
,	O
low	O
cost	O
and	O
high	O
sensitivity	O
.	O

By	O
using	O
this	O
array	O
,	O
we	O
can	O
readily	O
detect	O
contaminating	O
feeders	O
and	O
spontaneous	O
differentiation	O
,	O
differentiate	O
male	O
and	O
female	O
lines	O
and	O
distinguish	O
between	O
one	O
undifferentiated	O
population	O
and	O
another	O
.	O

Such	O
a	O
global	O
analysis	O
allows	O
us	O
to	O
assess	O
context	O
dependent	O
signaling	O
and	O
identify	O
biomarkers	O
of	O
particular	O
states	O
of	O
cells	O
.	O

Our	O
future	O
efforts	O
will	O
focus	O
on	O
data	O
mining	O
and	O
developing	O
better	O
cross	O
platform	O
comparison	O
tools	O
and	O
generating	O
focused	O
high	O
throughput	O
arrays	O
for	O
quality	O
control	O
in	O
clinical	O
and	O
research	O
settings	O
.	O

hESC	O
cultureThe	O
hESC	O
lines	O
H1	B
,	O
H7	B
and	O
H9	B
(	O
WiCell	O
,	O
Madison	O
,	O
WI	O
)	O
were	O
cultured	O
on	O
feeder	O
layers	O
derived	O
from	O
mitotically	O
inactivated	O
HS27	B
human	O
fibroblast	O
cells	O
(	O
HS27	B
,	O
ATCC	O
)	O
,	O
or	O
mouse	O
embryonic	O
fibroblsts	O
or	O
under	O
feeder	O
-	O
free	O
conditions	O
on	O
Matrigel	O
(	O
BD	O
,	O
Franklin	O
Lakes	O
,	O
NJ	O
)	O
coated	O
plates	O
for	O
at	O
least	O
10	O
passages	O
.	O

Culture	O
medium	O
for	O
all	O
cultures	O
was	O
composed	O
of	O
DMEM	O
/	O
F12-Glutamax	O
1:1	O
,	O
20	O
%	O
Knockout	O
Serum	O
Replacement	O
,	O
2	O
mM	O
nonessential	O
amino	O
acids	O
,	O
100	O
μM	O
beta	O
-	O
mercaptoethanol	O
,	O
50	O
μg	O
/	O
ml	O
Pen	O
-	O
Strep	O
(	O
all	O
from	O
Invitrogen	O
,	O
Carlsbad	O
,	O
CA	O
)	O
,	O
and	O
4	O
ng	O
/	O
ml	O
human	O
recombinant	O
basic	O
fibroblast	O
growth	O
factor	O
(	O
bFGF	O
/	O
FGF2	O
;	O
PeproTech	O
Inc.	O
,	O
Rocky	O
Hill	O
,	O
NJ	O
.	O
)	O

Feeder	O
-	O
free	O
cultures	O
were	O
prepared	O
for	O
gene	O
expression	O
analysis	O
by	O
manually	O
harvesting	O
individual	O
colonies	O
with	O
uniform	O
typical	O
undifferentiated	O
ESC	O
morphology	O
.	O

BG01	B
(	O
46	O
,	O
XY	O
)	O
,	O
BG02	B
(	O
46	O
,	O
XY	O
)	O
,	O
BG03	B
(	O
46	O
,	O
XX	O
)	O
,	O
I6	B
(	O
46	O
,	O
XY	O
)	O
and	O
BG01V	B
(	O
BG01	B
karyotypic	O
variant	O
:	O
49	O
,	O
XXY	O
,	O
+	O
12	O
,	O
+	O
17	O
)	O
:	O
Cells	O
were	O
maintained	O
for	O
3	O
(	O
BG01V	B
)	O
,	O
7	O
(	O
BG02	B
)	O
,	O
8	O
(	O
BG01	B
)	O
,	O
or	O
21	O
(	O
BG03	B
)	O
passages	O
under	O
feeder	O
-	O
free	O
condition	O
on	O
fibronectin	O
-	O
coated	O
plates	O
in	O
medium	O
that	O
had	O
been	O
conditioned	O
by	O
mouse	O
embryonic	O
fibroblasts	O
for	O
24	O
hours	O
.	O

Culture	O
medium	O
was	O
DMEM	O
/	O
F12	O
,	O
1:1	O
supplemented	O
with	O
20	O
%	O
Knockout	O
Serum	O
Replacement	O
,	O
2	O
mM	O
non	O
-	O
essential	O
amino	O
acids	O
,	O
2	O
mM	O
L	O
-	O
glutamine	O
,	O
50	O
μg	O
/	O
ml	O
Pen	O
-	O
Strep	O
,	O
100	O
μM	O
beta	O
-	O
mercaptoethanol	O
,	O
and	O
4	O
ng	O
/	O
ml	O
of	O
bFGF.Different	O
hESC	O
lines	O
were	O
grown	O
in	O
slightly	O
different	O
culture	O
conditions	O
as	O
described	O
above	O
.	O

H	O
lines	O
were	O
grown	O
on	O
Matrigel	O
coated	O
dishes	O
,	O
while	O
BG	O
lines	O
on	O
fibronectin	O
treated	O
dishes	O
.	O

These	O
coating	O
substrata	O
supported	O
the	O
growth	O
of	O
hESCs	O
similarly	O
,	O
as	O
evaluated	O
by	O
colony	O
morphology	O
,	O
immunocytochemistry	O
and	O
proliferation	O
rate	O
(	O
data	O
not	O
shown	O
)	O
.Embryoid	O
bodies	O
(	O
EBs	O
)	O
were	O
prepared	O
from	O
BG	O
lines	O
as	O
described	O
in	O
[	O
5	O
]	O
.	O

Cells	O
were	O
aggregated	O
and	O
cultured	O
on	O
non	O
-	O
adherent	O
substrata	O
for	O
fourteen	O
days	O
.	O

Other	O
cellsNTera2	O
cells	O
were	O
purchased	O
from	O
ATCC	O
and	O
cultured	O
in	O
parallel	O
with	O
hESCssamples	O
using	O
protocols	O
described	O
previously	O
[	O
21	O
]	O
.	O

HS27	B
embryonic	O
human	O
newborn	O
foreskin	O
cells	O
(	O
ATCC	O
CRL-1634	O
)	O
were	O
grown	O
in	O
DMEM	O
with	O
10%FBS.All	O
samples	O
included	O
in	O
this	O
study	O
can	O
be	O
found	O
in	O
Additional	O
file	O
6.Bead	O
array	O
gene	O
expression	O
analysisRNA	O
was	O
isolated	O
from	O
cultured	O
cells	O
using	O
the	O
Qiagen	O
RNEasy	O
kit	O
(	O
Qiagen	O
,	O
Inc	O
,	O
Valencia	O
,	O
CA	O
)	O
.	O

Sample	O
amplification	O
was	O
performed	O
using	O
100	O
ng	O
of	O
total	O
RNA	O
as	O
input	O
material	O
by	O
the	O
method	O
of	O
Van	O
Gelder	O
et	O
al	O
[	O
30	O
]	O
.	O

Amplified	O
RNA	O
synthesized	O
from	O
limited	O
quantities	O
of	O
heterogenous	O
cDNA	O
[	O
30	O
]	O
was	O
performed	O
using	O
the	O
Illumina	O
RNA	O
Amplification	O
kit	O
(	O
Ambion	O
,	O
Inc.	O
,	O
Austin	O
,	O
TX	O
)	O
following	O
the	O
Manufacturer	O
instructions	O
.	O

Labeling	O
was	O
achieved	O
by	O
use	O
of	O
the	O
incorporation	O
of	O
biotin-16-UTP	O
(	O
Perkin	O
Elmer	O
Life	O
and	O
Analytical	O
Sciences	O
,	O
Boston	O
,	O
MA	O
)	O
present	O
at	O
a	O
ratio	O
of	O
1:1	O
with	O
unlabeled	O
UTP	O
.	O

Labeled	O
,	O
amplified	O
material	O
(	O
700	O
ng	O
per	O
array	O
)	O
was	O
hybridized	O
to	O
a	O
pilot	O
version	O
of	O
the	O
Illumina	O
HumanRef-8	O
BeadChip	O
according	O
to	O
the	O
Manufacturer	O
's	O
instructions	O
(	O
Illumina	O
,	O
Inc.	O
,	O
San	O
Diego	O
,	O
CA	O
)	O
.	O

Amersham	O
fluorolink	O
streptavidin	O
-	O
Cy3	O
(	O
GE	O
Healthcare	O
Bio	O
-	O
Sciences	O
,	O
Little	O
Chalfont	O
,	O
UK	O
)	O
following	O
the	O
BeadChip	O
manual	O
.	O

Arrays	O
were	O
scanned	O
with	O
an	O
Illumina	O
Bead	O
array	O
Reader	O
confocal	O
scanner	O
according	O
to	O
the	O
Manufacturer	O
's	O
instructions	O
.	O

Array	O
data	O
processing	O
and	O
analysis	O
was	O
performed	O
using	O
Illumina	O
BeadStudio	O
software	O
.	O

Identification	O
of	O
differentially	O
expressed	O
genes	O
and	O
clustering	O
analysisDifferentially	O
expressed	O
genes	O
between	O
ES	O
and	O
EB	O
were	O
identified	O
by	O
ANOVA	O
at	O
p	O
value	O
0.05	O
using	O
bioconductor	O
[	O
17	O
]	O
.	O

Unsupervised	O
hierarchical	O
clustering	O
analysis	O
and	O
principal	O
component	O
analysis	O
(	O
PCA	O
)	O
were	O
conducted	O
using	O
software	O
Pcluster	O
[	O
31	O
]	O
and	O
TreeView	O
[	O
18	O
]	O
.Identification	O
of	O
diagnostic	O
markersPAM	O
(	O
prediction	O
analysis	O
of	O
microarray	O
)	O
was	O
employed	O
for	O
the	O
identification	O
of	O
diagnostic	O
markers	O
from	O
insulin	O
pathway	O
genes	O
by	O
using	O
the	O
software	O
package	O
bioconductor	O
[	O
17	O
]	O
.	O

PAM	O
is	O
a	O
class	O
prediction	O
method	O
for	O
expression	O
data	O
mining	O
.	O

It	O
can	O
provide	O
a	O
list	O
of	O
significant	O
genes	O
whose	O
expression	O
characterizes	O
each	O
diagnostic	O
class	O
.	O

The	O
average	O
gene	O
expression	O
level	O
in	O
multiple	O
classes	O
,	O
such	O
as	O
ES	O
,	O
EB	O
,	O
NS	O
,	O
and	O
FB	O
,	O
was	O
divided	O
by	O
the	O
within	O
-	O
class	O
standard	O
deviation	O
for	O
that	O
gene	O
.	O

The	O
nearest	O
centroid	O
classification	O
computed	O
by	O
PAM	O
takes	O
the	O
protein	O
expression	O
profile	O
from	O
a	O
new	O
sample	O
,	O
and	O
compares	O
it	O
to	O
each	O
of	O
these	O
class	O
centroids	O
[	O
26	O
]	O
.RT	O
-	O
PCR	O
and	O
quantitative	O
real	O
-	O
time	O
PCR	O
analysisTotal	O
RNA	O
was	O
isolated	O
with	O
TRIzol	O
(	O
Invitrogen	O
.	O

cDNA	O
was	O
synthesized	O
using	O
2.5	O
μg	O
total	O
RNA	O
in	O
a	O
20-μl	O
reaction	O
with	O
Superscript	O
II	O
(	O
Invitrogen	O
)	O
and	O
oligo	O
(	O
dT	O
)	O
12–18	O
(	O
Promega	O
;	O
Madison	O
,	O
WI	O
)	O
.	O

One	O
microliter	O
RNase	O
H	O
(	O
Invitrogen	O
)	O
was	O
added	O
to	O
each	O
tube	O
and	O
incubated	O
for	O
20	O
minutes	O
at	O
37	O
°	O
C	O
before	O
proceeding	O
to	O
the	O
RT	O
-	O
PCR	O
analysis	O
.	O

The	O
PCR	O
primers	O
are	O
:	O
RPS4Y	O
-	O
forward	O
:	O
5	O
'	O
AGATTCTCTTCCGTCGCAG	O
3	O
'	O
,	O
RPS4Y	O
-	O
reverse	O
,	O
5	O
'	O
CTCCACCAATCACCATACAC	O
3	O
'	O
;	O
EIFAY	O
-	O
forward	O
,	O
5	O
'	O
CTGCTGCATCTTAGTTCAGTC	O
3	O
'	O
;	O
EIFAY	O
-	O
reverse	O
5	O
'	O
CTTCCAATCGTCCATTTCCC	O
3	O
'	O
.	O

Quantitative	O
real	O
time	O
PCR	O
gene	O
specific	O
primer	O
pairs	O
and	O
probes	O
were	O
purchased	O
from	O
Applied	O
Biosystems	O
(	O
Foster	O
City	O
,	O
CA	O
)	O
for	O
the	O
following	O
genes	O
:	O
MMP3	O
(	O
Hs00233962_m1	O
)	O
,	O
TFRSF11B	O
(	O
Hs00171068_m1	O
)	O
,	O
THBS1	O
(	O
Hs00170236_m1	O
)	O
,	O
KRTHA4	O
(	O
Hs00606019_gH	O
)	O
,	O
and	O
for	O
internal	O
control	O
β	O
-	O
actin	O
(	O
ACTB	O
,	O
Hs99999903_m1	O
)	O
.	O

This	O
work	O
uncovers	O
novel	O
mechanisms	O
of	O
aging	O
within	O
stem	O
cell	O
niches	O
that	O
are	O
evolutionarily	O
conserved	O
between	O
mice	O
and	O
humans	O
and	O
affect	O
both	O
embryonic	O
and	O
adult	O
stem	O
cells	O
.	O

Specifically	O
,	O
we	O
have	O
examined	O
the	O
effects	O
of	O
aged	O
muscle	O
and	O
systemic	O
niches	O
on	O
key	O
molecular	O
identifiers	O
of	O
regenerative	O
potential	O
of	O
human	O
embryonic	O
stem	O
cells	O
(	O
hESCs	O
)	O
and	O
post	O
-	O
natal	O
muscle	O
stem	O
cells	O
(	O
satellite	O
cells	O
)	O
.	O

Our	O
results	O
reveal	O
that	O
aged	O
differentiated	O
niches	O
dominantly	O
inhibit	O
the	O
expression	O
of	O
Oct4	O
in	O
hESCs	O
and	O
Myf-5	O
in	O
activated	O
satellite	O
cells	O
,	O
and	O
reduce	O
proliferation	O
and	O
myogenic	O
differentiation	O
of	O
both	O
embryonic	O
and	O
tissue	O
-	O
specific	O
adult	O
stem	O
cells	O
(	O
ASCs	O
)	O
.	O

Therefore	O
,	O
despite	O
their	O
general	O
neoorganogenesis	O
potential	O
,	O
the	O
ability	O
of	O
hESCs	O
,	O
and	O
the	O
more	O
differentiated	O
myogenic	O
ASCs	O
to	O
contribute	O
to	O
tissue	O
repair	O
in	O
the	O
old	O
will	O
be	O
greatly	O
restricted	O
due	O
to	O
the	O
conserved	O
inhibitory	O
influence	O
of	O
aged	O
differentiated	O
niches	O
.	O

Significantly	O
,	O
this	O
work	O
establishes	O
that	O
hESC	O
-	O
derived	O
factors	O
enhance	O
the	O
regenerative	O
potential	O
of	O
both	O
young	O
and	O
,	O
importantly	O
,	O
aged	O
muscle	O
stem	O
cells	O
in	O
vitro	O
and	O
in	O
vivo	O
;	O
thus	O
,	O
suggesting	O
that	O
the	O
regenerative	O
outcome	O
of	O
stem	O
cell	O
-	O
based	O
replacement	O
therapies	O
will	O
be	O
determined	O
by	O
a	O
balance	O
between	O
negative	O
influences	O
of	O
aged	O
tissues	O
on	O
transplanted	O
cells	O
and	O
positive	O
effects	O
of	O
embryonic	O
cells	O
on	O
the	O
endogenous	O
regenerative	O
capacity	O
.	O

Comprehensively	O
,	O
this	O
work	O
points	O
toward	O
novel	O
venues	O
for	O
in	O
situ	O
restoration	O
of	O
tissue	O
repair	O
in	O
the	O
old	O
and	O
identifies	O
critical	O
determinants	O
of	O
successful	O
cell	O
-	O
replacement	O
therapies	O
for	O
aged	O
degenerating	O
organs	O
.	O

Embryonic	O
stem	O
cells	O
(	O
ESCs	O
)	O
are	O
distinguished	O
by	O
their	O
ability	O
to	O
self	O
-	O
renew	O
and	O
to	O
differentiate	O
into	O
any	O
other	O
cell	O
type	O
via	O
asymmetric	O
cell	O
divisions	O
,	O
in	O
which	O
one	O
daughter	O
cell	O
maintains	O
'	O
stemness	O
'	O
while	O
the	O
other	O
daughter	O
cell	O
differentiates	O
into	O
a	O
particular	O
tissue	O
type	O
.	O

ESCs	O
,	O
including	O
those	O
of	O
human	O
origin	O
(	O
hESCs	O
)	O
,	O
are	O
derived	O
from	O
the	O
blastocyst	O
and	O
can	O
be	O
propagated	O
in	O
vitro	O
(	O
Evans	O
&	O
Kaufman	O
,	O
1981	O
;	O
Thomson	O
et	O
al.	O
,	O
1998	O
;	O
Wobus	O
&	O
Boheler	O
,	O
2005	O
)	O
.	O

Their	O
tremendous	O
potential	O
for	O
organogenesis	O
has	O
created	O
a	O
great	O
interest	O
in	O
using	O
hESCs	O
for	O
replacing	O
tissues	O
and	O
organs	O
lost	O
to	O
disease	O
,	O
or	O
old	O
age	O
(	O
reviewed	O
in	O
Wobus	O
&	O
Boheler	O
,	O
2005	O
)	O
.	O

As	O
such	O
,	O
the	O
use	O
of	O
hESCs	O
is	O
particularly	O
important	O
,	O
due	O
to	O
the	O
fact	O
that	O
adult	O
organ	O
stem	O
cells	O
are	O
often	O
limited	O
in	O
number	O
,	O
cell	O
-	O
fate	O
plasticity	O
,	O
expansion	O
capacity	O
,	O
telomere	O
length	O
,	O
and	O
lifespan	O
(	O
Mayhall	O
et	O
al.	O
,	O
2004	O
)	O
.	O

The	O
general	O
goal	O
behind	O
most	O
cell	O
-	O
replacement	O
approaches	O
is	O
to	O
expand	O
and	O
then	O
differentiate	O
hESCs	O
in	O
vitro	O
,	O
thus	O
producing	O
a	O
cell	O
type	O
of	O
interest	O
,	O
such	O
as	O
neuronal	O
,	O
blood	O
,	O
endothelial	O
,	O
pancreatic	O
,	O
bone	O
,	O
and	O
others	O
.	O

These	O
differentiated	O
cells	O
are	O
expected	O
to	O
replace	O
their	O
dysfunctional	O
counterparts	O
in	O
vivo	O
.	O

The	O
scope	O
of	O
disorders	O
that	O
can	O
be	O
potentially	O
treated	O
with	O
a	O
neoorganogenesis	O
approach	O
is	O
large	O
and	O
includes	O
many	O
that	O
are	O
currently	O
incurable	O
,	O
such	O
as	O
muscle	O
atrophy	O
,	O
diabetes	O
,	O
Alzheimer	O
's	O
disease	O
,	O
Parkinson	O
's	O
disease	O
,	O
and	O
other	O
degenerative	O
diseases	O
that	O
often	O
accompany	O
human	O
aging	O
(	O
McDonald	O
et	O
al.	O
,	O
1999	O
;	O
Liu	O
et	O
al.	O
,	O
2000	O
;	O
Hori	O
et	O
al.	O
,	O
2002	O
;	O
Kim	O
et	O
al.	O
,	O
2002	O
;	O
Blyszczuk	O
et	O
al.	O
,	O
2003	O
)	O
.	O

While	O
many	O
studies	O
have	O
focused	O
on	O
the	O
derivation	O
,	O
propagation	O
,	O
and	O
in	O
vitro	O
differentiation	O
of	O
hESCs	O
(	O
reviewed	O
in	O
Hoffman	O
&	O
Carpenter	O
,	O
2005	O
;	O
Wobus	O
&	O
Boheler	O
,	O
2005	O
)	O
,	O
relatively	O
few	O
have	O
examined	O
the	O
properties	O
of	O
these	O
cells	O
and	O
their	O
more	O
differentiated	O
progeny	O
in	O
the	O
aged	O
,	O
as	O
opposed	O
to	O
the	O
young	O
,	O
systemic	O
and	O
local	O
organ	O
environments	O
.	O

Recently	O
published	O
data	O
suggest	O
that	O
these	O
extrinsic	O
cues	O
become	O
altered	O
with	O
age	O
in	O
ways	O
that	O
preclude	O
activation	O
of	O
organ	O
stem	O
cells	O
(	O
such	O
as	O
satellite	O
cells	O
)	O
,	O
inhibit	O
repair	O
-	O
specific	O
molecular	O
signaling	O
(	O
such	O
as	O
delta	O
-	O
Notch	O
)	O
,	O
and	O
interfere	O
with	O
productive	O
tissue	O
repair	O
(	O
Conboy	O
et	O
al.	O
,	O
2003	O
,	O
2005	O
;	O
Janzen	O
et	O
al.	O
,	O
2006	O
;	O
Krishnamurthy	O
et	O
al.	O
,	O
2006	O
;	O
Molofsky	O
et	O
al.	O
,	O
2006	O
)	O
.	O

Furthermore	O
,	O
at	O
least	O
two	O
lines	O
of	O
evidence	O
suggest	O
that	O
stem	O
cell	O
-	O
based	O
tissue	O
-	O
replacement	O
therapies	O
might	O
be	O
hindered	O
in	O
the	O
elderly	O
,	O
because	O
all	O
cells	O
along	O
the	O
developmental	O
lineage	O
(	O
e.g.	O
,	O
stem	O
cells	O
,	O
more	O
differentiated	O
progenitor	O
cells	O
or	O
even	O
tissues	O
containing	O
a	O
pool	O
of	O
precursors	O
)	O
might	O
rapidly	O
'	O
age	O
'	O
and	O
fail	O
to	O
contribute	O
to	O
organ	O
repair	O
when	O
introduced	O
into	O
the	O
old	O
organism	O
in	O
vivo	O
.	O

First	O
,	O
in	O
heterochronic	O
tissue	O
-	O
transplantation	O
studies	O
,	O
the	O
age	O
of	O
the	O
host	O
environment	O
determined	O
the	O
regenerative	O
outcome	O
,	O
as	O
both	O
young	O
and	O
old	O
skeletal	O
muscle	O
explants	O
containing	O
differentiated	O
and	O
precursor	O
cells	O
effectively	O
regenerated	O
in	O
young	O
,	O
but	O
not	O
in	O
old	O
animals	O
(	O
Zacks	O
&	O
Sheff	O
,	O
1982	O
;	O
Carlson	O
&	O
Faulkner	O
,	O
1989	O
)	O
.	O

Second	O
,	O
using	O
parabiotically	O
paired	O
young	O
and	O
old	O
mice	O
,	O
the	O
regenerative	O
potential	O
of	O
muscle	O
and	O
liver	O
was	O
shown	O
to	O
be	O
influenced	O
by	O
the	O
age	O
of	O
the	O
systemic	O
environment	O
(	O
Conboy	O
et	O
al.	O
,	O
2005	O
)	O
.	O

Thus	O
,	O
we	O
sought	O
to	O
determine	O
whether	O
key	O
molecular	O
identifiers	O
of	O
stem	O
cell	O
properties	O
,	O
the	O
rate	O
of	O
cell	O
proliferation	O
,	O
and	O
the	O
myogenic	O
capacity	O
would	O
be	O
influenced	O
by	O
the	O
age	O
of	O
extrinsic	O
milieu	O
,	O
regardless	O
of	O
whether	O
stem	O
cells	O
are	O
embryonic	O
or	O
the	O
more	O
differentiated	O
,	O
muscle	O
-	O
specific	O
satellite	O
cells	O
.	O

Satellite	O
cells	O
are	O
muscle	O
stem	O
cells	O
situated	O
in	O
direct	O
contact	O
with	O
myofibers	O
,	O
the	O
differentiated	O
muscle	O
cells	O
.	O

When	O
myofibers	O
are	O
damaged	O
,	O
quiescent	O
satellite	O
cells	O
are	O
activated	O
to	O
proliferate	O
and	O
then	O
differentiate	O
into	O
fusion	O
-	O
competent	O
myoblasts	O
that	O
continue	O
to	O
proliferate	O
and	O
can	O
form	O
primary	O
cultures	O
,	O
but	O
are	O
also	O
capable	O
of	O
producing	O
new	O
,	O
multinucleated	O
myofibers	O
or	O
myotubes	O
in	O
vitro	O
and	O
in	O
vivo	O
(	O
Morgan	O
et	O
al.	O
,	O
2002	O
;	O
Collins	O
et	O
al.	O
,	O
2005	O
;	O
Wagers	O
&	O
Conboy	O
,	O
2005	O
)	O
.	O

Activated	O
satellite	O
cells	O
express	O
myogenic	O
markers	O
,	O
such	O
as	O
Myf5	O
,	O
M	O
-	O
cadherin	O
,	O
and	O
Paired	O
box	O
gene	O
7	O
(	O
Pax7	O
)	O
;	O
fusion	O
-	O
competent	O
myoblasts	O
express	O
high	O
levels	O
of	O
desmin	O
,	O
and	O
de	O
novo	O
generated	O
myofibers	O
or	O
myotubes	O
express	O
embryonic	O
myosin	O
heavy	O
chain	O
(	O
eMyHC	O
)	O
and	O
continue	O
to	O
express	O
desmin	O
(	O
Schultz	O
&	O
McCormick	O
,	O
1994	O
;	O
Wagers	O
&	O
Conboy	O
,	O
2005	O
)	O
.	O

While	O
desmin	O
can	O
be	O
also	O
present	O
in	O
smooth	O
and	O
cardiac	O
muscle	O
cells	O
,	O
the	O
isolation	O
of	O
hind	O
limb	O
skeletal	O
muscle	O
with	O
subsequent	O
purification	O
of	O
myofibers	O
away	O
from	O
all	O
interstitial	O
cells	O
,	O
as	O
well	O
as	O
purification	O
of	O
associated	O
muscle	O
stem	O
cells	O
results	O
in	O
primary	O
cultures	O
that	O
are	O
uniformly	O
of	O
skeletal	O
muscle	O
lineage	O
.	O

Every	O
desmin+	O
cell	O
in	O
such	O
cultures	O
is	O
a	O
fusion	O
-	O
competent	O
myoblast	O
,	O
and	O
is	O
able	O
to	O
produce	O
multinucleated	O
myotubes	O
after	O
48	O
h	O
of	O
culture	O
in	O
differentiation	O
-	O
promoting	O
medium	O
[	O
Dulbecco	O
's	O
modified	O
Eagle	O
's	O
medium	O
(	O
DMEM	O
)	O
with	O
2	O
%	O
horse	O
serum	O
]	O
.	O

Some	O
of	O
these	O
myogenic	O
cells	O
fuse	O
into	O
myotubes	O
,	O
even	O
in	O
the	O
mitogen	O
-	O
rich	O
medium	O
[	O
(	O
Opti	O
-	O
MEM	O
(	O
Invitrogen	O
,	O
Carlsbad	O
,	O
CA	O
,	O
USA	O
)	O
with	O
5–10	O
%	O
mouse	O
serum	O
or	O
DMEM	O
with	O
10	O
%	O
fetal	O
bovine	O
serum	O
,	O
FBS	O
]	O
(	O
Conboy	O
&	O
Rando	O
,	O
2002	O
;	O
Conboy	O
et	O
al.	O
,	O
2003	O
;	O
and	O
see	O
below	O
)	O
.	O

An	O
experimental	O
system	O
was	O
developed	O
that	O
(	O
i	O
)	O
provided	O
the	O
ability	O
to	O
study	O
the	O
regenerative	O
response	O
of	O
hESCs	O
and	O
of	O
muscle	O
stem	O
cells	O
in	O
various	O
heterochronic	O
environments	O
in	O
vitro	O
;	O
and	O
(	O
ii	O
)	O
allowed	O
examination	O
of	O
the	O
effects	O
of	O
hESCs	O
on	O
muscle	O
repair	O
,	O
in	O
vivo	O
,	O
after	O
transplantation	O
into	O
young	O
vs.	O
old	O
hosts	O
.	O

This	O
model	O
allowed	O
us	O
to	O
address	O
both	O
the	O
negative	O
effects	O
of	O
the	O
aged	O
niche	O
on	O
key	O
stem	O
cell	O
properties	O
and	O
the	O
positive	O
effects	O
of	O
hESCs	O
on	O
the	O
aged	O
muscle	O
-	O
specific	O
organ	O
progenitor	O
cells	O
in	O
vitro	O
,	O
and	O
on	O
the	O
regenerative	O
capacity	O
of	O
old	O
muscle	O
in	O
vivo	O
.	O

The	O
resulting	O
data	O
demonstrate	O
that	O
the	O
composition	O
of	O
conserved	O
extrinsic	O
cues	O
,	O
regulating	O
stem	O
cell	O
responses	O
,	O
becomes	O
altered	O
with	O
age	O
in	O
ways	O
that	O
inhibit	O
both	O
hESCs	O
and	O
adult	O
stem	O
cell	O
regenerative	O
potential	O
.	O

Specifically	O
,	O
molecular	O
markers	O
of	O
stem	O
cell	O
functionality	O
,	O
e.g.	O
Oct4	O
(	O
in	O
hESCs	O
)	O
and	O
Myf5	O
(	O
in	O
muscle	O
stem	O
cells	O
)	O
,	O
the	O
rate	O
of	O
cell	O
proliferation	O
,	O
and	O
the	O
capacity	O
for	O
myogenic	O
differentiation	O
are	O
all	O
dominantly	O
inhibited	O
by	O
the	O
aged	O
systemic	O
milieu	O
,	O
and	O
by	O
the	O
old	O
differentiated	O
muscle	O
tissue	O
.	O

However	O
,	O
while	O
satellite	O
cells	O
are	O
unable	O
to	O
deter	O
the	O
inhibitory	O
affects	O
of	O
aged	O
systemic	O
and	O
local	O
niches	O
,	O
hESCs	O
are	O
capable	O
of	O
antagonizing	O
the	O
aged	O
environments	O
,	O
thereby	O
enhancing	O
the	O
regenerative	O
potential	O
of	O
both	O
young	O
and	O
old	O
muscle	O
stem	O
cells	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Thus	O
,	O
a	O
complex	O
interplay	O
between	O
negative	O
regulation	O
of	O
hESCs	O
and	O
adult	O
muscle	O
stem	O
cells	O
by	O
the	O
aged	O
niche	O
,	O
and	O
positive	O
regulation	O
of	O
the	O
host	O
's	O
regenerative	O
responses	O
by	O
hESCs	O
will	O
likely	O
determine	O
the	O
success	O
of	O
hESC	O
-	O
based	O
cell	O
-	O
replacement	O
therapies	O
in	O
the	O
old	O
.	O

Regenerative	O
responses	O
of	O
adult	O
muscle	O
stem	O
cells	O
and	O
hESCs	O
are	O
dominantly	O
inhibited	O
by	O
the	O
aged	O
systemic	O
milieuPrevious	O
work	O
established	O
that	O
the	O
upregulation	O
of	O
repair	O
-	O
specific	O
molecular	O
signaling	O
mechanisms	O
,	O
such	O
as	O
Notch	O
,	O
and	O
successful	O
engagement	O
of	O
resident	O
muscle	O
stem	O
cells	O
in	O
tissue	O
repair	O
are	O
largely	O
determined	O
by	O
the	O
age	O
of	O
the	O
systemic	O
milieu	O
,	O
rather	O
than	O
by	O
the	O
cell	O
-	O
autonomous	O
age	O
of	O
muscle	O
cells	O
,	O
or	O
by	O
the	O
differences	O
in	O
their	O
numbers	O
(	O
Conboy	O
&	O
Rando	O
,	O
2005	O
;	O
Conboy	O
et	O
al.	O
,	O
2005	O
)	O
.	O

Intriguingly	O
,	O
these	O
experiments	O
also	O
hinted	O
at	O
a	O
small	O
but	O
persistent	O
inhibitory	O
effect	O
of	O
the	O
aged	O
systemic	O
milieu	O
on	O
the	O
performance	O
of	O
young	O
stem	O
cells	O
.	O

Exploring	O
this	O
further	O
,	O
we	O
found	O
that	O
young	O
serum	O
permits	O
satellite	O
cells	O
to	O
be	O
myogenic	O
,	O
while	O
old	O
serum	O
inhibits	O
the	O
satellite	O
cell	O
regenerative	O
potential	O
not	O
only	O
alone	O
,	O
but	O
also	O
when	O
mixed	O
with	O
young	O
serum	O
,	O
suggesting	O
a	O
dominant	O
over	O
-	O
riding	O
of	O
'	O
young	O
'	O
serum	O
factors	O
(	O
Fig.	O
1	O
)	O
.	O

Myofiber	O
cultures	O
,	O
in	O
which	O
satellite	O
cells	O
have	O
been	O
activated	O
by	O
injury	O
in	O
vivo	O
,	O
were	O
established	O
from	O
young	O
(	O
2–3	O
months	O
)	O
and	O
old	O
(	O
22–24	O
months	O
)	O
C57-BL	O
/	O
6	O
male	O
mice	O
,	O
as	O
previously	O
described	O
(	O
Conboy	O
&	O
Rando	O
,	O
2002	O
;	O
Conboy	O
et	O
al.	O
,	O
2005	O
)	O
.	O

As	O
previously	O
shown	O
,	O
this	O
method	O
is	O
well	O
suited	O
for	O
the	O
assessment	O
of	O
satellite	O
cell	O
regenerative	O
myogenic	O
capacity	O
(	O
Conboy	O
&	O
Rando	O
,	O
2002	O
;	O
Wagers	O
&	O
Conboy	O
,	O
2005	O
)	O
.	O

Isolated	O
myofiber	O
explants	O
with	O
associated	O
satellite	O
cells	O
were	O
cultured	O
overnight	O
in	O
the	O
presence	O
of	O
young	O
or	O
old	O
serum	O
(	O
alone	O
at	O
5	O
%	O
and	O
10	O
%	O
,	O
and	O
mixed	O
at	O
5	O
%	O
young	O
+	O
5	O
%	O
old	O
)	O
;	O
bromodeoxyuridine	O
(	O
BrdU	O
)	O
was	O
added	O
for	O
the	O
last	O
2	O
h	O
of	O
culture	O
to	O
measure	O
the	O
rate	O
of	O
cell	O
proliferation	O
.	O

The	O
effects	O
of	O
heterochronic	O
systemic	O
milieu	O
on	O
myogenic	O
potential	O
were	O
examined	O
as	O
generation	O
of	O
proliferating	O
myoblasts	O
that	O
express	O
desmin	O
and	O
Myf5	O
,	O
and	O
that	O
spontaneously	O
form	O
multinucleated	O
nascent	O
myotubes	O
.	O

As	O
shown	O
in	O
Fig.	O
1A	O
and	O
quantified	O
in	O
Fig.	O
1B	O
,	O
the	O
age	O
of	O
sera	O
clearly	O
determined	O
satellite	O
cell	O
regenerative	O
potential	O
and	O
old	O
serum	O
strongly	O
inhibited	O
the	O
myogenic	O
potential	O
of	O
young	O
satellite	O
cells	O
either	O
when	O
present	O
alone	O
,	O
or	O
when	O
mixed	O
with	O
young	O
sera	O
.	O

Similar	O
data	O
was	O
obtained	O
by	O
using	O
another	O
myogenic	O
marker	O
,	O
Pax7	O
(	O
Supplementary	O
Fig.	O
S1	O
)	O
.	O

Additionally	O
,	O
there	O
were	O
two	O
to	O
three	O
times	O
fewer	O
total	O
cells	O
generated	O
in	O
the	O
presence	O
of	O
aged	O
serum	O
(	O
not	O
shown	O
)	O
.Fig	O
.	O

1The	O
age	O
of	O
sera	O
determined	O
the	O
regenerative	O
potential	O
of	O
satellite	O
cells	O
.	O

(	O
A	O
)	O
Young	O
satellite	O
cells	O
were	O
cultured	O
either	O
in	O
5	O
%	O
or	O
10	O
%	O
young	O
(	O
Young	O
)	O
,	O
10	O
%	O
old	O
(	O
Old	O
)	O
,	O
or	O
in	O
a	O
5%+	O
5	O
%	O
mouse	O
sera	O
combination	O
(	O
young	O
+	O
old	O
)	O
.	O

Cells	O
were	O
analyzed	O
by	O
immunofluorescence	O
microscopy	O
,	O
using	O
anti	O
-	O
BrdU	O
(	O
red	O
)	O
,	O
antidesmin	O
(	O
green	O
)	O
or	O
anti	O
-	O
Myf5	O
antibodies	O
(	O
green	O
,	O
small	O
panels	O
)	O
.	O

Similar	O
results	O
are	O
shown	O
for	O
Pax7	O
immunodetection	O
(	O
Supplementary	O
Fig.	O
S1	O
)	O
.	O

Hoechst	O
(	O
blue	O
)	O
labeled	O
nuclei	O
.	O

(	O
B	O
)	O
Three	O
independent	O
experiments	O
were	O
quantified	O
[	O
300	O
young	O
myofibers	O
per	O
experiment	O
]	O
as	O
percentage	O
of	O
desmin+	O
/	O
Myf5+	O
/	O
BrdU+	O
de	O
novo	O
generated	O
cells	O
for	O
each	O
age	O
and	O
culture	O
condition	O
.	O

On	O
average	O
,	O
two	O
to	O
three	O
fewer	O
cells	O
were	O
generated	O
when	O
cultured	O
in	O
the	O
presence	O
of	O
old	O
.	O

Shown	O
are	O
identical	O
microscope	O
fields	O
at	O
×40	O
magnification	O
.	O

At	O
least	O
three	O
independent	O
experiments	O
produced	O
similar	O
results	O
.	O

(	O
*	O
)	O
indicates	O
P≤	O
0.001	O
as	O
compared	O
to	O
young	O
sera	O
.	O

Importantly	O
,	O
it	O
was	O
not	O
simply	O
the	O
dilution	O
of	O
young	O
serum	O
factors	O
that	O
resulted	O
in	O
diminished	O
myogenic	O
capacity	O
when	O
young	O
and	O
old	O
sera	O
were	O
mixed	O
,	O
because	O
young	O
sera	O
promoted	O
robust	O
myogenesis	O
both	O
at	O
10	O
%	O
and	O
5	O
%	O
.	O

Thus	O
,	O
old	O
serum	O
factors	O
dominantly	O
inhibited	O
the	O
myogenic	O
capacity	O
of	O
young	O
satellite	O
cells	O
even	O
in	O
the	O
presence	O
of	O
young	O
serum	O
.	O

This	O
observation	O
suggests	O
that	O
satellite	O
cells	O
of	O
young	O
mice	O
engage	O
in	O
efficient	O
myogenic	O
responses	O
,	O
in	O
part	O
,	O
because	O
the	O
inhibitory	O
influence	O
of	O
old	O
circulatory	O
milieu	O
is	O
absent	O
.	O

These	O
data	O
reveal	O
that	O
the	O
regenerative	O
potential	O
of	O
young	O
muscle	O
stem	O
cells	O
is	O
determined	O
by	O
the	O
age	O
of	O
the	O
systemic	O
milieu	O
,	O
prompting	O
us	O
to	O
investigate	O
whether	O
hESCs	O
would	O
similarly	O
succumb	O
to	O
inhibitory	O
factors	O
present	O
in	O
the	O
aged	O
circulation	O
.	O

To	O
determine	O
the	O
effects	O
of	O
aged	O
serum	O
on	O
stem	O
cell	O
self	O
-	O
renewal	O
/	O
pluripotency	O
,	O
we	O
analyzed	O
hESC	O
expression	O
of	O
Oct4	O
and	O
studied	O
the	O
rate	O
of	O
hESC	O
proliferation	O
,	O
by	O
assessing	O
BrdU	O
incorporation	O
(	O
Fig.	O
2	O
)	O
and	O
Ki67	O
expression	O
(	O
Supplementary	O
Fig.	O
S2	O
)	O
.	O

Specifically	O
,	O
these	O
determinants	O
of	O
hESC	O
regenerative	O
potential	O
were	O
examined	O
in	O
the	O
presence	O
of	O
heterochronic	O
(	O
young	O
vs.	O
old	O
)	O
mouse	O
sera	O
added	O
to	O
typical	O
hESC	O
medium	O
,	O
e.g.	O
,	O
MEF	O
-	O
conditioned	O
medium	O
(	O
MCM	O
)	O
.	O

Oct4	O
is	O
expressed	O
by	O
self	O
-	O
renewing	O
,	O
pluripotent	O
ESCs	O
in	O
culture	O
,	O
by	O
the	O
totipotent	O
inner	O
cell	O
mass	O
of	O
the	O
blastocyst	O
and	O
by	O
the	O
germ	O
cells	O
(	O
Nichols	O
et	O
al.	O
,	O
1998	O
;	O
Pesce	O
et	O
al.	O
,	O
1999	O
)	O
.	O

Most	O
cells	O
in	O
control	O
cultures	O
or	O
young	O
conditions	O
expressed	O
high	O
levels	O
of	O
this	O
marker	O
of	O
'	O
stemness	O
'	O
,	O
and	O
maintained	O
their	O
normal	O
phenotype	O
and	O
morphology	O
throughout	O
the	O
various	O
co	O
-	O
culture	O
experiments	O
performed	O
in	O
this	O
study	O
(	O
see	O
below	O
)	O
.Fig	O
.	O

2The	O
regenerative	O
potential	O
of	O
embryonic	O
stem	O
cells	O
was	O
negatively	O
affected	O
by	O
aged	O
mouse	O
sera	O
.	O

(	O
A	O
)	O
hESCs	O
were	O
cultured	O
in	O
MCM	O
with	O
10	O
%	O
young	O
(	O
young	O
)	O
or	O
old	O
(	O
old	O
)	O
mouse	O
serum	O
,	O
or	O
in	O
three	O
control	O
media	O
:	O
MCM	O
without	O
mouse	O
sera	O
;	O
GM	O
(	O
myoblast	O
medium	O
of	O
Ham	O
's	O
F10	O
with	O
20	O
%	O
FBS	O
)	O
and	O
DMEM	O
/	O
FBS	O
(	O
hESC	O
differentiation	O
medium	O
of	O
DMEM	O
with	O
10	O
%	O
FBS	O
)	O
.	O

BrdU	O
was	O
added	O
for	O
the	O
last	O
2	O
h	O
of	O
culture	O
to	O
measure	O
the	O
rate	O
of	O
cell	O
proliferation	O
.	O

Immunodetection	O
assays	O
were	O
performed	O
for	O
BrdU	O
(	O
red	O
)	O
,	O
Oct4	O
(	O
red	O
)	O
,	O
and	O
Ki67	O
(	O
Supplementary	O
Fig.	O
S2	O
)	O
.	O

Hoechst	O
(	O
blue	O
)	O
labels	O
nuclei	O
.	O

A	O
high	O
rate	O
of	O
hESC	O
proliferation	O
and	O
Oct4	O
expression	O
is	O
displayed	O
in	O
all	O
control	O
media	O
and	O
in	O
the	O
presence	O
of	O
young	O
mouse	O
serum	O
.	O

In	O
contrast	O
,	O
hESC	O
proliferation	O
and	O
Oct4	O
expression	O
are	O
inhibited	O
in	O
the	O
presence	O
of	O
old	O
mouse	O
serum	O
,	O
either	O
alone	O
or	O
when	O
mixed	O
with	O
young	O
serum	O
.	O

MCM	O
with	O
mouse	O
sera	O
at	O
5	O
%	O
gave	O
results	O
similar	O
to	O
those	O
observed	O
with	O
10	O
%	O
young	O
mouse	O
sera	O
or	O
in	O
control	O
media	O
(	O
Supplementary	O
Fig.	O
S3	O
)	O
.	O

(	O
B	O
)	O
Three	O
independent	O
experiments	O
yielded	O
similar	O
results	O
and	O
were	O
quantified	O
as	O
percentage	O
of	O
BrdU+	O
and	O
Oct4	O
+	O
cells	O
for	O
each	O
culture	O
condition	O
.	O

*	O
indicates	O
P	O
<	O
0.001	O
as	O
compared	O
to	O
young	O
serum	O
.	O

Importantly	O
,	O
at	O
10	O
%	O
aged	O
serum	O
dramatically	O
inhibited	O
the	O
self	O
-	O
renewal	O
and	O
proliferative	O
potential	O
of	O
hESCs	O
,	O
as	O
judged	O
by	O
highly	O
diminished	O
Oct4	O
expression	O
and	O
a	O
lack	O
of	O
BrdU	O
incorporation	O
.	O

Again	O
,	O
the	O
inhibitory	O
factors	O
in	O
the	O
aged	O
milieu	O
were	O
dominant	O
over	O
the	O
young	O
,	O
as	O
evidenced	O
by	O
a	O
decline	O
in	O
Oct4	O
expression	O
,	O
the	O
low	O
rate	O
of	O
BrdU	O
incorporation	O
,	O
and	O
Ki67	O
expression	O
in	O
young	O
and	O
old	O
mixed	O
environments	O
(	O
5	O
%	O
young	O
+	O
5	O
%	O
old	O
sera	O
in	O
MCM	O
)	O
.	O

Similar	O
to	O
the	O
data	O
shown	O
for	O
adult	O
stem	O
cells	O
(	O
ASCs	O
)	O
(	O
Fig.	O
1	O
)	O
,	O
it	O
was	O
not	O
simply	O
a	O
dilution	O
of	O
young	O
serum	O
factors	O
as	O
hESCs	O
robustly	O
proliferated	O
and	O
expressed	O
high	O
levels	O
of	O
Oct4	O
when	O
cultured	O
with	O
5	O
%	O
young	O
sera	O
in	O
MCM	O
(	O
Supplementary	O
Fig.	O
S3	O
)	O
.	O

Quantification	O
of	O
multiple	O
independent	O
experiments	O
has	O
demonstrated	O
that	O
hESC	O
expression	O
of	O
Oct4	O
and	O
BrdU	O
incorporation	O
have	O
been	O
reduced	O
by	O
two-	O
to	O
threefold	O
in	O
the	O
aged	O
milieu	O
(	O
Fig.	O
2B	O
)	O
.As	O
expected	O
,	O
hESCs	O
cultured	O
in	O
control	O
media	O
,	O
including	O
MCM	O
alone	O
that	O
does	O
not	O
contain	O
either	O
young	O
or	O
old	O
serum	O
,	O
also	O
displayed	O
a	O
high	O
rate	O
of	O
proliferation	O
and	O
Oct4	O
expression	O
(	O
Fig.	O
2	O
,	O
control	O
medium	O
)	O
.	O

Additionally	O
,	O
in	O
this	O
experimental	O
set	O
-	O
up	O
there	O
was	O
no	O
general	O
inhibitory	O
effect	O
of	O
sera	O
per	O
se	O
on	O
hESC	O
proliferation	O
and	O
Oct4	O
expression	O
,	O
as	O
10	O
%	O
young	O
mouse	O
sera	O
(	O
young	O
)	O
and	O
10–20	O
%	O
of	O
FBS	O
(	O
growth	O
medium	O
and	O
DMEM	O
/	O
FBS	O
)	O
allowed	O
for	O
a	O
high	O
rate	O
of	O
cell	O
proliferation	O
and	O
for	O
uniformly	O
high	O
Oct4	O
levels	O
(	O
Fig.	O
2	O
)	O
.When	O
instead	O
of	O
immediate	O
exposure	O
to	O
aged	O
mouse	O
serum	O
,	O
hESCs	O
were	O
first	O
cultured	O
overnight	O
in	O
MCM	O
,	O
these	O
cells	O
were	O
no	O
longer	O
susceptible	O
to	O
the	O
negative	O
effects	O
of	O
old	O
systemic	O
milieu	O
(	O
Fig.	O
3	O
)	O
,	O
suggesting	O
that	O
hESC	O
-	O
produced	O
factors	O
established	O
an	O
embryonic	O
microniche	O
that	O
may	O
provide	O
temporary	O
protection	O
from	O
the	O
aged	O
environment	O
.	O

It	O
appears	O
that	O
satellite	O
cells	O
do	O
not	O
have	O
such	O
anti	O
-	O
aging	O
ability	O
,	O
because	O
despite	O
an	O
initial	O
activation	O
in	O
entirely	O
young	O
environments	O
,	O
e.g.	O
,	O
after	O
muscle	O
injury	O
to	O
young	O
muscle	O
,	O
isolated	O
satellite	O
cells	O
remain	O
susceptible	O
to	O
inhibition	O
by	O
the	O
old	O
mouse	O
serum	O
(	O
Figs	O
1	O
and	O
4C	O
)	O
.	O

Similarly	O
,	O
culturing	O
satellite	O
cells	O
isolated	O
from	O
noninjured	O
muscle	O
in	O
growth	O
-	O
promoting	O
medium	O
for	O
1–2	O
days	O
does	O
not	O
protect	O
against	O
the	O
inhibitory	O
affects	O
of	O
aged	O
systemic	O
milieu	O
(	O
not	O
shown	O
)	O
.Fig	O
.	O

3Embryonic	O
stem	O
cells	O
produce	O
youthful	O
microniche	O
in	O
culture	O
.	O

(	O
A	O
)	O
As	O
opposed	O
to	O
immediate	O
exposure	O
to	O
old	O
mouse	O
serum	O
after	O
passaging	O
(	O
10	O
%	O
old	O
)	O
,	O
preculturing	O
of	O
hESCs	O
for	O
24	O
h	O
in	O
feeder	O
-	O
free	O
conditions	O
,	O
e.g.	O
,	O
Matrigel	O
™	O
+	O
MCM	O
,	O
prior	O
to	O
replacing	O
MCM	O
with	O
MCM	O
+	O
10	O
%	O
old	O
mouse	O
sera	O
,	O
resulted	O
in	O
continuously	O
high	O
BrdU	O
incorporation	O
and	O
Oct4	O
expression	O
(	O
embryonic	O
microniche	O
+	O
10	O
%	O
old	O
)	O
.	O

BrdU	O
was	O
added	O
for	O
the	O
last	O
2	O
h	O
of	O
culture	O
to	O
measure	O
the	O
rate	O
of	O
cell	O
proliferation	O
.	O

Immunodetection	O
of	O
BrdU	O
and	O
Oct4	O
(	O
both	O
in	O
red	O
)	O
was	O
performed	O
as	O
described	O
in	O
Experimental	O
procedures	O
.	O

Hoechst	O
(	O
blue	O
)	O
labels	O
nuclei	O
.	O

(	O
B	O
)	O
Three	O
independent	O
experiments	O
yielded	O
similar	O
results	O
and	O
were	O
quantified	O
as	O
percentage	O
of	O
BrdU+	O
/	O
Oct4	O
+	O
for	O
each	O
condition	O
.	O

*	O
indicates	O
P	O
<	O
0.001	O
as	O
compared	O
to	O
'	O
old	O
+	O
MCM'.Fig	O
.	O

4Aged	O
muscle	O
niche	O
inhibits	O
the	O
regenerative	O
potential	O
of	O
hESCs	O
and	O
satellite	O
cells	O
.	O

(	O
A	O
)	O
Immunodetection	O
of	O
a	O
mouse	O
-	O
specific	O
M	O
-	O
cadherin	O
(	O
green	O
)	O
or	O
desmin	O
(	O
red	O
;	O
both	O
human	O
and	O
mouse	O
proteins	O
are	O
detected	O
)	O
revealed	O
that	O
hESCs	O
underwent	O
muscle	O
lineage	O
differentiation	O
when	O
co	O
-	O
cultured	O
with	O
young	O
,	O
but	O
not	O
old	O
myofibers	O
.	O

The	O
myogenic	O
progeny	O
of	O
hESCs	O
appears	O
M	O
-	O
cadherin−	O
/	O
desmin+	O
(	O
white	O
arrow	O
in	O
young	O
)	O
,	O
as	O
opposed	O
to	O
M	O
-	O
cadherin−	O
/	O
desmin−	O
hESCs	O
that	O
lack	O
myogenic	O
commitment	O
(	O
white	O
arrow	O
in	O
old	O
)	O
.	O

M	O
-	O
cadherin+	O
/	O
desmin+	O
cells	O
are	O
the	O
myogenic	O
progeny	O
of	O
mouse	O
satellite	O
cells	O
(	O
yellow	O
arrows	O
)	O
.	O

To	O
assess	O
the	O
effects	O
of	O
secreted	O
factors	O
produced	O
by	O
young	O
vs.	O
old	O
myofibers	O
on	O
the	O
rate	O
of	O
hESC	O
proliferation	O
,	O
transient	O
,	O
2	O
h	O
BrdU	O
incorporation	O
was	O
examined	O
in	O
hESCs	O
cultured	O
for	O
48	O
h	O
with	O
supernatants	O
produced	O
by	O
heterochronic	O
myofiber	O
explants	O
(	O
See	O
Experimental	O
procedures	O
for	O
details	O
)	O
.	O

As	O
compared	O
to	O
young	O
myofiber	O
-	O
derived	O
supernatants	O
(	O
young	O
myofiber	O
supernant	O
)	O
,	O
exposure	O
to	O
old	O
myofiber	O
-	O
derived	O
supernatants	O
(	O
old	O
myofiber	O
supernant	O
)	O
inhibited	O
hESCs	O
proliferation	O
,	O
as	O
judged	O
by	O
BrdU	O
immunodetection	O
(	O
red	O
)	O
.	O

As	O
expected	O
,	O
the	O
rate	O
of	O
hESCs	O
proliferation	O
was	O
high	O
in	O
control	O
media	O
(	O
shown	O
in	O
Fig.	O
2	O
)	O
.	O

Hoechst	O
(	O
blue	O
)	O
labels	O
nuclei	O
in	O
all	O
experiments	O
.	O

Quantification	O
of	O
desmin+	O
/	O
BrdU+	O
hESCs	O
in	O
direct	O
myofiber	O
cocultures	O
,	O
or	O
with	O
muscle	O
supernatants	O
,	O
is	O
shown	O
in	O
(	O
B	O
)	O
.	O

*	O
indicates	O
P≤	O
0.001	O
as	O
compared	O
to	O
young	O
.	O

(	O
C	O
)	O
Transwell	O
co	O
-	O
cultures	O
between	O
purified	O
young	O
satellite	O
cells	O
and	O
myofibers	O
isolated	O
from	O
uninjured	O
young	O
(	O
young	O
myofiber	O
)	O
and	O
old	O
(	O
old	O
myofiber	O
)	O
muscle	O
demonstrated	O
that	O
satellite	O
cell	O
regenerative	O
myogenic	O
capacity	O
was	O
inhibited	O
by	O
the	O
aged	O
differentiated	O
muscle	O
.	O

Myogenic	O
potential	O
was	O
determined	O
by	O
the	O
ability	O
of	O
satellite	O
cells	O
to	O
generate	O
proliferating	O
desmin+	O
myoblasts	O
(	O
immunodetection	O
shown	O
in	O
green	O
)	O
and	O
by	O
rate	O
of	O
proliferation	O
(	O
2	O
h	O
BrdU	O
incorporation	O
;	O
immunodetection	O
shown	O
in	O
red	O
)	O
.	O

(	O
D	O
)	O
Satellite	O
cell	O
regenerative	O
potential	O
was	O
quantified	O
as	O
percentage	O
of	O
desmin+	O
/	O
BrdU+	O
cells	O
for	O
transwell	O
co	O
-	O
cultures	O
with	O
young	O
or	O
old	O
uninjured	O
myofibers	O
(	O
i.e.	O
,	O
RM	O
,	O
resting	O
muscle	O
)	O
.	O

n	O
=	O
3	O
;	O
*	O
indicates	O
P≤	O
0.05	O
as	O
compared	O
to	O
young	O
.	O

Comprehensively	O
,	O
these	O
data	O
establish	O
that	O
the	O
inhibition	O
of	O
stem	O
cell	O
regenerative	O
potential	O
by	O
the	O
aged	O
systemic	O
milieu	O
is	O
conserved	O
between	O
species	O
(	O
mouse	O
vs.	O
human	O
)	O
and	O
cell	O
types	O
(	O
adult	O
vs.	O
embryonic	O
stem	O
cells	O
)	O
.	O

As	O
summarized	O
in	O
Table	O
1	O
,	O
aged	O
mouse	O
sera	O
similarly	O
affected	O
the	O
expression	O
of	O
key	O
molecular	O
identifiers	O
of	O
both	O
embryonic	O
and	O
adult	O
stem	O
cells	O
,	O
e.g.	O
,	O
Oct4	O
in	O
hESCs	O
and	O
Myf5	O
in	O
mouse	O
ASCs	O
.	O

As	O
expected	O
,	O
adult	O
mouse	O
stem	O
cells	O
did	O
not	O
express	O
Oct4	O
,	O
and	O
hESCs	O
did	O
not	O
express	O
Myf5	O
in	O
these	O
experimental	O
conditions	O
(	O
not	O
shown	O
)	O
.	O

Moreover	O
,	O
aged	O
systemic	O
milieu	O
had	O
similar	O
inhibitory	O
effects	O
on	O
proliferation	O
of	O
hESCs	O
and	O
ASCs	O
,	O
suggesting	O
that	O
not	O
only	O
the	O
regenerative	O
capacity	O
,	O
but	O
also	O
the	O
presence	O
and	O
expansion	O
of	O
stem	O
cells	O
will	O
be	O
significantly	O
restricted	O
in	O
aged	O
organs	O
.	O

Intriguingly	O
,	O
prolonged	O
culturing	O
of	O
hESCs	O
in	O
their	O
preferred	O
in	O
vitro	O
conditions	O
enables	O
generation	O
of	O
an	O
embryonic	O
microniche	O
that	O
antagonizes	O
the	O
inhibitory	O
influences	O
of	O
aged	O
circulatory	O
factors	O
.	O

Table	O
1Conservation	O
of	O
stem	O
cell	O
aging	O
in	O
the	O
systemic	O
environmentRate	O
of	O
proliferation	O
ESC	O
/	O
ASC	O
(	O
percentage	O
of	O
BrdU	O
)	O
Call	O
-	O
fate	O
identifier	O
ESC	O
(	O
percentage	O
of	O
Oct4	O
)	O
/	O
ASC	O
(	O
percentage	O
of	O
Myf5	O
)	O
10	O
%	O
young59.5	O
±	O
0.8	O
,	O
59.3	O
±	O
4.099.0	O
±	O
0.1	O
,	O
50.7	O
±	O
9.510	O
%	O
old32.7	O
±	O
2.1	O
,	O
27.3	O
±	O
3.517.6	O
±	O
3.2	O
,	O
18.1	O
±	O
5.95	O
%	O
young	O
+	O
5	O
%	O
old31.0	O

±	O
2.6	O
,	O
38.0	O
±	O
2.020.6	O
±	O
3.5	O
,	O
17.1	O
±	O
4.2Quantified	O
results	O
from	O
Figs	O
1	O
,	O
2	O
are	O
summarized	O
and	O
presented	O
as	O
mean	O
percentages	O
from	O
experimental	O
replicates	O
±	O
SE	O
.	O

Rate	O
of	O
proliferation	O
(	O
BrdU	O
)	O
and	O
cell	O
-	O
fate	O
identifier	O
(	O
Oct4	O
or	O
Myf5	O
)	O
are	O
shown	O
for	O
both	O
ESCs	O
and	O
ASCs	O
cultured	O
in	O
heterochronic	O
systemic	O
conditions	O
of	O
10	O
%	O
young	O
(	O
young	O
)	O
,	O
10	O
%	O
old	O
(	O
old	O
)	O
or	O
in	O
5%+	O
5	O
%	O
mouse	O
sera	O
combination	O
(	O
young	O
+	O
old	O
)	O
.	O

Results	O
for	O
5	O
%	O
young	O
mouse	O
sera	O
are	O
very	O
similar	O
to	O
those	O
for	O
10	O
%	O
young	O
mouse	O
sera	O
and	O
are	O
shown	O
in	O
Fig.	O
1	O
(	O
ASCs	O
)	O
and	O
Supplementary	O
Fig.	O
S3	O
(	O
hESCs	O
)	O
.	O

The	O
regenerative	O
potential	O
of	O
hESCs	O
and	O
ASCs	O
is	O
inhibited	O
by	O
aged	O
differentiated	O
muscleAfter	O
establishing	O
that	O
the	O
aged	O
systemic	O
niche	O
negatively	O
affects	O
the	O
regenerative	O
capacity	O
of	O
hESCs	O
and	O
of	O
ASCs	O
,	O
we	O
then	O
assessed	O
whether	O
myogenic	O
potential	O
and	O
the	O
rate	O
of	O
cell	O
proliferation	O
would	O
be	O
inhibited	O
in	O
hESCs	O
and	O
ASCs	O
by	O
the	O
aged	O
local	O
muscle	O
niche	O
.	O

Myofibers	O
with	O
associated	O
satellite	O
cells	O
were	O
isolated	O
from	O
young	O
and	O
old	O
injured	O
muscle	O
,	O
and	O
were	O
directly	O
co	O
-	O
cultured	O
with	O
hESCs	O
in	O
typical	O
hESC	O
differentiation	O
medium	O
(	O
DMEM	O
/	O
FBS	O
)	O
.	O

Similar	O
to	O
Fig.	O
1	O
,	O
the	O
myogenic	O
potential	O
in	O
these	O
co	O
-	O
cultures	O
was	O
assayed	O
by	O
the	O
expression	O
of	O
desmin	O
,	O
which	O
is	O
present	O
in	O
both	O
fusion	O
-	O
competent	O
myoblasts	O
and	O
newly	O
formed	O
myotubes	O
.	O

To	O
analyze	O
whether	O
hESCs	O
,	O
mouse	O
myogenic	O
progenitor	O
cells	O
or	O
both	O
could	O
express	O
desmin	O
in	O
direct	O
co	O
-	O
cultures	O
,	O
we	O
costained	O
these	O
cells	O
with	O
a	O
mouse	O
-	O
specific	O
antibody	O
to	O
a	O
myogenic	O
marker	O
,	O
M	O
-	O
cadherin	O
,	O
which	O
does	O
not	O
react	O
with	O
human	O
protein	O
,	O
and	O
a	O
desmin	O
-	O
specific	O
antibody	O
that	O
recognizes	O
both	O
mouse	O
and	O
human	O
proteins	O
.	O

As	O
shown	O
in	O
Fig.	O
4A	O
,	O
hESCs	O
underwent	O
myogenic	O
differentiation	O
in	O
co	O
-	O
cultures	O
with	O
young	O
myofibers	O
(	O
M	O
-	O
cadherin−	O
/	O
desmin+	O
mononucleated	O
cells	O
,	O
white	O
arrow	O
in	O
young	O
)	O
.	O

These	O
myogenic	O
progeny	O
of	O
hESCs	O
in	O
co	O
-	O
cultures	O
with	O
young	O
myofibers	O
could	O
be	O
of	O
skeletal	O
,	O
smooth	O
or	O
cardiac	O
muscle	O
lineages	O
(	O
Debus	O
et	O
al.	O
,	O
1983	O
;	O
Fischman	O
&	O
Danto	O
,	O
1985	O
;	O
Schultz	O
&	O
McCormick	O
,	O
1994	O
)	O
.	O

As	O
expected	O
,	O
the	O
young	O
mouse	O
muscle	O
progenitor	O
cells	O
(	O
M	O
-	O
cadherin+	O
/	O
desmin+	O
)	O
were	O
more	O
advanced	O
in	O
their	O
degree	O
of	O
myogenic	O
differentiation	O
,	O
which	O
was	O
of	O
skeletal	O
muscle	O
lineage	O
,	O
as	O
judged	O
by	O
the	O
formation	O
of	O
large	O
,	O
multinucleated	O
de	O
novo	O
myotubes	O
(	O
yellow	O
arrow	O
in	O
young	O
)	O
.	O

In	O
addition	O
to	O
the	O
myogenically	O
differentiated	O
human	O
cells	O
,	O
co	O
-	O
cultures	O
with	O
young	O
myofiber	O
explants	O
also	O
contained	O
some	O
small	O
undifferentiated	O
hESC	O
colonies	O
,	O
as	O
determined	O
by	O
immunoreactivity	O
to	O
a	O
human	O
-	O
specific	O
antibody	O
to	O
the	O
nuclear	O
mitotic	O
apparatus	O
protein	O
,	O
NuMA	O
and	O
Oct4	O
expression	O
(	O
Supplementary	O
Fig.	O
S4	O
)	O
.In	O
contrast	O
,	O
when	O
co	O
-	O
cultured	O
with	O
the	O
aged	O
mouse	O
myofibers	O
,	O
only	O
mouse	O
cells	O
appeared	O
desmin+	O
(	O
Fig.	O
4A	O
,	O
yellow	O
arrow	O
in	O
old	O
)	O
.	O

These	O
aged	O
myogenic	O
cells	O
were	O
of	O
skeletal	O
muscle	O
lineage	O
,	O
based	O
on	O
spontaneous	O
generation	O
of	O
multinucleated	O
myotubes	O
(	O
see	O
Fig.	O
5B	O
)	O
and	O
based	O
on	O
induced	O
differentiation	O
into	O
myotubes	O
in	O
DMEM	O
+	O
2	O
%	O
horse	O
serum	O
(	O
not	O
shown	O
)	O
.	O

Importantly	O
,	O
the	O
myogenic	O
differentiation	O
of	O
hESCs	O
failed	O
in	O
the	O
aged	O
co	O
-	O
cultures	O
(	O
Fig.	O
4A	O
,	O
white	O
arrow	O
in	O
old	O
)	O
.	O

Furthermore	O
,	O
colonies	O
of	O
hESCs	O
in	O
co	O
-	O
cultures	O
with	O
aged	O
myofibers	O
typically	O
differentiated	O
into	O
cells	O
with	O
fibroblast	O
morphology	O
,	O
which	O
lacked	O
Oct4	O
expression	O
(	O
not	O
shown	O
)	O
.	O

Spontaneous	O
production	O
of	O
desmin+	O
myogenic	O
cells	O
in	O
control	O
hESC	O
cultures	O
without	O
myofibers	O
,	O
or	O
with	O
young	O
/	O
old	O
mouse	O
sera	O
was	O
less	O
than	O
0.1	O
%	O
(	O
not	O
shown	O
)	O
.Fig	O
.	O

5In	O
vitro	O
co	O
-	O
culture	O
with	O
hESCs	O
enhanced	O
myogenesis	O
of	O
mouse	O
cells	O
.	O

(	O
A	O
)	O
1	O
×	O
105	O
hESCs	O
or	O
control	O
hMSCs	O
were	O
co	O
-	O
cultured	O
with	O
5	O
×	O
106	O
primary	O
mouse	O
myoblasts	O
.	O

hESCs	O
expressing	O
Oct4	O
(	O
immunodetection	O
shown	O
in	O
red	O
)	O
dramatically	O
enhanced	O
myotube	O
formation	O
of	O
co	O
-	O
cultured	O
mouse	O
myoblasts	O
(	O
immunodetection	O
of	O
eMyHC	O
is	O
shown	O
in	O
green	O
)	O
,	O
as	O
compared	O
to	O
co	O
-	O
cultures	O
between	O
mouse	O
myoblasts	O
and	O
human	O
mesenchymal	O
stem	O
cells	O
(	O
Mb	O
+	O
hMSCs	O
)	O
or	O
myoblasts	O
alone	O
(	O
Mb	O
alone	O
)	O
.	O

Experiments	O
were	O
carried	O
out	O
in	O
myoblast	O
differentiation	O
medium	O
.	O

Hoechst	O
(	O
blue	O
)	O
labels	O
nuclei	O
throughout	O
this	O
figure	O
.	O

(	O
B	O
)	O
1	O
×	O
105	O
hESCs	O
or	O
control	O
hMSCs	O
were	O
co	O
-	O
cultured	O
with	O
young	O
or	O
old	O
myofiber	O
-	O
associated	O
satellite	O
cells	O
,	O
as	O
described	O
in	O
Experimental	O
procedures	O
.	O

Co	O
-	O
culture	O
with	O
hESCs	O
(	O
myofiber	O
+	O
hESC	O
)	O
,	O
but	O
not	O
hMSCs	O
(	O
myofiber	O
+	O
hMSC	O
)	O
or	O
control	O
medium	O
(	O
DMEM	O
/	O
FBS	O
)	O
,	O
greatly	O
enhanced	O
the	O
myogenic	O
potential	O
of	O
both	O
young	O
and	O
old	O
myofiber	O
-	O
associated	O
satellite	O
cells	O
,	O
based	O
on	O
immunodetection	O
of	O
percentage	O
of	O
desmin+	O
de	O
novo	O
generated	O
myoblasts	O
and	O
multinucleated	O
myotubes	O
.	O

These	O
experiments	O
were	O
carried	O
out	O
in	O
GM	O
.	O

Shown	O
are	O
myogenic	O
responses	O
of	O
mouse	O
cells	O
only	O
,	O
judged	O
by	O
lack	O
of	O
immunoreactivity	O
to	O
human	O
-	O
specific	O
/	O
hESC	O
-	O
specific	O
antigens	O
,	O
such	O
as	O
NuMA	O
and	O
Oct4	O
;	O
and	O
presence	O
of	O
mouse	O
-	O
specific	O
immunoreactivity	O
,	O
e.g.	O
,	O
M	O
-	O
cadherin	O
(	O
not	O
shown	O
)	O
.	O

Both	O
young	O
and	O
old	O
myofiber	O
associated	O
satellite	O
cells	O
exhibited	O
considerable	O
myogenic	O
improvement	O
over	O
control	O
conditions	O
.	O

n	O
=	O
3.In	O
concert	O
with	O
the	O
conservation	O
of	O
inhibitory	O
affects	O
of	O
aged	O
systemic	O
niche	O
,	O
the	O
negative	O
influence	O
of	O
local	O
muscle	O
niche	O
was	O
also	O
found	O
to	O
be	O
conserved	O
in	O
its	O
inhibition	O
of	O
hESC	O
and	O
ASC	O
regenerative	O
responses	O
.	O

Specifically	O
,	O
the	O
myogenic	O
capacity	O
(	O
generation	O
of	O
desmin+	O
myoblasts	O
)	O
was	O
inhibited	O
in	O
young	O
satellite	O
cells	O
co	O
-	O
cultured	O
in	O
a	O
transwell	O
system	O
with	O
aged	O
myofibers	O
(	O
Fig.	O
4B	O
)	O
.	O

In	O
addition	O
,	O
hESC	O
and	O
ASC	O
proliferation	O
(	O
BrdU	O
incorporation	O
)	O
was	O
also	O
inhibited	O
by	O
aged	O
differentiated	O
muscle	O
(	O
Fig.	O
4A	O
,	O
C	O
)	O
.	O

These	O
data	O
suggest	O
that	O
not	O
only	O
systemic	O
but	O
also	O
local	O
organ	O
niches	O
would	O
inhibit	O
key	O
stem	O
cell	O
properties	O
,	O
e.g.	O
,	O
myogenic	O
capacity	O
and	O
the	O
rate	O
of	O
proliferation	O
in	O
the	O
aged	O
organism	O
.	O

The	O
conserved	O
inhibitory	O
influences	O
of	O
the	O
differentiated	O
muscle	O
niche	O
on	O
hESC	O
and	O
ASC	O
regenerative	O
responses	O
are	O
summarized	O
in	O
Table	O
2.Table	O
2Conservation	O
of	O
stem	O
cell	O
aging	O
in	O
the	O
local	O
organ	O
nicheRate	O
of	O
proliferation	O
ESC	O
/	O
ASC	O
(	O
percentage	O
of	O
BrdU	O
)	O
Myogenic	O
differentiation	O
ESC	O
/	O
ASC	O
(	O
percentage	O
of	O
desmin	O
)	O
Young	O
myofiber60.2	O
±	O
2.5	O
,	O
40.5	O
±	O
2.67.4	O
±	O
0.9	O
,	O
47.6	O
±	O
5.0Old	O
myofiber30.1	O
±	O
4.3	O
,	O
21.5	O
±	O
4.11.3	O
±	O
0.7	O
,	O
19.7	O
±	O
4.7Quantified	O
results	O
from	O
Fig.	O
4	O
are	O
summarized	O
and	O
presented	O
as	O
mean	O
percentages	O
from	O
experimental	O
replicates	O
±	O
SE	O
.	O

Rate	O
of	O
proliferation	O
(	O
BrdU	O
)	O
and	O
myogenic	O
differentiation	O
(	O
desmin	O
)	O
are	O
shown	O
for	O
both	O
ESCs	O
and	O
ASCs	O
,	O
in	O
the	O
presence	O
of	O
young	O
vs.	O
old	O
differentiated	O
muscle	O
environments	O
(	O
young	O
myofiber	O
or	O
old	O
myofiber	O
)	O
.	O

hESCs	O
indirectly	O
enhance	O
and	O
rejuvenate	O
the	O
regeneration	O
of	O
skeletal	O
muscleWhile	O
hESC	O
properties	O
were	O
inhibited	O
by	O
aged	O
differentiated	O
muscle	O
,	O
the	O
myogenic	O
potential	O
of	O
aged	O
satellite	O
cells	O
seemed	O
to	O
be	O
enhanced	O
by	O
co	O
-	O
cultures	O
with	O
hESCs	O
(	O
Fig.	O
4A	O
)	O
.	O

Therefore	O
,	O
we	O
further	O
explored	O
the	O
enhancing	O
and	O
rejuvenating	O
effects	O
of	O
hESCs	O
on	O
myogenic	O
potential	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
using	O
human	O
mesenchymal	O
stem	O
cells	O
(	O
hMSCs	O
)	O
as	O
a	O
negative	O
control	O
.	O

First	O
,	O
we	O
examined	O
the	O
effects	O
of	O
hESCs	O
on	O
myotube	O
generation	O
by	O
co	O
-	O
culture	O
with	O
primary	O
myoblasts	O
freshly	O
derived	O
from	O
activated	O
-	O
by	O
-	O
injury	O
satellite	O
cells	O
(	O
Conboy	O
et	O
al.	O
,	O
2003	O
)	O
.	O

As	O
shown	O
in	O
Fig.	O
5A	O
(	O
Mb	O
+	O
hESC	O
)	O
,	O
primary	O
myoblasts	O
underwent	O
very	O
rapid	O
and	O
robust	O
nascent	O
myotube	O
formation	O
,	O
when	O
co	O
-	O
cultured	O
with	O
hESCs	O
for	O
48	O
h	O
in	O
myoblast	O
differentiation	O
medium	O
.	O

Namely	O
,	O
remarkably	O
large	O
fused	O
myotubes	O
containing	O
approximately	O
50–70	O
nuclei	O
formed	O
around	O
hESCs	O
colonies	O
(	O
Fig.	O
5A	O
)	O
.	O

In	O
contrast	O
,	O
when	O
co	O
-	O
cultured	O
with	O
hMSCs	O
,	O
myotube	O
formation	O
was	O
no	O
greater	O
than	O
in	O
myoblast	O
cultures	O
alone	O
(	O
Fig.	O
5A	O
,	O
Mb	O
+	O
hMSC	O
and	O
Mb	O
alone	O
)	O
.	O

Encouraged	O
by	O
these	O
data	O
,	O
we	O
analyzed	O
the	O
myogenic	O
potential	O
of	O
young	O
and	O
old	O
satellite	O
cells	O
co	O
-	O
cultured	O
with	O
hESCs	O
for	O
48	O
h.	O
As	O
shown	O
in	O
Fig.	O
5B	O
,	O
hESCs	O
conferred	O
a	O
much	O
-	O
enhanced	O
myogenic	O
capacity	O
on	O
both	O
young	O
and	O
,	O
importantly	O
,	O
old	O
myofiber	O
-	O
associated	O
satellite	O
cells	O
(	O
rapid	O
formation	O
of	O
desmin+	O
myogenic	O
cells	O
,	O
many	O
of	O
which	O
formed	O
de	O
novo	O
multinucleated	O
myotubes	O
)	O
.	O

Control	O
co	O
-	O
cultures	O
of	O
these	O
satellite	O
cells	O
with	O
hMSCs	O
displayed	O
no	O
enhanced	O
myogenicity	O
.	O

In	O
summary	O
,	O
while	O
the	O
myogenic	O
potential	O
(	O
production	O
of	O
desmin+	O
fusion	O
-	O
competent	O
cells	O
)	O
was	O
more	O
pronounced	O
in	O
young	O
vs.	O
old	O
myofiber	O
-	O
associated	O
satellite	O
cells	O
under	O
all	O
experimental	O
conditions	O
,	O
a	O
finding	O
that	O
is	O
consistent	O
with	O
previous	O
data	O
(	O
Conboy	O
et	O
al.	O
,	O
2003	O
)	O
,	O
a	O
clear	O
increase	O
in	O
myogenic	O
potential	O
of	O
old	O
satellite	O
cells	O
was	O
noted	O
in	O
co	O
-	O
cultures	O
with	O
hESCs	O
,	O
as	O
compared	O
to	O
control	O
cultures	O
devoid	O
of	O
hESCs	O
(	O
Fig.	O
4A	O
,	O
B	O
)	O
.Interestingly	O
,	O
in	O
addition	O
to	O
the	O
rejuvenating	O
effects	O
of	O
direct	O
co	O
-	O
cultures	O
shown	O
in	O
Fig.	O
5	O
,	O
soluble	O
factors	O
present	O
in	O
hESC	O
-	O
conditioned	O
culture	O
supernatants	O
were	O
also	O
able	O
to	O
enhance	O
myogenesis	O
of	O
aged	O
satellite	O
cells	O
(	O
Supplementary	O
Fig.	O
S5	O
)	O
.	O

Thus	O
,	O
in	O
agreement	O
with	O
the	O
notion	O
that	O
an	O
established	O
embryonic	O
microniche	O
antagonizes	O
the	O
inhibitory	O
effects	O
of	O
the	O
aged	O
environment	O
on	O
stem	O
cell	O
responses	O
(	O
Fig.	O
3	O
)	O
,	O
the	O
hESC	O
-	O
produced	O
factors	O
enhanced	O
myogenic	O
capacity	O
of	O
even	O
old	O
mouse	O
satellite	O
cells	O
.	O

Establishing	O
that	O
hESC	O
-	O
produced	O
factors	O
enhance	O
adult	O
myogenesis	O
and	O
rejuvenate	O
the	O
regenerative	O
capacity	O
of	O
even	O
aged	O
satellite	O
cells	O
in	O
vitro	O
prompted	O
us	O
to	O
examine	O
whether	O
the	O
regeneration	O
of	O
old	O
injured	O
muscle	O
will	O
be	O
improved	O
by	O
hESC	O
transplantation	O
in	O
vivo	O
.	O

Additionally	O
,	O
based	O
on	O
the	O
data	O
shown	O
above	O
,	O
we	O
speculated	O
that	O
even	O
if	O
the	O
host	O
's	O
repair	O
capacity	O
is	O
improved	O
,	O
hESCs	O
themselves	O
will	O
not	O
be	O
efficiently	O
maintained	O
or	O
expanded	O
in	O
the	O
context	O
of	O
old	O
systemic	O
and	O
local	O
organ	O
environments	O
,	O
and	O
will	O
not	O
directly	O
contribute	O
to	O
the	O
repair	O
of	O
aged	O
skeletal	O
muscle	O
.	O

To	O
test	O
these	O
hypotheses	O
,	O
we	O
injected	O
5	O
×	O
105	O
hESCs	O
or	O
control	O
hMSCs	O
into	O
the	O
tibialis	O
anterior	O
(	O
TA	O
)	O
and	O
gastrocnemius	O
muscles	O
of	O
young	O
and	O
old	O
mice	O
at	O
24	O
h	O
after	O
cardiotoxin	O
-	O
induced	O
injury	O
,	O
when	O
activation	O
/	O
proliferation	O
of	O
endogenous	O
satellite	O
cells	O
normally	O
begins	O
(	O
Conboy	O
et	O
al.	O
,	O
2003	O
,	O
2005	O
;	O
Wagers	O
&	O
Conboy	O
,	O
2005	O
)	O
.	O

To	O
avoid	O
immune	O
response	O
against	O
hESC	O
antigens	O
,	O
mice	O
were	O
immunosuppressed	O
using	O
FK506	O
(	O
Ito	O
&	O
Tanaka	O
,	O
1997	O
;	O
Dumont	O
,	O
2000	O
)	O
.	O

Muscle	O
was	O
isolated	O
5	O
days	O
post	O
-	O
injury	O
,	O
when	O
nascent	O
differentiated	O
myofibers	O
normally	O
replace	O
the	O
damaged	O
tissue	O
(	O
Conboy	O
et	O
al.	O
,	O
2003	O
)	O
,	O
and	O
10	O
µm	O
cryosections	O
were	O
analyzed	O
for	O
the	O
success	O
in	O
tissue	O
repair	O
using	O
hematoxylin	O
and	O
eosin	O
(	O
H&E	O
)	O
histochemistry	O
and	O
eMyHC	O
immunodetection	O
.	O

H&E	O
analysis	O
reveals	O
newly	O
formed	O
myofibers	O
,	O
based	O
on	O
their	O
smaller	O
size	O
and	O
centrally	O
located	O
nuclei	O
.	O

Additionally	O
,	O
de	O
novo	O
myofibers	O
in	O
the	O
damaged	O
area	O
appear	O
positive	O
for	O
eMyHC	O
,	O
while	O
undamaged	O
myofibers	O
remain	O
negative	O
.	O

As	O
shown	O
in	O
Fig.	O
6A	O
and	O
quantified	O
in	O
6B	O
,	O
injection	O
of	O
hESCs	O
significantly	O
enhanced	O
regeneration	O
of	O
skeletal	O
muscle	O
.	O

Remarkably	O
,	O
this	O
positive	O
embryonic	O
effect	O
was	O
especially	O
pronounced	O
in	O
old	O
tissue	O
.	O

Fig.	O

6Skeletal	O
muscle	O
regeneration	O
following	O
hESC	O
transplantation	O
is	O
a	O
balance	O
between	O
the	O
inhibitory	O
influence	O
of	O
aged	O
niches	O
and	O
the	O
rejuvenating	O
effects	O
of	O
hESCs	O
.	O

Young	O
and	O
old	O
tibialis	O
anterior	O
and	O
gastrocnemius	O
muscles	O
were	O
injured	O
by	O
cardiotoxin	O
injection	O
.	O

hESCs	O
or	O
hMSCs	O
were	O
transplanted	O
at	O
the	O
site	O
of	O
injury	O
and	O
were	O
analyzed	O
by	O
cryosectioning	O
at	O
Day	O
5	O
after	O
injury	O
(	O
as	O
described	O
in	O
Experimental	O
procedures	O
)	O
.	O

(	O
A	O
)	O
Newly	O
regenerated	O
myofibers	O
were	O
detected	O
using	O
eMyHC	O
-	O
specific	O
antibody	O
(	O
green	O
)	O
and	O
staining	O
with	O
H&E.	O
In	O
H&E	O
staining	O
,	O
newly	O
regenerated	O
areas	O
contain	O
smaller	O
,	O
immature	O
myofibers	O
with	O
centrally	O
located	O
nuclei	O
.	O

Uninjured	O
myofibers	O
are	O
much	O
larger	O
,	O
by	O
comparison	O
,	O
with	O
peripherally	O
restricted	O
nuclei	O
.	O

Poorly	O
regenerated	O
areas	O
lack	O
new	O
myofibers	O
and	O
contain	O
areas	O
of	O
fibrosis	O
and	O
inflammation	O
.	O

eMyHC	O
immunodetection	O
is	O
specific	O
for	O
regenerating	O
areas	O
of	O
muscle	O
only	O
.	O

Both	O
assays	O
showed	O
dramatic	O
enhancement	O
of	O
muscle	O
regeneration	O
in	O
'	O
old	O
+	O
hESC	O
'	O
vs.	O
'	O
old	O
+	O
hMSC	O
'	O
.	O

Regeneration	O
improvement	O
was	O
also	O
seen	O
in	O
young	O
+	O
hESC	O
,	O
as	O
compared	O
to	O
young	O
+	O
hMSC	O
.	O

(	O
B	O
)	O
Quantification	O
of	O
muscle	O
regeneration	O
was	O
performed	O
by	O
analyzing	O
the	O
density	O
of	O
newly	O
formed	O
myofibers	O
per	O
mm2	O
of	O
injury	O
site	O
,	O
which	O
is	O
the	O
volume	O
that	O
typically	O
covers	O
the	O
whole	O
injured	O
area	O
.	O

Multiple	O
,	O
10	O
µm	O
H&E	O
sections	O
were	O
examined	O
through	O
the	O
entire	O
volume	O
of	O
injury	O
in	O
multiple	O
,	O
independently	O
injured	O
muscles	O
.	O

n	O
=	O
20	O
;	O

*	O
indicates	O
P	O
<	O
0.001	O
(	O
'	O
old	O
+	O
hMSC	O
'	O
compared	O
to	O
young	O
+	O
hMSC	O
and	O
'	O
old	O
+	O
hMSC	O
'	O
compared	O
to	O
'	O
old	O
+	O
hESC	O
'	O
.	O

(	O
C	O
)	O
H&E	O
and	O
immunofluoresence	O
staining	O
for	O
Oct4	O
,	O
and	O
a	O
human	O
-	O
specific	O
antibody	O
to	O
NuMA	O
,	O
revealed	O
the	O
failure	O
of	O
hESCs	O
to	O
expand	O
or	O
persist	O
in	O
old	O
,	O
but	O
the	O
presence	O
of	O
hESCs	O
in	O
young	O
muscle	O
at	O
5	O
days	O
post	O
-	O
transplantation	O
.	O

Hoechst	O
(	O
blue	O
)	O
labels	O
nuclei	O
.	O

Importantly	O
,	O
such	O
enhanced	O
and	O
rejuvenated	O
muscle	O
repair	O
stems	O
from	O
an	O
indirect	O
induction	O
,	O
as	O
hESCs	O
themselves	O
(	O
or	O
control	O
hMSCs	O
)	O
did	O
not	O
physically	O
contribute	O
to	O
the	O
mouse	O
myofibers	O
,	O
as	O
judged	O
by	O
near	O
absence	O
(	O
less	O
than	O
0.1	O
%	O
)	O
of	O
human	O
-	O
specific	O
NuMA+	O
nuclei	O
in	O
de	O
novo	O
desmin+	O
myofibers	O
,	O
analyzed	O
through	O
multiple	O
injury	O
sites	O
.	O

An	O
example	O
of	O
one	O
regenerated	O
myofiber	O
from	O
young	O
muscle	O
injected	O
with	O
hESCs	O
,	O
with	O
NuMA+	O
nucleus	O
in	O
a	O
field	O
of	O
NuMA−	O
/	O
desmin+	O
mouse	O
myofibers	O
,	O
is	O
shown	O
in	O
Supplementary	O
Fig.	O
S6	O
.	O

No	O
such	O
NuMA+	O
/	O
desmin+	O
myofibers	O
were	O
detected	O
in	O
aged	O
regenerated	O
muscle	O
(	O
not	O
shown	O
)	O
.In	O
agreement	O
with	O
the	O
in	O
vitro	O
data	O
,	O
establishing	O
that	O
aged	O
systemic	O
and	O
local	O
niches	O
inhibit	O
hESC	O
proliferation	O
and	O
Oct4	O
expression	O
(	O
Figs	O
2	O
and	O
4	O
and	O
Supplementary	O
Fig.	O
S2	O
)	O
,	O
hESCs	O
failed	O
to	O
expand	O
or	O
even	O
persist	O
in	O
old	O
muscle	O
,	O
as	O
judged	O
by	O
the	O
absence	O
of	O
NuMA+	O
/	O
Oct4	O
+	O
hESC	O
-	O
derived	O
cells	O
in	O
the	O
aged	O
tissue	O
.	O

In	O
contrast	O
,	O
colonies	O
of	O
Numa+	O
/	O
Oct4	O
+	O
hESC	O
-	O
derived	O
cells	O
that	O
did	O
not	O
undergo	O
myogenic	O
differentiation	O
were	O
easily	O
detected	O
in	O
young	O
regenerating	O
muscle	O
(	O
Fig.	O
6C	O
)	O
.	O

This	O
finding	O
validates	O
several	O
technical	O
aspects	O
of	O
these	O
experiments	O
,	O
and	O
confirms	O
the	O
contrasting	O
effects	O
of	O
young	O
and	O
old	O
systemic	O
and	O
local	O
organ	O
niches	O
on	O
hESC	O
self	O
-	O
renewal	O
.	O

These	O
data	O
further	O
confirm	O
and	O
extrapolate	O
our	O
findings	O
and	O
demonstrate	O
that	O
when	O
exposed	O
to	O
both	O
aged	O
systemic	O
and	O
local	O
organ	O
niches	O
,	O
hESCs	O
fail	O
to	O
persist	O
and	O
do	O
not	O
contribute	O
to	O
tissue	O
repair	O
directly	O
.	O

At	O
the	O
same	O
time	O
,	O
these	O
embryonic	O
cells	O
indirectly	O
but	O
significantly	O
improve	O
the	O
repair	O
of	O
aged	O
injured	O
muscle	O
in	O
vivo	O
.	O

The	O
data	O
presented	O
here	O
establish	O
for	O
the	O
first	O
time	O
that	O
both	O
the	O
local	O
environment	O
of	O
old	O
differentiated	O
organ	O
,	O
e.g.	O
,	O
skeletal	O
muscle	O
and	O
the	O
systemic	O
milieu	O
dramatically	O
affect	O
the	O
regenerative	O
potential	O
of	O
both	O
hESCs	O
and	O
mouse	O
post	O
-	O
natal	O
myogenic	O
progenitor	O
cells	O
.	O

Not	O
only	O
are	O
the	O
factors	O
promoting	O
myogenic	O
differentiation	O
and	O
proliferation	O
of	O
hESCs	O
likely	O
to	O
become	O
depleted	O
with	O
age	O
,	O
but	O
the	O
aged	O
systemic	O
and	O
local	O
organ	O
niches	O
are	O
likely	O
to	O
contain	O
dominant	O
inhibitors	O
of	O
ASC	O
and	O
hESC	O
regenerative	O
potential	O
(	O
Figs	O
1	O
,	O
2	O
,	O
and	O
4	O
,	O
summarized	O
in	O
Tables	O
1	O
and	O
2	O
)	O
.	O

Importantly	O
,	O
the	O
similar	O
inhibitory	O
effects	O
of	O
old	O
mouse	O
serum	O
and	O
old	O
myofibers	O
on	O
satellite	O
cell	O
(	O
Figs	O
1	O
and	O
4C	O
)	O
and	O
hESC	O
(	O
Figs	O
2	O
and	O
4A	O
)	O
proliferation	O
and	O
regenerative	O
capacity	O
suggest	O
the	O
conservation	O
of	O
elements	O
in	O
age	O
-	O
specific	O
extrinsic	O
regulatory	O
mechanisms	O
between	O
evolutionarily	O
distinct	O
species	O
and	O
stem	O
cell	O
types	O
.	O

Additionally	O
,	O
a	O
similarity	O
in	O
the	O
inhibitory	O
properties	O
between	O
systemic	O
and	O
local	O
organ	O
niches	O
is	O
also	O
of	O
interest	O
and	O
may	O
indicate	O
that	O
molecules	O
produced	O
by	O
old	O
tissues	O
have	O
circulatory	O
/	O
endocrine	O
activity	O
;	O
and/or	O
that	O
age	O
-	O
specific	O
systemic	O
inhibitory	O
components	O
become	O
deposited	O
in	O
the	O
old	O
tissues	O
.	O

Humans	O
display	O
broad	O
genetic	O
polymorphisms	O
and	O
behavioral	O
variations	O
,	O
which	O
makes	O
the	O
identification	O
of	O
age	O
-	O
specific	O
molecular	O
changes	O
complicated	O
.	O

In	O
contrast	O
,	O
laboratory	O
mice	O
are	O
genetically	O
and	O
environmentally	O
controlled	O
.	O

Establishing	O
that	O
age	O
-	O
specific	O
signals	O
,	O
regulating	O
stem	O
cell	O
responses	O
,	O
are	O
evolutionarily	O
conserved	O
and	O
soluble	O
enables	O
the	O
formation	O
of	O
rational	O
approaches	O
for	O
the	O
identification	O
and	O
characterization	O
of	O
the	O
inhibitors	O
involved	O
,	O
and	O
for	O
revealing	O
the	O
precise	O
timing	O
of	O
their	O
first	O
appearance	O
in	O
serum	O
and	O
differentiated	O
tissues	O
with	O
advancing	O
age	O
.	O

Significantly	O
,	O
these	O
experiments	O
have	O
also	O
revealed	O
that	O
not	O
only	O
are	O
hESCs	O
able	O
to	O
protect	O
themselves	O
against	O
the	O
negative	O
influences	O
of	O
aged	O
mouse	O
sera	O
(	O
Fig.	O
3	O
)	O
,	O
but	O
these	O
cells	O
also	O
produce	O
factors	O
that	O
dramatically	O
enhance	O
the	O
myogenic	O
capacity	O
of	O
primary	O
myoblasts	O
and	O
young	O
and	O
old	O
satellite	O
cells	O
(	O
Fig.	O
5	O
)	O
,	O
and	O
also	O
significantly	O
improve	O
repair	O
of	O
young	O
and	O
old	O
injured	O
muscle	O
in	O
vivo	O
(	O
Fig.	O
6	O
)	O
.	O

Identification	O
of	O
these	O
embryonic	O
factors	O
would	O
allow	O
us	O
to	O
potentially	O
enrich	O
the	O
arsenal	O
of	O
therapeutic	O
tools	O
for	O
combating	O
age	O
-	O
specific	O
degenerative	O
disorders	O
.	O

The	O
interactions	O
between	O
hESCs	O
and	O
heterochronic	O
differentiated	O
niches	O
,	O
initially	O
identified	O
in	O
vitro	O
,	O
have	O
been	O
confirmed	O
by	O
in	O
vivo	O
experiments	O
.	O

Namely	O
,	O
while	O
the	O
regenerative	O
capacity	O
,	O
or	O
presence	O
,	O
of	O
hESCs	O
is	O
greatly	O
restricted	O
in	O
aged	O
,	O
as	O
compared	O
to	O
young	O
skeletal	O
muscle	O
(	O
where	O
transplanted	O
cells	O
experience	O
both	O
old	O
systemic	O
and	O
local	O
environments	O
)	O
,	O
embryonic	O
cells	O
indirectly	O
enhance	O
and	O
rejuvenate	O
muscle	O
repair	O
when	O
introduced	O
at	O
the	O
time	O
of	O
muscle	O
stem	O
cell	O
activation	O
in	O
the	O
host	O
,	O
e.g.	O
,	O
at	O
Day	O
1	O
after	O
the	O
injury	O
(	O
Fig.	O
6	O
)	O
.	O

It	O
remains	O
to	O
be	O
determined	O
whether	O
the	O
percentage	O
of	O
hESCs	O
direct	O
contribution	O
to	O
desmin+	O
myofibers	O
in	O
young	O
muscle	O
will	O
be	O
increased	O
by	O
transplanting	O
these	O
cells	O
at	O
a	O
different	O
time	O
-	O
point	O
after	O
muscle	O
injury	O
,	O
e.g.	O
,	O
at	O
Days	O
3–5	O
(	O
as	O
in	O
co	O
-	O
cultures	O
with	O
myofibers	O
pre	O
-	O
injured	O
for	O
3	O
days	O
,	O
Fig.	O
4A	O
)	O
.	O

In	O
any	O
case	O
,	O
the	O
virtual	O
lack	O
of	O
hESC	O
and	O
hMSC	O
direct	O
contribution	O
to	O
the	O
newly	O
regenerated	O
skeletal	O
muscle	O
,	O
when	O
small	O
numbers	O
of	O
these	O
cells	O
were	O
injected	O
into	O
injured	O
tissue	O
,	O
is	O
completely	O
consistent	O
with	O
the	O
body	O
of	O
previous	O
data	O
demonstrating	O
that	O
myofiber	O
-	O
associated	O
satellite	O
cells	O
conduct	O
rapid	O
and	O
robust	O
muscle	O
repair	O
and	O
greatly	O
outnumber	O
injected	O
human	O
cells	O
(	O
Collins	O
et	O
al.	O
,	O
2005	O
;	O
Wagers	O
&	O
Conboy	O
,	O
2005	O
)	O
;	O
that	O
compared	O
to	O
muscle	O
-	O
specific	O
satellite	O
cells	O
,	O
the	O
myogenic	O
differentiation	O
of	O
hESCs	O
in	O
vitro	O
remains	O
very	O
small	O
(	O
Fig.	O
5	O
,	O
Table	O
2	O
)	O
,	O
and	O
that	O
control	O
hMSCs	O
are	O
not	O
normally	O
myogenic	O
unless	O
these	O
cells	O
overexpress	O
exogenous	O
constitutively	O
active	O
domain	O
of	O
Notch	O
(	O
Dezawa	O
et	O
al.	O
,	O
2005	O
)	O
.	O

Intriguingly	O
,	O
the	O
failure	O
of	O
hESCs	O
to	O
strive	O
in	O
old	O
skeletal	O
muscle	O
might	O
represent	O
a	O
therapeutically	O
desirable	O
outcome	O
.	O

For	O
example	O
,	O
while	O
in	O
young	O
tissue	O
hESC	O
derivatives	O
putatively	O
would	O
go	O
on	O
to	O
produce	O
teratomas	O
,	O
it	O
is	O
unlikely	O
that	O
teratoma	O
formation	O
would	O
occur	O
after	O
hESC	O
transplantation	O
into	O
aged	O
skeletal	O
muscle	O
.	O

Thus	O
,	O
the	O
indirect	O
beneficial	O
effects	O
of	O
hESCs	O
on	O
tissue	O
repair	O
are	O
unlikely	O
to	O
be	O
compromised	O
by	O
the	O
oncogenic	O
properties	O
of	O
these	O
embryonic	O
cells	O
in	O
the	O
context	O
of	O
old	O
skeletal	O
muscle	O
.	O

Comprehensively	O
,	O
the	O
results	O
of	O
this	O
work	O
increase	O
our	O
understanding	O
of	O
aging	O
as	O
a	O
process	O
,	O
reveal	O
evolutionary	O
conserved	O
age	O
-	O
specific	O
interactions	O
between	O
stem	O
cells	O
and	O
their	O
differentiated	O
niches	O
,	O
and	O
suggest	O
novel	O
therapeutic	O
approaches	O
for	O
improving	O
the	O
regenerative	O
responses	O
of	O
endogenous	O
or	O
transplanted	O
stem	O
cells	O
in	O
old	O
individuals	O
.	O

Animal	O
strainsYoung	O
(	O
2–3	O
months	O
)	O
,	O
C57-BL	O
/	O
6	O
male	O
mice	O
were	O
obtained	O
from	O
pathogen	O
-	O
free	O
breeding	O
colonies	O
at	O
Jackson	O
Laboratories	O
(	O
Bar	O
Harbor	O
,	O
ME	O
,	O
USA	O
)	O
.	O

Aged	O
22–24	O
months	O
C57-BL	O
/	O
6	O
male	O
mice	O
were	O
obtained	O
from	O
the	O
National	O
Institute	O
on	O
Aging	O
(	O
NIH	O
)	O
.	O

Animals	O
were	O
maintained	O
in	O
the	O
North	O
-	O
West	O
Animal	O
Facility	O
of	O
the	O
University	O
of	O
California	O
,	O
Berkeley	O
,	O
CA	O
,	O
USA	O
,	O
and	O
handled	O
in	O
accordance	O
with	O
the	O
Administrative	O
Panel	O
on	O
Laboratory	O
Animal	O
Care	O
at	O
UC	O
Berkeley	O
.	O

Muscle	O
injury	O
and	O
isolationMyofiber	O
cultures	O
,	O
in	O
which	O
satellite	O
cells	O
were	O
activated	O
by	O
in	O
vivo	O
injury	O
,	O
were	O
set	O
up	O
as	O
previously	O
described	O
(	O
Conboy	O
&	O
Rando	O
,	O
2002	O
;	O
Conboy	O
et	O
al.	O
,	O
2005	O
)	O
.	O

Briefly	O
,	O
mice	O
were	O
injured	O
by	O
direct	O
injection	O
with	O
5	O
ng	O
cardiotoxin	O
(	O
CTX-1	O
)	O
(	O
Sigma	O
,	O
St	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
into	O
the	O
tibialis	O
anterior	O
and	O
gastrocnemius	O
muscles	O
using	O
a	O
28-gauge	O
needle	O
.	O

After	O
1–5	O
days	O
post	O
-	O
injection	O
,	O
injured	O
or	O
uninjured	O
muscle	O
tissue	O
was	O
dissected	O
out	O
.	O

Once	O
isolated	O
,	O
whole	O
muscle	O
was	O
prepared	O
for	O
cryosectioning	O
(	O
see	O
below	O
)	O
or	O
myofiber	O
fragments	O
were	O
obtained	O
from	O
hind	O
limb	O
muscles	O
by	O
enzymatic	O
digestion	O
(	O
see	O
below	O
)	O
,	O
trituration	O
,	O
and	O
multiple	O
sedimentation	O
and	O
washing	O
procedures	O
.	O

Additionally	O
,	O
blood	O
was	O
collected	O
from	O
mice	O
for	O
the	O
isolation	O
of	O
sera	O
.	O

Briefly	O
,	O
blood	O
cells	O
were	O
coagulated	O
at	O
37	O
°	O
C	O
for	O
15	O
'	O
and	O
then	O
were	O
centrifuged	O
repeatedly	O
at	O
5900	O
g	O
,	O
4	O
°	O
C	O
in	O
a	O
microfuge	O
for	O
3	O
'	O
to	O
isolate	O
sera	O
.	O

Mixtures	O
of	O
young	O
and	O
old	O
sera	O
were	O
made	O
1	O
:	O
1	O
.	O

For	O
example	O
,	O
in	O
5%+	O
5	O
%	O
conditions	O
,	O
50	O
µL	O
of	O
young	O
and	O
50	O
µL	O
old	O
serum	O
were	O
added	O
to	O
900	O
µL	O
of	O
culture	O
medium	O
(	O
Opti	O
-	O
MEM	O
or	O
MCM	O
,	O
see	O
co	O
-	O
culture	O
procedures	O
below	O
)	O
.	O

Myofiber	O
explant	O
culturesExplant	O
and	O
primary	O
cell	O
cultures	O
were	O
generated	O
from	O
C57-BL	O
/	O
6	O
mice	O
,	O
as	O
previously	O
described	O
(	O
Conboy	O
&	O
Rando	O
,	O
2002	O
;	O
Conboy	O
et	O
al.	O
,	O
2003	O
)	O
.	O

Dissected	O
gastrocnemius	O
and	O
tibialis	O
anterior	O
muscles	O
underwent	O
enzymatic	O
digestion	O
at	O
37	O
°	O
C	O
in	O
DMEM	O
(	O
Invitrogen	O
)	O
/	O
Pen	O
-	O
Strep	O
(	O
Invitrogen	O
)	O
/	O
0.2	O
%	O
Collagenase	O
Type	O
IIA	O
(	O
Sigma	O
)	O
solution	O
.	O

Isolated	O
fibers	O
were	O
resuspended	O
in	O
GM	O
(	O
Ham	O
's	O
F10	O
nutrient	O
mixture	O
(	O
Mediatech	O
,	O
Inc.	O
,	O
Herndon	O
,	O
VA	O
,	O
USA	O
)	O
,	O
20	O
%	O
FBS	O
(	O
Mediatech	O
)	O
,	O
5	O
ng	O
mL−1	O
bFGF	O
(	O
Chemicon	O
,	O
Temecula	O
,	O
CA	O
,	O
USA	O
)	O
and	O
1	O
%	O
Pen	O
-	O
Strep	O
,	O
and	O
cultured	O
on	O
ECM	O
-	O
coated	O
(	O
BD	O
Biosciences	O
,	O
San	O
Jose	O
,	O
CA	O
,	O
USA	O
)	O
plates	O
(	O
diluted	O
1	O
:	O
500	O
in	O
PBS	O
)	O
.	O

Cultures	O
of	O
primary	O
myoblasts	O
were	O
derived	O
from	O
isolated	O
fibers	O
,	O
through	O
repeated	O
passaging	O
,	O
and	O
were	O
maintained	O
in	O
GM	O
.	O

Myoblast	O
differentiation	O
medium	O
[	O
DMEM	O
,	O
supplemented	O
with	O
2	O
%	O
horse	O
serum	O
(	O
Mediatech	O
)	O
]	O
was	O
used	O
to	O
promote	O
rapid	O
formation	O
of	O
myotubes	O
from	O
cultured	O
myoblasts	O
(	O
Morgan	O
&	O
Partridge	O
,	O
2003	O
)	O
.	O

Human	O
embryonic	O
and	O
mesenchymal	O
stem	O
cell	O
cultureThe	O
federally	O
approved	O
hESC	O
line	O
,	O
H7	B
(	O
NIH	O
no.	O
WA07	B
,	O
obtained	O
from	O
WiCell	O
Research	O
Institue	O
,	O
Madison	O
,	O
WI	O
,	O
USA	O
)	O
,	O
was	O
used	O
in	O
accordance	O
with	O
the	O
UC	O
Berkeley	O
and	O
UC	O
San	O
Francisco	O
Committee	O
on	O
Human	O
Research	O
guidelines	O
,	O
and	O
in	O
accordance	O
with	O
NIH	O
guidelines	O
.	O

To	O
propagate	O
hESCs	O
,	O
routine	O
culturing	O
and	O
maintenance	O
was	O
performed	O
using	O
standard	O
in	O
vitro	O
conditions	O
for	O
both	O
feeder	O
-	O
dependent	O
and	O
feeder	O
-	O
free	O
cultures	O
(	O
Geron	O
Corporation	O
,	O
2002	O
)	O
.	O

Briefly	O
,	O
hESCs	O
grown	O
on	O
MEFs	O
were	O
cultured	O
in	O
standard	O
hESC	O
medium	O
[	O
Knockout	O
™	O
DMEM	O
,	O
20	O
%	O
KSR	O
,	O
1	O
%	O
NEAA	O
,	O
1	O
mm	O
l	O
-	O
glutamine	O
(	O
Invitrogen	O
)	O
,	O
0.1	O
mmβ	O
-	O
mercaptoethanol	O
(	O
Sigma	O
)	O
]	O
and	O
were	O
supplemented	O
with	O
4	O
ng	O
mL−1	O
hbFGF	O
(	O
Invitrogen	O
)	O
.	O

Feeder	O
-	O
free	O
hESC	O
cultures	O
were	O
maintained	O
in	O
MEF	O
-	O
conditioned	O
hESC	O
medium	O
(	O
MCM	O
)	O
,	O
4	O
ng	O
mL−1	O
hbFGF	O
.	O

Differentiation	O
medium	O
for	O
hESCs	O
(	O
DMEM	O
/	O
FBS	O
)	O
was	O
made	O
by	O
replacing	O
KSR	O
with	O
20	O
%	O
FBS	O
(	O
Hyclone	O
,	O
Logan	O
,	O
UH	O
,	O
USA	O
)	O
.	O

hMSCs	O
were	O
maintained	O
in	O
mesenchymal	O
stem	O
cell	O
GM	O
,	O
MSC	O
-	O
GM	O
™	O
and	O
were	O
cultured	O
according	O
to	O
supplier	O
recommendations	O
(	O
Cambrex	O
Walkersville	O
,	O
MD	O
,	O
USA	O
)	O
.	O

hESCs	O
and	O
hMSCs	O
were	O
typically	O
seeded	O
onto	O
chambered	O
slides	O
coated	O
with	O
a	O
3	O
%	O
GFR	O
Matrigel	O
™	O
(	O
BD	O
Biosciences	O
)	O
substrate	O
in	O
PBS	O
.	O

Cells	O
were	O
typically	O
incubated	O
for	O
48	O
h	O
at	O
37	O
°	O
C	O
,	O
5	O
%	O
CO2	O
,	O
under	O
the	O
various	O
experimental	O
conditions	O
employed	O
,	O
then	O
were	O
fixed	O
with	O
70	O
%	O
EtOH	O
/	O
PBS	O
at	O
4	O
°	O
C	O
.	O

hESCs	O
and	O
hMSCs	O
were	O
analyzed	O
24–48	O
h	O
after	O
experimental	O
treatments	O
,	O
during	O
which	O
no	O
apoptosis	O
-	O
related	O
differences	O
in	O
cell	O
numbers	O
were	O
observed	O
.	O

Heterochronic	O
co	O
-	O
culture	O
systemsHeterochronic	O
systemic	O
cultures	O
were	O
established	O
by	O
culturing	O
myofiber	O
explants	O
(	O
in	O
GM	O
)	O
or	O
hESCs	O
(	O
in	O
MCM	O
)	O
in	O
the	O
presence	O
of	O
young	O
,	O
old	O
or	O
young	O
+	O
old	O
sera	O
for	O
48	O
h	O
(	O
Figs	O
1	O
and	O
2	O
and	O
Supplementary	O
Figs	O
S1–3	O
)	O
.	O

In	O
such	O
cultures	O
,	O
hESCs	O
were	O
passaged	O
immediately	O
prior	O
to	O
sera	O
exposure	O
.	O

In	O
contrast	O
,	O
preculturing	O
of	O
hESCs	O
for	O
24	O
h	O
in	O
MCM	O
,	O
prior	O
to	O
replacing	O
MCM	O
with	O
MCM	O
+	O
10	O
%	O
old	O
mouse	O
sera	O
was	O
done	O
for	O
embryonic	O
microniche	O
experiments	O
(	O
Fig.	O
3	O
)	O
.	O

For	O
heterochronic	O
local	O
organ	O
niche	O
cultures	O
,	O
hESCs	O
were	O
co	O
-	O
cultured	O
directly	O
with	O
myofiber	O
explants	O
for	O
48	O
h	O
in	O
GM	O
,	O
or	O
were	O
cultured	O
in	O
the	O
presence	O
of	O
supernatants	O
derived	O
from	O
cultured	O
myofiber	O
explants	O
for	O
48	O
h	O
(	O
Figs	O
4A	O
and	O
5	O
)	O
.	O

Specifically	O
,	O
1	O
×	O
105	O
hESCs	O
or	O
control	O
hMSCs	O
were	O
co	O
-	O
cultured	O
with	O
identical	O
volume	O
,	O
e.g.	O
,	O
100	O
µL	O
,	O
of	O
young	O
or	O
old	O
myofiber	O
fragments	O
with	O
their	O
associated	O
satellite	O
cells	O
(	O
Fig.	O
5	O
)	O
.	O

In	O
experiments	O
shown	O
in	O
Supplementary	O
Fig.	O
S5	O
,	O
culture	O
-	O
conditioned	O
supernatant	O
produced	O
by	O
hESCs	O
grown	O
in	O
MCM	O
was	O
used	O
as	O
a	O
medium	O
in	O
which	O
1	O
×	O
105	O
of	O
myofiber	O
-	O
associated	O
young	O
or	O
old	O
satellite	O
cells	O
were	O
cultured	O
for	O
48	O
h.	O
In	O
direct	O
co	O
-	O
cultures	O
,	O
mouse	O
vs.	O
human	O
cells	O
were	O
distinguished	O
by	O
immunodetection	O
with	O
human	O
-	O
specific	O
/	O
hESC	O
-	O
specific	O
and	O
mouse	O
-	O
specific	O
antibodies	O
(	O
Supplementary	O
Fig.	O
S4	O
and	O
see	O
below	O
)	O
.	O

To	O
prepare	O
muscle	O
supernatants	O
,	O
explants	O
were	O
cultured	O
for	O
24	O
h	O
in	O
GM	O
and	O
cellular	O
debris	O
was	O
removed	O
from	O
conditioned	O
media	O
by	O
multiple	O
rounds	O
of	O
centrifugation	O
.	O

The	O
absence	O
of	O
cells	O
was	O
confirmed	O
by	O
microscopic	O
examination	O
.	O

To	O
mimic	O
the	O
local	O
organ	O
niche	O
for	O
satellite	O
cell	O
assays	O
(	O
Fig.	O
4B	O
)	O
,	O
1.0	O
µm	O
transwell	O
(	O
Corning	O
,	O
NY	O
,	O
USA	O
)	O
co	O
-	O
cultures	O
of	O
uninjured	O
explants	O
with	O
activated	O
satellite	O
cells	O
were	O
established	O
.	O

Activated	O
-	O
by	O
-	O
injury	O
(	O
24	O
h	O
post	O
-	O
injury	O
)	O
satellite	O
cells	O
were	O
seeded	O
onto	O
ECM	O
-	O
coated	O
12-well	O
plates	O
in	O
Opti	O
-	O
MEM	O
(	O
Invitrogen	O
)	O
and	O
5	O
%	O
FBS	O
.	O

Transwells	O
were	O
placed	O
over	O
satellite	O
cells	O
and	O
contained	O
isolated	O
myofiber	O
explants	O
from	O
uninjured	O
young	O
or	O
old	O
muscle	O
(	O
i.e.	O
,	O
resting	O
muscle	O
)	O
.	O

Satellite	O
cells	O
were	O
cultured	O
for	O
72–96	O
h	O
in	O
the	O
presence	O
of	O
myofiber	O
explants	O
and	O
were	O
fixed	O
for	O
immunodetection	O
,	O
as	O
described	O
above	O
.	O

Cell	O
transplantationhESCs	O
were	O
grown	O
on	O
MEFs	O
and	O
expanded	O
in	O
6-well	O
plates	O
.	O

Cells	O
were	O
treated	O
with	O
1	O
mg	O
mL−1	O
Collagenase	O
Type	O
IV	O
(	O
Invitrogen	O
)	O
for	O
5–10	O
min	O
,	O
were	O
washed	O
and	O
then	O
incubated	O
with	O
0.5	O
mg	O
mL−1	O
Dispase	O
(	O
Invitrogen	O
)	O
to	O
lift	O
only	O
human	O
cell	O
colonies	O
.	O

Isolated	O
hESCs	O
were	O
washed	O
several	O
times	O
and	O
resuspended	O
in	O
100	O
µL	O
hESC	O
medium	O
.	O

Similarly	O
,	O
hMSCs	O
were	O
expanded	O
in	O
6-well	O
plates	O
,	O
lifted	O
with	O
Trypsin	O
/	O
EDTA	O
(	O
Invitrogen	O
)	O
,	O
washed	O
and	O
resuspended	O
in	O
100	O
µL	O
hESC	O
medium	O
.	O

Approximately	O
5	O
×	O
105	O
hESCs	O
or	O
hMSCs	O
were	O
injected	O
into	O
24	O
h	O
post	O
-	O
injured	O
gastrocnemius	O
and	O
tibialis	O
anterior	O
muscles	O
of	O
young	O
and	O
old	O
mice	O
,	O
using	O
a	O
21-gauge	O
needle	O
.	O

Immunosuppression	O
of	O
animals	O
was	O
achieved	O
by	O
intraperitoneal	O
injection	O
of	O
1	O
mg	O
kg−1	O
FK506	O
(	O
Sigma	O
)	O
at	O
48	O
h	O
prior	O
to	O
cell	O
transplantation	O
,	O
and	O
on	O
each	O
day	O
following	O
transplantation	O
.	O

Immunodetection	O
and	O
histological	O
analysisTo	O
assay	O
the	O
affects	O
of	O
heterochronic	O
local	O
and	O
systemic	O
environments	O
on	O
stem	O
cell	O
regenerative	O
potential	O
,	O
hESC	O
,	O
hMSC	O
,	O
and	O
myofiber	O
-	O
derived	O
precursor	O
cell	O
cultures	O
were	O
fixed	O
with	O
70	O
%	O
EtOH	O
/	O
PBS	O
at	O
4	O
°	O
C	O
,	O
and	O
were	O
analyzed	O
by	O
indirect	O
immunofluorescence	O
.	O

Combinations	O
of	O
antibodies	O
were	O
used	O
to	O
co	O
-	O
stain	O
cultures	O
and	O
histosections	O
,	O
in	O
order	O
to	O
determine	O
the	O
percentages	O
of	O
cells	O
that	O
proliferated	O
or	O
differentiated	O
and	O
to	O
distinguish	O
hESCs	O
from	O
mouse	O
cells	O
.	O

Antibodies	O
to	O
the	O
myogenic	O
transcription	O
factors	O
,	O
Myf5	O
/	O
Pax7	O
,	O
the	O
intermediate	O
filament	O
protein	O
,	O
desmin	O
,	O
and	O
the	O
marker	O
of	O
newly	O
formed	O
myotubes	O
,	O
eMyHC	O
,	O
were	O
used	O
to	O
reveal	O
commitment	O
to	O
myogenic	O
differentiation	O
.	O

Cell	O
commitment	O
to	O
this	O
differentiation	O
program	O
was	O
assessed	O
by	O
the	O
efficiency	O
of	O
myotube	O
formation	O
,	O
estimated	O
by	O
the	O
number	O
of	O
nuclei	O
per	O
myotube	O
.	O

Ki67	O
,	O
a	O
cell	O
cycle	O
related	O
nuclear	O
protein	O
consistently	O
absent	O
in	O
quiescent	O
cells	O
,	O
was	O
used	O
as	O
a	O
marker	O
for	O
proliferation	O
.	O

Whereas	O
Ki67	O
appears	O
in	O
all	O
active	O
phases	O
of	O
the	O
cell	O
cycle	O
,	O
BrdU	O
staining	O
allowed	O
exclusive	O
detection	O
of	O
cells	O
in	O
S	O
-	O
phase	O
,	O
thereby	O
enabling	O
accurate	O
quantification	O
of	O
DNA	O
synthesis	O
.	O

In	O
select	O
cultures	O
,	O
10	O
µm	O
BrdU	O
was	O
added	O
for	O
2	O
h	O
prior	O
to	O
fixation	O
.	O

BrdU	O
-	O
specific	O
immunostaining	O
required	O
nuclear	O
permeabilization	O
with	O
treatment	O
of	O
4N	O
HCl	O
.	O

hESCs	O
were	O
distinguished	O
from	O
mouse	O
cells	O
by	O
using	O
a	O
species	O
-	O
specific	O
antibody	O
to	O
the	O
cell	O
-	O
surface	O
marker	O
M	O
-	O
cadherin	O
for	O
murine	O
and	O
the	O
nuclear	O
marker	O
NuMA	O
for	O
human	O
cells	O
.	O

Antibodies	O
to	O
Oct4	O
were	O
used	O
as	O
a	O
marker	O
of	O
hESC	O
self	O
-	O
renewal	O
/	O
pluripotency	O
.	O

Following	O
permeabilization	O
in	O
PBS	O
,	O
+	O
1	O
%	O
FBS	O
,	O
+	O
0.25	O
%	O
Triton	O
X-100	O
,	O
cells	O
were	O
incubated	O
with	O
primary	O
antibodies	O
(	O
concentration	O
determined	O
as	O
per	O
manufacturer	O
's	O
recommendations	O
)	O
for	O
1	O
h	O
at	O
room	O
temperature	O
in	O
PBS	O
,	O
+	O
1	O
%	O
FBS	O
,	O
washed	O
several	O
times	O
,	O
and	O
then	O
incubated	O
with	O
fluorophore	O
-	O
conjugated	O
,	O
species	O
-	O
specific	O
secondary	O
antibodies	O
(	O
diluted	O
1	O
:	O
500	O
in	O
PBS	O
+	O
1	O
%	O
FBS	O
)	O
for	O
1	O
h	O
at	O
room	O
temperature	O
.	O

For	O
histological	O
analysis	O
,	O
dissected	O
muscle	O
was	O
treated	O
in	O
a	O
25	O
%	O
sucrose	O
/	O
PBS	O
solution	O
,	O
frozen	O
in	O
OCT	O
compound	O
(	O
Tissue	O
Tek	O
)	O
and	O
cryosectioned	O
at	O
10	O
µm	O
.	O

Immunostaining	O
was	O
performed	O
in	O
the	O
manner	O
described	O
above	O
,	O
or	O
H&E	O
staining	O
of	O
cryosections	O
was	O
performed	O
.	O

Nuclei	O
were	O
visualized	O
by	O
Hoechst	O
staining	O
for	O
all	O
immunostains	O
.	O

Samples	O
were	O
analyzed	O
at	O
room	O
temperature	O
by	O
using	O
a	O
Zeiss	O
Axioscope	O
40	O
fluorescent	O
microscope	O
,	O
and	O
imaged	O
with	O
an	O
Axiocan	O
MRc	O
camera	O
and	O
AxioVision	O
software	O
.	O

All	O
images	O
depict	O
identical	O
microscope	O
fields	O
at	O
×20	O
magnification	O
,	O
unless	O
otherwise	O
noted	O
.	O

ReagentsAntibodies	O
to	O
Oct4	O
(	O
ab18976	O
)	O
,	O
BrdU	O
(	O
BU1	O
/	O
75	O
(	O
ICR1	O
)	O
,	O
and	O
Ki67	O
(	O
ab15580	O
)	O
were	O
purchased	O
from	O
Abcam	O
(	O
Cambridge	O
,	O
MA	O
,	O
USA	O
)	O
.	O

Antibody	O
to	O
M	O
-	O
cadherin	O
(	O
clone	O
12G4	O
)	O
was	O
acquired	O
from	O
Upstate	O
Biotechnology	O
(	O
Lake	O
Placid	O
,	O
NY	O
,	O
USA	O
)	O
,	O
and	O
NuMA	O
antibody	O
(	O
Catalog	O
number	O
NA09L	O
)	O
from	O
EMD	O
Biosciences	O
(	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Antibody	O
to	O
developmental	O
eMyHC	O
(	O
clone	O
RNMy2	O
/	O
9D2	O
)	O
was	O
acquired	O
from	O
Vector	O
Laboratories	O
(	O
Burlingame	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Myf5	O
(	O
GTX77876	O
)	O
and	O
Pax7	O
(	O
GTX77888	O
)	O
antibodies	O
were	O
obtained	O
from	O
GeneTex	O
(	O
San	O
Antonio	O
,	O
TX	O
,	O
USA	O
)	O
.	O

Desmin	O
antibodies	O
(	O
clone	O
DE	O
-	O
U-10	O
and	O
Catalog	O
number	O
D8281	O
)	O
,	O
BrdU	O
labeling	O
reagent	O
and	O
FK506	O
(	O
Catalog	O
number	O
F4679	O
)	O
were	O
obtained	O
from	O
Sigma	O
.	O

Fluorophore	O
-	O
conjugated	O
secondary	O
antibodies	O
(	O
Alexa	O
Fluor	O
)	O
were	O
obtained	O
from	O
Molecular	O
Probes	O
(	O
Eugene	O
,	O
OR	O
,	O
USA	O
)	O
.	O

Statistical	O
analysesA	O
minimum	O
of	O
three	O
replicates	O
were	O
undertaken	O
for	O
each	O
experimental	O
condition	O
.	O

Quantified	O
data	O
are	O
presented	O
as	O
means	O
±	O
SE	O
.	O

Significance	O
testing	O
was	O
performed	O
using	O
one	O
-	O
way	O
analysis	O
of	O
variance	O
(	O
anova	O
)	O
to	O
compare	O
data	O
from	O
different	O
experimental	O
groups	O
.	O

P	O
values	O
of	O
<	O
0.05	O
were	O
considered	O
as	O
statistically	O
significant	O
.	O

